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Abstract
In this thesis, the interactions of a number of classes of compounds with the enzyme 
peptidylglycine oc-amidating monooxygenase (PAM) are investigated. The studies 
were conducted to establish the effects a range of modifications to natural PAM 
substrates have on binding affinity with the enzyme.
Incorporation of a hydrophobic or a copper binding functional group was found to 
preserve binding affinity with PAM, while extensions to the backbone of natural 
PAM substrates resulted in a loss in binding affinity.
Based on comparisons of the stability and the relative ease of formation of the a- 
carbon centred radical of an acylglycine, with that of the corresponding glycolic acid 
derivatives and y-keto acids led to the latter two classes of compounds being 
identified as inhibitors of PAM. The glycolic acid derivatives displayed higher 
binding affinity with PAM than the analogous y-keto acids.
The presence of the ester carbonyl group of glycolic acid derivatives was established 
to be important in preserving binding affinity with PAM. Unexpectedly, two of the 
ß-oxa acids appeared to enhance the activity of the enzyme, which may be as a result 
of an activating allosteric effect.
a,ß-Unsaturated y-keto acids, which mimic the geometries of the glycyl NH and that 
of the a-carbon centred radical of natural PAM substrates were found to inhibit 
PAM activity.
Amino acid based analogues of (£}-4-phenyl-3-butenoic acid, an established PAM 
inactivator, displayed effective inhibition of the enzyme.
Analogues of natural PAM substrates that possess a thio ether substituent were found 
to inhibit PAM activity. The methionine containing dipeptides displayed greater
xiii
binding affinity with PAM than the corresponding leucine derivatives. In contrast, 
the methionyl glycolic acid derivative displayed poorer binding affinity than the 
corresponding leucyl glycolic acid.
Compounds possessing diamino substituents as copper binding functional groups did 
not display high binding affinity to PAM. Interestingly, one of the diamines behaved 
in a similar manner to the two ß-oxa acids and appeared to act as an enzyme 
activator.
xiv
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Chapter One
Introduction
1.1 Peptide Hormones
Peptide hormones are a class of peptides secreted directly into the bloodstream by 
the endocrine glands1 and involved in a wide range of biological roles. Substance P, 
a member of the tachykinin neuropeptide family, has been shown to affect 
cardiovascular functions as well as the transmission of pain. The peptide hormone 
oxytocin is involved in the modulation of milk ejection and uterine contractions in 
mammals.4 Vasopressin, a nonapeptide similar in structure to oxytocin, functions as 
an antidiuretic regulator.5 The body’s metabolism of calcium and phosphorus is 
regulated by the 32 amino acid polypeptide, calcitonin.5 The neuropeptide bombesin 
along with calcitonin has been shown to induce the proliferation of prostate 
carcinoma cells by inhibiting cell apoptosis/’ The fatty acid primary amide, 
oleamide (c/s-9-octadecenamide) is involved in sleep induction and enhances the 
anti-proliferation of breast cancer cells by arachidonylethanolamide.7
1.2 Peptidylglycine a-Amidating Monooxygenase (PAM)
C-Terminal amidation is a ubiquitous post-translational modification of bioactive 
peptides, including peptide hormones. Over half of all bioactive peptides require 
amidation to achieve full biological activity.8 The post-translational activation of the 
peptides is catalysed by peptidylglycine a-amidating monooxygenase (PAM) via the 
oxidative cleavage of the terminal glycine residue to give the corresponding 
bioactive C-terminal amides (Scheme 1). PAM is a bifunctional enzyme consisting 
of two catalytic subunits - peptidylglycine a-hydroxylating monooxygenase (PHM; 
EC 1.14.17.3) and peptidylamidoglycolate lyase (PAL; EC 4.3.2.5).
1
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Scheme 1. Mechanism PAM catalysis
In the amidation process, PHM is responsible for the rate-limiting, catalytic 
hydroxylation of the glycine-extended precursor to give the corresponding a- 
hydroxyglycine intermediate. The activity of PHM is dependent on the presence of 
copper, molecular oxygen and ascorbate. PHM belongs to the same family of 
monooxygenases as dopamine ß-monooxygenase (DßM), a norepinephrine 
synthesizing enzyme. DßM’s activity is also dependent on molecular oxygen and 
ascorbate.
The mechanism of the PHM catalysed reaction of glycine extended precursors is 
outlined in Scheme 2.
LCu
P e p t i d e ^  
O *  »
,COOH Peptide COOH Peptide> ,COOH
LCum( I ) -0 X
r-
LC um(II)-OH
o
Scheme 2. Reaction at the a-carbon of a substrate catalysed by PHM
The initial step in the PHM mechanism involves the reduction of the two copper 
ions, Cuh and Cum, from the cupric to cuprous states by two one electron transfers 
from two ascorbates.8 Next, molecular oxygen is bound to Copper M (Cum) in the 
presence of a substrate to give a copper-peroxy radical. The radical species then
2
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abstracts the pro-(IS)-hydrogen from the a-carbon of the bound substrate’s glycine, 
resulting in the formation of an a-carbon centred radical. This is followed by the 
radical cleavage of the oxygen to oxygen bond in the copper bound hydroperoxide 
species to give an a-hydroxyglycine as the product.9
According to a crystal structure of an oxidised PHM-substrate complex, a number of 
interactions take place between the substrate and the enzyme (Figure 1). Two 
interactions in particular are considered to be especially important in the binding of 
substrates to the enzyme active site. As observed in the crystal structure, the free 
carboxyl group of the substrate is anchored in a bidentate bridge by the guanidinium 
group of the R240 residue and also forms a hydrogen interaction with the hydroxyl 
group of the tyrosine residue Y318.‘° The other key interaction involves the 
hydrogen bonding of the glycyl NH of the substrate with the oxygen of the 
asparagine residue N316. In addition to the two interactions mentioned, the 
diiodotyrosine side chain of the bound substrate appears to occupy a hydrophobic
opocket within the PHM active site.
Figure 1. Crystal structure of oxidised PHM catalytic core with bound substrate (Ac- 
Dil-YG).8,9 The image was generated from protein data bank (PDB) file lopm.
3
Introduction -  Chapter One
The carbinol product from the PHM catalysed reaction is then processed by PAL, the 
second enzymatic functional subunit. The presence of zinc has been shown to be 
necessary for maintaining the catalytic activity of PAL.11 However, its specific role 
in the PAL mechanism remains unknown. The mode of catalysis by PAL has been 
suggested to be similar to that of ureidoglycolate lyase, which converts 
ureidoglycolate into urea and glyoxylate. The PAL mechanism has also been
o
suggested to be closely related to that of alcohol dehydrogenase, with the a- 
hydroxyglycine species being cleaved to the corresponding C-terminal amide and 
glyoxylate as products (Scheme 3).8,13
Scheme 3. Proposed reaction mechanism of PAL
It has been established that the two enzyme components of PAM process their 
substrates in an asymmetric manner.14 PHM stereoselectively produces (S)- 
configured a-hydroxyglycine intermediates and the PAL enzyme has been shown to 
be only active towards (^-configured carbinol products in the conversion to give the 
corresponding amidated peptides and glyoxylate.
1.3 Quantification of interactions with PAM
The purpose of the research discussed in the Chapters of the Results and Discussion 
of this thesis was to quantify then evaluate the effects of modifications to PAM 
substrates on binding affinity with the enzyme. In order to establish the binding 
affinities of individual compounds with PAM, enzyme assays are carried out. A 
brief description of the parameters used to define enzyme-substrate and enzyme- 
inhibitor interactions is now provided.
4
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The simplest equation to represent an enzyme (E) catalysed reaction of substrates (S) 
is referred to as the Michaelis-Menten equation (Scheme 4). E.S represents the 
enzyme-substrate complex formed in the reaction between an enzyme (E) and a 
substrate (S). The enzyme-substrate complex is then converted into the enzyme- 
product complex (E.P), followed by the dissociation of the complex to give the 
product (P). The Km, or the Michaelis-Menten constant, represents the substrate 
concentration required to produce a reaction rate that is half its maximal rate (VmaJ2) 
or the dissociation constant of the enzyme-substrate complex.15,16
Km vmax
E + S .  ■- E.S ------------ - E.P ------------ -- E + P
Scheme 4. Michaelis-Menten Equation
The two most common parameters use to describe the activity of an inhibitor with an 
enzyme are the K\ and IC50 values. The inhibition constant, K\, represents the 
equilibrium constant of the dissociation of the enzyme-inhibitor complex. An IC50 
denotes the concentration of inhibitor necessary to reduce the rate of the enzyme 
catalysed reaction by 50 percent.
In order to establish a K\ value, the activity of the enzyme catalysed reaction must be 
measured at a number of substrate concentrations, against a specific inhibitor 
concentration. The experiment is then repeated at various inhibitor concentrations. 
Based on the rate measurements collected, the values are interpreted in graphical 
form, which allows the extrapolation and determination of a K\ value.
On the other hand, fewer experimental measurements are required in the 
determination of an IC50 value. The IC50 value is established at one substrate 
concentration over a range of inhibitor concentrations.17 Given the high cost of the 
PAM enzyme solution, the methodology used to establish IC50 values was used to 
establish the binding affinities of all the compounds researched as part of this thesis.
The relationship between an IC50 and a K\ value is described in the Cheng-Prusoff 
relationship (Equation 1).
5
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ICso = K
\  Km j
Equation 1. Cheng-Prusoff equation1
The Cheng-Prusoff equation states that the IC50 value for any given competitive 
inhibitor is related to the K\ value of the inhibitor as a function of the substrate 
concentration [S] and the Michaelis constant K m , of the substrate. A competitive 
inhibitor is defined as an inhibitor which prevents the substrate from binding to the 
enzyme active site.16
The Dixon plot of a competitive inhibitor is displayed in Figure 2. A Dixon plot is 
created from a series of data points generated at a number of substrate concentrations 
([Sa] and [Sb]). The negative K\ value is acknowledged as the point at which the 
two lines [Sa] and [Sb] intersect.17
[Inhibitor]
• 17Figure 2. Dixon plot of a competitive inhibitor
The Dixon plot may also be used to express how an IC50 value and a K\ value of a 
given inhibitor are related. By viewing the lines of the Dixon plot as a series of IC50 
determinations, it can be seen that as the concentration of substrate decreases, the 
intercept of the line approaches the K\ value, as illustrated in Figure 3.
6
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- I C 5 0 B  - I C 5 0 A (Inhibitor]
N -ATl -IC m
Figure 3. Dixon plot for K\ and IC50 value determinations17
In the case of competitive inhibition, an IC50 value approximates the K\ value when 
the concentration of substrate used in the assay is lower than the K m value. 17 The 
starting concentration of the substrate (^)-Tyr-(iS)-Val-Gly employed in the enzyme 
assays conducted as part of the research for this thesis was 0.1 mM, with a K m ,*PP 
value of 0.2 mM,19 therefore, in this instance, the IC50 value should correlate 
reasonably well to the K\ value.
1.4 PAM inhibitors
PAM is a broad spectrum enzyme which catalyses the conversion of a large selection 
of prohormones to give their corresponding bioactive amide products.20 The enzyme 
has been associated with the development of a large number of diverse pathological 
conditions, which are brought about by an overproduction of peptide hormones, 
including chronic inflammation or arthritis, neuropathic pain, ’ cancer, and 
asthma. This has led to significant interest in the scientific community in 
developing pharmacological interventions of PAM’s activity.24
A number of compounds which inhibit PAM activity have been identified including, 
(^)-4-phenyl-3-butenoic acid (PBA) (1), which was one of the earliest established
7
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potent inhibitors of PAM.25'26 The proposed mechanism of inhibition by PBA is
77outlined in Scheme 5.
Scheme 5. PBA mechanism of PAM inhibition
PBA has been established to be a mechanism based inhibitor of PAM, with a K\ 
value of 1 pM.28 PAM activity is irreversibly inhibited by the formation of a 
delocalised radical which prohibits the normal oxidative cleavage process by the 
enzyme from being carried out. Administration of PBA in rats was found to 
produce an anti-inflammatory effect.29 PBA has also been shown to compromise the 
enzyme’s activity in cardiac atrium, pituitary and brain tissue.26
Other proposed mechanism based inhibitors of PAM include AMormylamides, which 
are postulated to inactivate the enzyme via the formylation of a nucleophile in the 
enzyme active site.30
In the presence of benzylhydrazine, PHM activity in a rat a-amidating enzyme was 
lost in a time and concentration dependent manner.31 Inorganic sulfites ( S O 3 2') ,  
which are common food additives, displayed potent inhibition of both PAM and the 
copper-dependent DßM. The sulfite mediated inactivation is suggested to proceed 
via modifications of amino acid residues in the enzyme active site by a sulfite radical 
(SO3-).32
A number of existing drug treatments for a range of pathological conditions have 
also been found to be effective in inhibiting PAM activity.
8
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Captopril (2), a sulfhydryl group containing compound, which has been established 
as an angiotensin-converting enzyme (ACE) inhibitor, also displays PHM inhibitory 
activity in vitro at around 100 pmol/L dosage.33 While captopril (2) displayed PHM 
inhibition, nonsulfhydryl analogues such as enalprilat (3) did not inhibit the 
enzyme’s activity. The results from the study suggest that the observed inhibition is 
the result of the sulfhydryl group of captopril (2) impeding on electron transfers 
between the copper ions in the enzyme active site.
,COOH ,COOH
(2) (3)
Similarly, thiorphan (4), tiopronin (5) and related analogues have been shown to 
inhibit PAM activity.34 Thiorphan (4) is administered as an antidiarrheal
o c  o/ r
treatment, ’ while tiopronin (5) has been used to treat mercury and copper 
poisoning37 as well as rheumatoid arthritis. 18 Theoretical modeling studies attributed 
the high binding affinity displayed by both thiorphan (4) and tiopronin (5) to PAM 
being a result of interactions between the sulfur of the thiol group with the enzyme- 
bound copper.
To date the most potent inhibitors of PHM are A-substituted homocysteine 
analogues, with reported IC 50 values in the low nanomolar range.5 The potent 
inhibition expressed by the homocysteine analogues is postulated to be a result of the 
co-ordination of the thiolate with the enzyme’s copper.5 Ester derivatives of the 
homocysteine compounds were subsequently found to inhibit the production of the 
peptide hormone substance P. One example, the hydrocinnamoylphenylalanyl 
benzyl ester 6, displayed an IC50 value of 3 pM.
9
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(6)
Two other compounds which may also inhibit the peptide amidation process by 
chelating with the copper of the enzyme active site are disulfiram (7) and N,N- 
diethyldithiocarbamate (8).40
(7) (8)
A series of unsaturated thio acetic acids has also been determined to inhibit the 
activity of PHM.41 The compounds were investigated given the literature 
precedence of the conversion of sulfides to sulfoxides by PHM.42 The sulfoxides 
generated were proposed to act as Michael acceptors, alkylating a nucleophilic 
residue in the active site of PHM, leading to enzyme inactivation. The proposed 
mechanism is outlined in Scheme 6.41
10
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Ar^ ^ s PHM 41..........
;
Enz— Nu
S '
o
Scheme 6. Proposed PHM inhibition by unsaturated thio acetic acids41
Two classes of compounds have been identified to be specific towards the inhibition 
of PAL. The substrate analogue, phenylacetyl-a-hydroxyglycine (9) was determined 
to be a competitive inhibitor of PAL with a K\ value of 770 pM.43
A later study identified that pyruvate-extended A-acylamino acid derivatives with 
hydrophobic side chains preferentially inhibited the activity of PAL over PHM.44 
This class of compounds was designed to mimic the geometry of the transition state 
of the substrate likely to be formed along the PAL catalytic pathway. N- 
Acetylphenylalanylpyruvate (10) and A-acetyltyrosylpyruvate (11) displayed potent 
inhibition of PAL, exhibiting K\ values of 0.24 pM and 0.52 pM, respectively.44
AcHNAcHN
(10) (11)
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1.5 The stability and relative ease of formation of a-carbon centred 
amino acid radicals
In Chapter Three of this thesis, the use of an alternative approach to identify PAM 
inhibitors by evaluating the stability of a-carbon centred amino acid radicals and 
their relative ease of formation is discussed. A short review describing the 
characteristics of a-carbon centred amino acid radicals and the methods employed to 
quantify their stability and relative ease of formation is now provided.
a-Carbon centred amino acid radicals are readily formed in peptides, proteins and 
other amino acid derivatives. These radicals are much more stable compared to 
typical carbon radicals due to extensive radical stabilisation achieved by the 
captodative effect. The captodative effect enhances the stability of the radical 
through delocalisation of the unpaired spin density via a ‘push-pull’ mechanism 
initiated by the electron-donating (dative) action of the amino or amido substituent, 
and the electron withdrawing (capto) effect of the carboxyl group.45
Radical stabilisation energies (RSEs) are determined from a series of high level 
theoretical calculations that correspond to the difference in energy between the 
dissociation of the C-H bond in methane and the bond dissociation energy of the R- 
H bond in the compound of interest (Scheme 7).46,47
•R + CH4 ----------------------► RH + #CH3
Scheme 7. Isodesmic reactions used to determine RSE values
In the context of this thesis, the RSE values are used to establish the relative stability 
of radicals. The more stable a radical is, the more positive the calculated RSE value 
will be.
All RSEs reported in this thesis correspond to RMP2/G31arge//B3-LYP/6-31G(d) 
calculations at 0 K. The B3-LYP/6-31G(d) level of theory was used in the 
determination of geometries and zeropoint vibrational energies. Single point
12
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calculations were carried out on the optimised structures at the RMP2 level with the 
6-311+G(2df,p) and G3 large basis sets to obtain the improved relative energies 
values. The levels of theories mentioned have been established to be suitable for 
RSE calculations.46
The calculations for the RSE values discussed in Chapters Three and Six of this 
thesis were determined by Professor Leo Radom.19 Calculations for the RSE values 
reported in Chapters Four and Five were conducted by Dr. Michelle Coote.
The rate at which an amino acid derivative undergoes radical a-bromination reflects 
the relative ease of formation of the corresponding a-carbon centred amino acid 
radical (kTe\). The radical bromination experiments were carried out according to a 
literature method.48 A mixture of the substrate in the presence A-bromosuccinimide 
and carbon tetrachloride is heated at reflux and photolysed with a 300W sun lamp. 
Following the irradiation process, a small sample is obtained from the crude mixture 
and analysed by proton NMR to distinguish whether bromination had taken place.
The aim of the research discussed in this thesis was to investigate the effect a 
selection of modifications to PAM substrates have on binding affinity with the 
enzyme. The extent to which the modifications, which include atom substitutions 
and the incorporation of hydrophobic and copper coordinating substituents, affect 
binding with the enzyme was determined by comparing the binding affinities of the 
substrate analogues to that of the corresponding PAM substrates. The findings from 
the initial investigation of recognition features affecting binding affinity with PAM 
will now be described in Chapter Two of the Results and Discussion.
13
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Chapter Two
Preliminary investigation o f recognition features 
affecting binding affinity within the PAM enzyme 
active site
2.1 Introduction
Strong hydrogen bonds between the carboxyl functionality at the C-terminus of the 
substrate with guanidine and tyrosine residues of the active site of PAM are observed 
in the crystal structure of an enzyme-substrate complex.49 These play a vital role 
towards maintaining binding affinity within the enzyme active site. For this reason, 
all of the compounds considered in this project possess a free carboxyl group.
In order to maintain high binding affinity within the enzyme active site, the amino 
acid residues located at the penultimate position of peptide substrates should have 
either a hydrophobic or a sulfur containing side chain.'0 Peptides containing charged 
residues like aspartic acid or lysine displayed poor binding with PAM.51 A 
methionine residue at the penultimate position resulted in inhibition of the amidation 
process as demonstrated with the methionylglycine 12. The dipeptides 13 and 14 
containing phenylalanine and leucine, respectively, displayed high binding 
affinity.7'43
O O
o
( 12) (13) (14)
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The simplified analogues 15, 16 and 17 of the dipeptides 13, 14 and 12 were studied, 
to explore the binding effects of only the carboxyl group and the side chains.
The visual comparisons shown below illustrate the geometric similarities between 
the two classes of compounds (Table 1).
Dipeptides Acid analogues
AcNH
AcNH
Table 1. The structures of the dipeptides 13, 14 and 12 and the corresponding acid
analogues 15, 16 and 17
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Hydrogen bonding between the glycyl NH group of a substrate with an asparagine 
side chain in the enzyme active site has been established in a PHM-substrate crystal 
structure.9 It was envisaged that the absence of such interactions would affect the 
binding affinity of the three acids 15, 16 and 17 with PAM.
2.2 Syntheses of acids 15,16 and 17
2.2.1 6-Phenylhexanoic acid (15)
The synthesis of 6-phenylhexanoic acid (15) was not necessary as the compound was 
available commercially from Sigma-Aldrich, Inc.
2.2.2 7-Methyloctanoic Acid (16)
The synthesis of 7-methyloctanoic acid (16) is depicted below (Scheme 8). The 
preparation proceeded according to the experimental conditions and methods 
described by Davidson and Schumacher.53
Scheme 8. Synthesis of 7-methyloctanoic acid (16)
Firstly, the transformation of the ketone group of 7-oxooctanoic acid (19) to an 
alkene via a Wittig reaction was carried out. Methyltriphenylphosphonium chloride 
(18) in tetrahydrofiiran was treated with «-butyl lithium, followed by the addition of
17
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commercially available 7-oxooctanoic acid (19). The negative mode electrospray 
ionisation (ESI (-ve)) mass spectrum of the acid 20 displayed the deprotonated 
molecular ion at m/z 155 as the base peak. Hydrogenation of 7-methyloct-7-enoic 
acid (20) was carried out using hydrogen and 10% Pd/C in ethanol. Formation of 7- 
methyloctanoic acid (16) was confirmed by ]H NMR spectroscopy and high 
resolution mass spectrometry. The ’H NMR spectrum displayed resonances 
consistent with literature values,5:1 and the ESI (-ve) mass spectrum presented the 
base peak at m/z 157 for the deprotonated molecular ion.
2.2.3 6-Methylthiohexanoic acid (17)
Commercially available 6-bromohexanoic acid (21) was converted to 6- 
methylthiohexanoic acid (17) in one step by treatment with sodium thiomethoxide 
(Scheme 9). The conversion was carried out following the procedure described by 
Knaus and co-workers.54
(21) (17)
Scheme 9. Synthesis of 6-methylthiohexanoic acid (17)
A mixture of 6-bromohexanoic acid (21) and sodium thiomethoxide in methanol was 
heated at reflux overnight. The ]H NMR spectrum of the distilled product 17 
displayed resonances identical to those recorded in the literature.54 Further evidence 
for the successful conversion to the sulfide 17 was provided by the presence of a 
peak at m/z 162 due to the deprotonated molecular ion in the ESI (-ve) mass 
spectrum.
18
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2.3 PAM binding affinity of acids 15, 16 and 17
For the purpose of the work within this thesis, the binding affinity of individual 
compounds with PAM is quantified by the determination of IC50 values. An IC50 
value is defined as the concentration of an inhibitor that is necessary to reduce 
enzyme activity or turnover of substrate by fifty percent. The substrate subjected to 
the enzyme assays was the tripeptide 22 and the product from the substrate 
conversion by PAM was the amide 23. The overall reaction is outlined in Scheme 
10.
Scheme 10. Conversion of substrate 22 to product 23 catalysed by PAM
IC50 values were determined by conducting enzyme assays at varying concentrations 
of the compounds 15, 16 and 17. The experiments carried out were in the form of 
serial dilution assays, and solutions were analysed directly by HPLC to determine 
the ratio of the substrate 22 to the product 23. A Dixon plot is then generated from 
the inverse of the averaged substrate turnover values plotted against inhibitor 
concentration. The IC50 value is the value of -x  when y = 0 from the equation 
generated from the line of best fit in the Dixon plot. Although an IC50 value is only a 
preliminary indicator of inhibitor binding, a more thorough analysis of the mode of 
inhibition was not practical due to the expense of the enzyme.
A compiled table of the IC50 values of the acids 15,16 and 17 is provided in Table 2.
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C om pound IC 50 (m M )
( 1 5 )
,oh
0
0 .9
0
( 1 6 )
OH
4 .4
c
( 1 7 )
r 1 .7
Table 2. IC50 values of the compounds 15, 16 and 17
The IC50 values show that compounds bearing only a free carboxyl group and either 
a hydrophobic portion or a sulfide group inhibit the enzyme at millimolar 
concentrations. It seems likely that the aromatic and aliphatic groups of the acids 15 
and 16 reside in a hydrophobic pocket of the enzyme active site, while the sulfur of 
the sulfide 17 binds to the enzyme’s copper.
The compounds investigated in the remaining sections of this thesis were therefore 
chosen to incorporate either a hydrophobic moiety or a sulfur-containing group, 
which have been established to be beneficial in maintaining high binding affinity 
with the enzyme.
2.4 Effect on PAM binding affinity of substrates with backbone 
extension
Compounds possessing only a free carboxyl group and a hydrophobic moiety have 
thus been shown to inhibit the catalytic activity of the PAM enzyme, while systems 
containing both the mentioned characteristics as well as a C-terminal glycine residue
20
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displayed high binding affinity with PAM and are processed as substrates by the 
enzyme.7,42,43
To study changes to binding affinity of compounds with an extra methylene between 
the peptidyl nitrogen and carboxyl group of a substrate glycine residue, the three 
compounds 24, 25 and 26 all terminating with a ß-alanine residue were investigated.
AcHN
(25)
AcHN
A visual comparison of the structures of the PAM substrate 13 and the corresponding 
ß-alanyl dipeptide 25 is provided, with the key differentiation between the two 
classes of compounds highlighted.
AcHN AcHN
(13) (25)
The ß-alanine derivatives 25 and 26 of phenylalanine and leucine, respectively, were 
studied as the incorporation of a hydrophobic side chain in structures had been 
established to retain or enhance binding affinity in the PAM active site. In addition, 
the binding affinities of the phenylalanyl and leucyl dipeptides 13 and 14 terminating 
with a glycine residue had been reported.7,43 This allows comparisons of the binding 
affinities of a dipeptide system terminating with ß-alanine versus glycine to take 
place. Similarly the PAM binding affinity of N-benzoylglycine (27) had been 
established,42 which allows for comparison with A-benzoyl-ß-alanine (24).
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The binding affinity of the tripeptide Tyr-Val-ß-Ala with an a-amidating enzyme 
has previously been reported.51 No inhibition was observed at the highest 
concentration (2 mM) of the tripeptide examined, while the corresponding tripeptide 
terminating with glycine inhibited the enzyme activity at a concentration of 126 pM. 
As the enzyme from rats and employed in the study of the tripeptides mentioned 
above differs from the enzyme derived from frog skins and used in the current 
studies, direct comparisons of the results from the earlier work cannot be used to 
establish any conclusions or trends with the results from the present investigation.
2.5 Syntheses of ß-alanine derivatives 24, 25 and 26 
2.5.1 yV-Benzoyl-ß-alanine (24)
The preparation of the N-protected amino acid 24 is outlined in Scheme 11. 
soci2
ß-Alanine ----------------
MeOH
(28)
Li OH
THF/ H20
O
BzH N H
(24)
Scheme 11. Synthesis of N-benzoyl-ß-alanine (24)
The conversion of ß-alanine 28 to the methyl ester 29 was carried out by treatment 
with thionyl chloride and methanol. The melting point obtained for compound 29 is 
consistent with the reported value.55 Benzoylation of the methyl ester 29 was 
conducted by treatment with benzoyl chloride and sodium bicarbonate to give the 
amide 30. The product’s 'H NMR spectrum is consistent with data provided in 
literature.56 The ESI positive ion (+ve) mass spectrum presented the base peak as
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the sodiated molecular ion at m/z 230. Hydrolysis of the ester 30 was conducted in 
the presence of lithium hydroxide. Formation of the acid 24 was confirmed by ’H 
NMR spectroscopy. The spectral characteristics obtained are consistent with 
reported information.57 The high resolution ESI (-ve) mass spectrum presented the 
deprotonated molecular ion peak at m/z 192.0654.
2.5.2 (£)-./V-Acetylphenylalanyl-ß-aIanine (25)
The synthesis of (5)-A-acetylphenylalanyl-ß-alanine (25) is illustrated in Scheme 12.
Scheme 12. Synthesis of (iS)-iV-acetylphenylalanyl-ß-alanine (25)
The conversion of the amino acid (S)-phenylalanine (31) to the protected derivative 
32 was carried out by treatment with acetic anhydride. The ]H NMR spectrum of the 
amide 32 displayed a singlet resonance at 1.78 ppm, corresponding to the three 
protons of the newly installed A-acyl group. The melting point of the acid 32 
matches reported data.'8 The dipeptide 33 was synthesized by treating a mixture the 
methyl ester 29 and the iV-acetylated acid 32 with the BOP reagent. The successful 
synthesis of the protected dipeptide 33 was confirmed by the display of a singlet
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resonance at 3.64 ppm in the 'H NMR spectrum corresponding to methyl ester 
protons. The deprotection reaction was achieved by treating the ester 33 with 
lithium hydroxide. Formation of the acid 25 was confirmed by the observation of a 
molecular ion peak in the high resolution ESI (+ve) mass spectrum at m/z 278.1269. 
The 'H NMR spectrum displays characteristics consistent with those provided in the 
literature.59
Only a small sample of the dipeptide 25 was prepared, so its optical purity was not 
established. It is assumed to be homochiral with the stereochemistry illustrated, as 
the conditions selected for the synthesis of the dipeptide 33 from the A-acyl amino 
acid 32 and the methyl ester 29 have been established to result in negligible 
racemisation,60 and the saponficiation converting the ester 33 to the acid 25 was also 
not expected to cause racemisation. However, even in the unlikely event of 
isomerisation, the IC50 value would only be reduced by at most a factor of two, 
unless the enantiomer showed peculiarly enhanced binding. An earlier example 
suggests this is unlikely to be the case. The study found that the dipeptide (S)-N- 
acetylphenylalanylglycine (13) exhibited binding affinity with PAM over two orders 
of magnitude greater than that of the corresponding dipeptide (R)-N- 
acetylphenylalanylglycine.4^  So, should isomerisation have taken place, the 
variation introduced would be likely to reduce the observed binding affinity by 
approximately a factor of two, and this is within the limit of accuracy of a 
preliminary determination of IC50 values.
2.5.3 (SyA-Acetylleucyl-ß-alanine (26)
The A-protected dipeptide 26 was prepared by following reactions depicted in 
Scheme 13.
24
Results and Discussion -  Chapter Two
Scheme 13. Synthesis of (5)-7V-acetylleucyl-ß-alanine (26)
Protection of the amino functional group of OS)-leucine (34) was carried out by 
treatment with acetic anhydride to give the acid 35 . The melting point of the acid 35 
matches reported data.61 The coupling reaction between the acid 35 and the methyl 
ester 29 was carried out using BOP. Formation of the product 36 was confirmed by 
'H NMR spectroscopy, which displayed resonances at 2.54 and between 3.45-3.57 
ppm corresponding to the four methylene protons of the ß-alanine residue. The ester 
36 was deprotected to give the acid 26 via treatment with lithium hydroxide. The 
formation of the dipeptide 26 was confirmed by 'H NMR spectroscopy and high 
resolution ESI (+ve) mass spectrometry, which displayed the peak of the sodiated 
molecular ion at m/z 267.1326.
As for the phenylalanine derivative 25 discussed above, the leucine derivative 26 is 
assumed to be optically pure, although this was neither established nor considered to 
be particularly important in the current context.
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2.6 Binding studies of ß-alanine derivatives 24, 25 and 26
The IC50 values of the ß-alanine derivatives 24, 25 and 26 with PAM were 
determined by treating samples containing various concentrations of the compounds 
with aliquots of enzyme in the presence the substrate (7^-tyrosyl-(2>)-valylglycine 
(22). The reaction mixtures were analysed by HPLC to quantity any changes in the 
ratio of the substrate 22 to amidated product (7^-tyrosyl-(iS)-valinamide (23) to 
determine the activity displayed by the compound of interest with PAM. The 
concentrations of the ß-alanine derivatives 24, 25 and 26 ranged from 0 to 16 mM. 
It was deemed impractical to carry out enzyme assays at inhibitor concentrations 
greater than 16 mM due to limits on solubility. The binding affinities of the three ß- 
alanine derivatives 24, 25 and 26 and the corresponding glycine analogues 27, 13 
and 14 are presented in Table 3.
PAM substrate K m  value ß-Alanine derivative IC50 value
0
I ! r ^ iCfVr" 1.742
0  0
9.3
(27) (24)
0
'  '
0.00843 ™V^ Y"
0  O
>16
(13) (25)
0
V - ° 0.0967 O 0 >16
(14) (26)
Table 3. K m values of PAM substrates 27, 13, 14 and IC50 values of corresponding
ß-alanine derivatives 24, 25, 26
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The protected ß-alanine 24 inhibited PAM activity with an IC50 value o f 9.3 mM. 
Both the derivatives of leucyl-ß-alanine 26 and phenylalanyl-ß-alanine 25 did not 
display any activity.
Extension of the methylene chain by one carbon between the peptidyl nitrogen 
functionality and the carboxyl group leads to a significant loss of binding affinity, as 
observed with the ß-alanine derivatives 24, 25 and 26 in contrast to the 
corresponding acylglycines 27, 13 and 14. Even in the presence of a hydrophobic 
phenyl or isopropyl substituent, which has been demonstrated above to enhance 
binding affinity with PAM, the derivatives of leucine 26 and phenylalanine 25 
display poorer binding with PAM, at least two to three orders o f magnitude less than 
that observed for the corresponding acylglycines 14 and 13.
These results suggest the enzyme possesses quite tight geometric restrictions for the 
accommodation of compounds in the active site, limiting the degree of the 
modifications that can be made to PAM substrates before a loss of binding affinity 
results. Additionally, the IC50 values also signify the importance of the distance 
between key substrate recognition features like the free carboxyl group, the 
hydrophobic substituent and the amido functionality for maintaining high binding 
affinity with PAM.
Based on the results discussed in this Chapter, compounds designed as potential 
PAM inhibitors discussed in the upcoming Chapters exploit the characteristics that 
have been identified to preserve binding affinity with the enzyme. Such 
characteristics include a hydrophobic substituent like a phenyl or isopropyl group, or 
a copper-binding functional group, like a sulfide, and take into account the 
importance of the geometry of the C-terminal glycine.
27
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Chapter Three
Inhibition o f PAM by exploiting factors affecting 
the stability and ease o f formation o f glycyl 
radicals
3.1 Introduction
Radical stabilisation energies (RSEs) and the relative rates (&reis) at which 
compounds undergo bromination have been incorporated into a method to identify 
potential PAM inhibitors.19 As discussed in Chapter One, RSE values are theoretical 
calculations of the stability of a radical relative to the methyl radical. Irradiation of 
compounds in the presence of a bromine source provides a practical method of 
quantifying the relative ease of formation of the corresponding intermediate 
radicals.19 Previously, conventional bromination reactions were carried out with 
glycine derivatives using A-bromosuccinimide and the RSEs of the corresponding a- 
carbon centred radicals were used to determine the effect of substituents on the 
relative ease of radical formation and the stability of radicals, respectively.48,62
3.2 Impact of 7V-acyl substituents on glycyl radical stability and their 
relative ease of formation
The effects of different A-acyl substituents on the stability of a-carbon centred 
glycyl radicals and the relative ease of formation of the radicals were examined in an 
earlier study.19 Compounds 39 and 40, which possess electron withdrawing 
fluorines, were slower to undergo radical bromination than the corresponding non- 
halogenated analogues 37 and 38 (Table 4).
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Relative rateCompound Relative rate of Compound
of brominationbromination
4 o
Table 4. Relative rates of bromination of amides 37, 38, 39 and 40
As depicted in Table 4, the benzamide 37 was established to be four times more 
reactive than the pentafluorobenzamide 39 in the conversion to the corresponding 
brominated products, while the acetamide 38 was observed to be twenty four times 
more reactive than the trifluoroacetamide 40.
For comparison, the RSE values of the radicals 41 and 42, the intermediates in the 
bromination of the glycine derivatives 38 and 40, were established.19 The RSEs 
were not determined for the TV-benzoyl and the corresponding TV-pentafluorobenzoyl 
systems, as the aryl groups would significantly increase the complexity of the 
calculations.
Radical RSE (kJ m ol1) Radical RSE (kJ m ol1)
0
Me NH IO
(41)
79.1
oA v
o
(42)
69.9
Table 5. RSE values of the radicals 41 and 4219
30
Results and Discussion -  Chapter Three
As observed from the results presented in Table 5, the fluorines of the radical 42 
decrease its RSE by 9.2 kJ mol'1. It follows that the presence of electron
withdrawing groups on the A-acyl substituents reduces the stability of glycyl 
radicals, as well as the relative ease of their formation.
This is reflected in the interactions of analogous systems with PAM (Table 6).
Compound FM,app
(pmol min’1 m g 1)
Compound KM,app
(pmol min' 1 mg'1)
o
■•'Vy"o
(43)
6.4
o
-Ary"0
(44)
1.4
Table 6. Interactions of the glycine derivatives 43 and 44 with PAM19
The trifluoroacetamide 44 is turned over four- to five-fold more slowly than the 
acetamide 43. Thus, the presence of fluorines reduces the stability of glycyl radicals, 
the rates of their formation in bromination experiments, as well as their rates of 
formation through catalysis by PAM. However the effect of the fluorines is 
insufficient to stop enzyme catalysis.
3.3 Effect of substituents at the a-carbon on the stability and 
relative ease of formation of the a-carbon centred radicals
Substitution at the a-carbon also affects the stability and relative ease of formation 
of a-carbon centred amino acid radicals, as well as the interactions of analogous 
compounds with PAM. A trifluoromethyl group at the a-carbon causes a more 
marked reduction in the stability and relative ease of formation of the radicals than 
the presence of the electron withdrawing groups on the A-trifluoroacetyl substituent. 
No detectable bromination was recorded for the trifluoroalanine methyl ester 45, and
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the stability of the trifluoroalanyl radical 46 was determined to be 39.2 kJ mol'1 
lower than that of the corresponding glycyl radical 41.19,62
A study of the analogous compounds 47 and 48 found that neither was processed by 
PAM.19 Thus the trifluoromethyl substituent at the a-carbon sufficiently reduces the 
stability of the amino acid radical to the extent that it prevents bromination from 
taking place, and the radical does not form with PAM, resulting in the inhibition of 
PAM catalysis. However, substitution at the a-carbon with a trifluoromethyl group 
prevents tight binding to the enzyme, as reflected in the IC50 values obtained. IC50 
values of 5 mM and 5 mM were determined for the trifluoroalanine containing 
dipeptides 47 and 48 , compared with the Am values of 1.3 and 0.0079 mM for 
binding of the corresponding glycine derivatives 49 and 13.43 Thus trifluoroalanine 
derivatives are only poor inhibitors of PAM.
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3.4 Inhibition of PAM with glycolic acid derivatives
In a similar manner, the effects on PAM activity brought about by the exchange of 
the C-terminal peptidyl amido group in PAM substrates with an ester were 
established.19 As with the a-trifluoroalanyl system, subjecting the glycolic ester 50 
to conventional bromination reaction conditions did not result in any reaction, while 
comparisons of the RSE values of the glycyl radical 41 versus the glycolyl radical 51 
determined the latter to be 34.7 kJ mol'1 less stable.19
o o
(50) (51)
The reduction in radical stability may be explained by the change in the electro­
chemical properties of the glycolic acid. Replacing the acetamido group with an 
acetoxy group results in an increase in the a-electron withdrawing ability, while 
lowering the 7i-electron donating properties. Comparison of the RSEs of 
MeCONHCfV (41.3 kJ m ol') and MeCC^CfV (17.11 kJ mol'1) supports such an 
observation.19
The relative stability of the glycolyl and corresponding glycyl radicals and the 
relative ease of their formation correlate with the identification of glycolic acid 
derivatives as PAM inhibitors. The inhibition quotients of the glycolyl esters 55, 56, 
57, 58 and 59 are presented in Table 7, but none are processed by the enzyme.
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Acylglycine - /fM,app (mM) Glycolic Acid - K\ or IC5o (mM)
0.0079“ 0.045
0.096 0.060“
0 . 0012“
Table 7. Km, K\ and IC50 values of acylglycines 13, 14, 52, 53 and 54 and glycolyl
esters 55, 56, 57, 58 and 597’19’43
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It is noteworthy that the introduction of the ester functional group does not 
significantly compromise the binding affinity of the glycolic acid derivatives with 
PAM. The IC50 and K\ values of the glycolyl esters 55, 56, 57, 58 and 59 presented 
in Table 7 all fall into the range of 0.04-0.5 mM, while the ArM.app values of the 
corresponding acylglycine derivatives 13, 14, 52, 53 and 54 vary between 0.001-0.1 
mM .7' 19'43
Therefore, replacement of glycine by glycolate prevents catalytic turnover by PAM. 
Furthermore, glycolic acid derivatives retain binding affinity with PAM, comparable 
to that of the corresponding acylglycine derivatives.
3.5 Amino acid based y-keto acids as PAM inhibitors
In my contribution to this work, 19 y-keto acids were explored as a potential class of 
PAM inhibitors. The y-keto acid system is derived from replacing the NH of an 
acylglycine or the ether O of a glycolic acid with a methylene.
The interaction of one y-keto acid, 3-tyrosylalanylpropionic acid with PAM had been 
investigated, however, no substrate or inhibition activity had been observed at the 
highest concentration of the y-keto acid tested.51
The potential of y-keto acids as PAM inhibitors was established by following the 
approach used to identify glycolic acid derivatives as inhibitors of the enzyme, that 
is by evaluating the differences in the stability of radicals and the relative ease at 
which they form in comparison to the corresponding acylglycines.
Substitution of the NH in an acylglycine with a CH2 to give a y-keto acid had similar 
effects on radical stability and relative ease of radical formation as the exchange to 
the ester of the glycolate, as observed from the results of RSE calculations and 
measurements of relative rates of bromination that are presented in Table 8 .
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Compound k r e \ Radical RSE (kJ m ol1)
0
.A ,  / ^ / O M e
P n  NH 1 O
(37)
1.0
0
^ A ^ O M e
M e  NH Io
(41)
79.1
0
P n  O yy
0
(50)
<0.0005
0
M e o yy
0
(51)
44.4
0
0
(60)
<0.0005
o
J L  ^ A .  .O M e
M e ^  y A
O
(61)
34.9
Table 8. Values of kTe\ for bromination of the esters 37, 50 and 60 and the RSE 
values for the corresponding radicals 41, 51 and 61 19
The y-keto ester radical 61 was established to be 44.2 kJ m of1 less stable than the 
analogous glycyl radical 41 based on RSE calculations, and exposure of the ester 60 
to conventional bromination conditions did not result in any reaction. With the 
analytical methods used in the latter experiment, this indicates that the kTe\ for the 
glycolate 50 is < 0.0005 relative to that of the acylglycine 37.
The phenylalanyl and leucyl y-keto acids 62 and 63 were therefore selected for 
investigation with PAM as the presence of a hydrophobic substituent had already 
been proven to increase binding affinity with the enzyme. In addition, the 
interactions with PAM of the analogous glycolyl esters 55 and 56 and acylglycines 
13 and 14 had been reported,7'43 allowing direct comparisons of their activities with 
the enzyme to be made.
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AcHN AcHN
(62) (63)
3.6 Syntheses of y-keto acids 62 and 63
3.6.1 3-(7V-AcetyIleucyl)propionic acid (63)
The reactions used in the synthesis of the propionic acid 63 are shown in Scheme 14.
NaH
'BuOCOCH2Br 
DCM, 0 °C
AcHNAcHN
Scheme 14. Synthesis of 3-(7V-acetylleucyl)propionic acid (63)
The acid 35 was synthesized following general methods previously described.63 The 
successful synthesis of the acid 35 was confirmed by the presence of a singlet 
resonance corresponding to the acetyl protons at 1.98 ppm in the 'H NMR spectrum. 
The synthesis of the malonate 64 was carried out in two steps. First, a solution of the 
acid 35 was treated with l,r-carbonyldiimidazole. The resulting mixture was added 
to a mixture of lithium diisopropylamide (LDA) generated in situ. f-Butyl acetate
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was then added, affording malonate 64. The 'H NMR spectrum of the malonate 64 
displayed resonances at 3.41 ppm and 3.51 ppm corresponding to the diastereotopic 
geminal malonate protons. A mixture of the malonate 64 in dichloromethane was 
treated with /-butyl bromoacetate in the presence of sodium hydride to give the 
diester 65 as a 1:1 mixture of diastereomers. Formation of the diester 65 was 
confirmed by the exhibition of the protonated molecular ion at m/z 386 as the base 
peak in the ESI (+ve) mass spectrum. Hydrolysis and decarboxylation of the diester 
65 was carried out by treatment with trifluoroacetic acid in dichloromethane and 
heating the mixture to reflux, to yield the y-keto acid 63. The ’H NMR spectrum of 
the keto acid 63 lacked any evidence of resonances corresponding to /-butyl ester 
groups, confirming the reaction was successful. The purity of the acid 63 was 
confirmed by elemental analysis. Although a chirally pure starting material was 
used in the synthesis of the y-keto acid 63, the final product was not optically active 
and is expected to exist as a racemic mixture. Racemisation is likely to have 
occurred as a result of the use of strong bases like lithium diisopropylamide and 
sodium hydride during the reaction sequence. However, the nature of the chiral 
centre in the acid 63 is expected to have little consequence on the inhibition of PAM, 
for similar reasons to those discussed earlier in relation to the dipeptide 25.
3.6.2 3-(ALAcetylphenyIalanyI)propionic acid (62)
3-(A-Acetylphenylalanyl)propionic acid (62) was generously prepared by Dr. 
Brendon Barratt,19 employing procedures analogous to those outlined above for the 
synthesis of the corresponding leucine derivative 63.
AcHN
(62)
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3.7 Binding affinity of y-keto acids 63 and 62 with PAM
The IC50 values of the y-keto acids 63 and 62 with PAM were determined following 
the protocol described above, under which there was no evidence that either 
compound was a substrate of the enzyme.
The binding affinities of the acylglycines 14 and 13, glycolic acid derivatives 56 and 
55 and y-keto acids 63 and 62 are presented in Table 9.
C o m p o u n d K m, K\ or  
IC 50 
(m M )
C o m p o u n d K m, K\  or  
IC 50 
(m M )
0  0
0
(14)
0 .0 9 6 7
. X».
O
(13)
0 .0 0 7 9 43
0  0
0
(56)
0 .0 6 0 43
f 0 X
0 .0 4 5 43
I f !
Me X )H
H
O
(63)
6 19
0  0
H
O
(62)
3 19
Table 9. Km values of acylglycines 14 and 13, and K\ and IC50 values of glycolate 
esters 56 and 55 and y-keto acids 63 and 627,19,43
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The y-keto acids 63 and 62 inhibited PAM activity with IC50 values of 6 and 3 mM, 
respectively.
Although y-keto acids inhibit the activity of PAM, they also exhibited the poorest 
binding, based on comparisons with the binding affinities of the corresponding 
acylglycines and glycolic acids. Replacing the NH of an acylglycine with a 
methylene resulted in a greater loss in binding affinity in comparison to substitution 
with an ether O to give a glycolic acid.
The greater binding affinity displayed by the glycolic acid derivatives may be 
attributed to hydrogen bonding interactions between the ether O and the amide of an 
asparagine residue in the enzyme active site. Hydrogen bonding interactions 
between the NH of an acylglycine and an asparagine residue in the active site have 
been documented in a substrate-enzyme crystal structure (Figure l).9 Such 
interactions are not possible with the methylene of y-keto acids.
The reduced binding affinity exhibited by the y-keto acids could also be related to 
their geometry. The NH of an acylglycine and the ether O of a glycolic acid are both 
classified as sp2 hybridised adopting trigonal planar geometry. However, in the 
equivalent position of a y-keto acid, the methylene is sp' hybridized and adopts 
tetrahedral geometry. In addition, both the acylglycines and the glycolic acids have 
free rotation around only the bonds of the oc-carbon whilst there is free rotation 
around the bonds of the a- and ß-carbons of a y-keto acid.
The importance of geometric factors on binding affinity with PAM was already 
established with the ß-alanine dipeptides 25 and 26 discussed in Chapter Two. The 
RSE value of the ß-alanyl radical 66 (38.2 kJ mol'1) had indicated that analogous 
compounds would not be turned over by the enzyme but the dipeptides 25 and 26 did 
not inhibit PAM activity, presumably because their geometry was unsuitable for 
strong binding.
o o
(66)
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In summary, glycolic acid derivatives and y-keto acids were established to be 
inhibitors of PAM based on evaluations carried out comparing the stability and 
relative ease of formation of the corresponding a-carbon centred radicals in the two 
systems, relative to that of an acylglycine. The differences in binding affinities 
observed between the glycolic acid derivatives and the y-keto acids most probably 
highlight the significance of a compound’s geometry in effective binding with the 
enzyme.
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Chapter Four
Examination o f the interactions o f ß-oxa acids 
with PAM
4.1 Introduction
Glycolic acid derivatives have been established to be PAM inhibitors displaying high 
binding affinity. To determine the effect of the absence of the ester carbonyl group 
in glycolic acid derivatives on binding affinity with the enzyme, the interactions of 
ß-oxa acids were examined in the work described in this Chapter.
The phenylalanine, leucine and valine derived ß-oxa acids 67, 68 and 69 were 
selected for investigation as the binding affinities of the corresponding three esters 
55, 56 and 57 were available, as discussed in Chapter Three. This allows for direct 
comparisons to be made.
4.2 Syntheses of the ß-oxa acids 67, 68 and 69
4.2.1 (5)-5-Acetamido-3-oxa-6-phenylhexanoic acid (67)
(5)-5-Acetamido-3-oxa-6-phenylhexanoic acid (67) was synthesized following the 
reaction sequence presented in Scheme 15.
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TFA
DCM
AcHN
Scheme 15. Synthesis of (-S)-5-acetamido-3-oxa-6-phenylhexanoic acid (67)
The reduction of the carboxylic acid 32 to the alcohol 70 was carried out according 
to an established protocol.64 The acid 32 was firstly treated with ethyl chloroformate 
and triethylamine to generate the corresponding acyl chloride, followed by the 
addition of sodium borohydride to complete the reduction process. The melting 
point of the alcohol 70 (99-100 °C) is consistent with the literature value for (S)-N- 
acetylphenylalaninol (100-102 °C).65 The ester 71 was generated from treatment of 
a solution of the alcohol 70 with /-butyl bromoacetate. The high resolution ESI 
(+ve) mass spectrum of the ester 71 presented a peak for the sodiated molecular ion 
at m/z 330.1681. Further evidence for the successful synthesis was provided by the 
singlet resonance at 1.48 ppm observed in the !H NMR spectrum corresponding to 
the nine /-butyl ester protons. Deprotection of the ester 71 was carried out in the 
presence of trifluoroacetic acid to yield the acid 67 which was purified by high 
performance liquid chromatography. A peak corresponding to the deprotonated 
molecular ion was observed at m/z 250.1081 in the high resolution ESI (-ve) mass 
spectrum of the acid 67.
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4.2.2 (S)-5-Acetamido-7-methyl-3-oxaoctanoic acid (68)
(^-S-Acetamido-T-methyl-S-oxaoctanoic acid (68) was prepared following the 
experimental protocol outlined above in the synthesis of the acid 67 (Scheme 16).
Scheme 16. Synthesis of (5')-5-acetamido-7-methyl-3-oxaoctanoic acid (68)
Evidence for the successful preparation of the alcohol 72 was provided by the 
display of the peak of a molecular ion at m/z 160.1334 in the high resolution ESI 
(+ve) mass spectrum. The 'H NMR spectrum of the ester 73 displayed a singlet 
resonance at 1.45 ppm corresponding to the nine protons of the /-butyl group. 
Deprotection of the ester 73 gave the acid 68, which was purified by reverse phase 
high performance liquid chromatography. The characteristic singlet peak 
corresponding to the protons of the /-butyl ester substituent was not observed in the 
’H NMR spectrum of the acid 68, confirming the deprotection reaction was 
successful.
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4.2.3 (iS)-5-Acetamido-6-methyl-3-oxaheptanoic acid (69)
The acid 69 was prepared according to the general method used in the synthesis of 
the acid 67 described above (Scheme 17).
Scheme 17. Synthesis of (S)-5-acetamido-6-methyl-3-oxaheptanoic acid (69)
The acid 75 was generated through the acetylation of (^-valine (74). The 
experimentally obtained melting point of the protected valine 75 is consistent with 
literature data.66 The ESI (+ve) mass spectrum of the alcohol 76 displayed a peak 
corresponding to the protonated molecular ion at m/z 146, confirming the reaction 
was successful. The high resolution ESI (+ve) mass spectrum of the ester 77 
presented a peak for the sodiated molecular ion at m/z 282.1669. Formation of the 
acid 69 was confirmed by a peak at m/z 202.1076 in the high resolution ESI (-ve) 
mass spectrum corresponding to the deprotonated molecular ion.
The melting points recorded for the alcohols 76 and 70 correspond closely to those 
reported in literature, which indicates that isomerisation up to this point in the 
synthetic sequences had not taken place. The ß-oxa acids 67, 68 and 69 and the 
corresponding ester precursors are all assumed to exist as single enantiomers, given 
the literature precedence of compounds prepared under similar experimental 
conditions being established to be homochiral.67 However, no optical rotation
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measurements were carried out on the three ß-oxa acids 67, 68 and 69 as they were 
prepared only in small quantities and further analysis was not considered to be 
warranted.
4.3 Interactions of the ß-oxa acids 67, 68 and 69 with PAM
The PAM binding affinities of the three ß-oxa acids 67, 68 and 69 were investigated 
following the general procedure described earlier. No interaction was observed 
between PAM and the phenylalanyl ß-oxa acid 67 up to highest concentration (16 
mM) tested. The lack o f activity observed must relate to the absence o f the ester 
carbonyl functionality. The ß-oxa acid 67 displayed binding over two orders of 
magnitude less strong than that observed for the equivalent glycolic acid derivative 
55.
Interestingly and unexpectedly, as the concentration o f the ß-oxa acids 68 and 69 in 
the enzyme assay samples increased, the percentage of substrate 22 turned over also 
increased. At concentrations of 1.0, 4.0 and 8.0 mM of the leucyl ß-oxa acid 68, the 
yields of the amidated product 23 were greater by factors of 1.5, 1.6 and 2.4 
respectively, in relation to the sample with no ß-oxa acid 68 present. A more 
marked effect was observed from the results of the assays with the ß-oxa acid 69. 
At concentrations of 1.0, 4.0 and 8.0 mM of the valyl ß-oxa acid 69, the yields of 
the amidated product 23 were greater by factors o f 1.2, 2.5 and 4.1 respectively, 
relative to the sample with no ß-oxa acid 69 present.
The enhanced formation of the amidated product 23 is likely to be a result of an
z:o
activating allosteric effect imposed on the enzyme by the two ß-oxa acids 68 and 
69. These compounds probably induce modifications to the enzyme’s structure and 
as a result the substrate 22 is more readily accommodated.
It is not clear whether the ß-oxa acids 68 and 69 are processed by the enzyme or are 
simply allosteric activators. An RSE value of 67.6 kJ mol'1 was established for the 
radical 78, which is similar in magnitude to the RSE value of the A-trifluoroacetyl
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radical 42 (RSE value 69.9 kJ mol'1). The close proximity of the two values led to 
the assumption that the ß-oxa acids 67, 68 and 69 could be processed as PAM 
substrates, as the AMrifluoroacetyl substituted compound 44 was turned over by the 
enzyme. However, HPLC analysis of the enzyme assay mixtures showed no 
evidence of the reaction of the ß-oxa acids 68 and 69, although this was not 
examined in detail since the main focus of this investigation is the effect of 
compound modifications on binding affinity.
(78)
Nevertheless, the activating effect of the ß-oxa acids 68 and 69 may be useful in 
developing therapies associated with abnormally low hormone levels. A number of 
pathological conditions have been associated with depleted levels of peptide 
hormones,69 including stunted bone growth which has been linked with a deficiency 
in the growth hormone (GH),70 while a shortage in the peptide hormone calcitonin 
has been associated with the pathogenesis of osteoporosis.71 There is continual 
interest in the pharmaceutical industry in developing drug therapies to treat certain 
disease states by replenishing hormone levels.72,73
In summary, the poor binding displayed by the phenylalanyl ß-oxa acid 67 in 
comparison with the analogous glycolic acid derivative 55 highlights the importance 
of the ester carbonyl group in preserving binding affinity with the enzyme. 
However, this disparity in binding affinity was not observed with the other two ß- 
oxa acids. The ß-oxa acids 68 and 69 appeared to act as activators of the enzyme by 
enhancing the release of the amidated product 23. The two acids may be useful 
leads towards the development of therapeutic agents in treating conditions linked 
with hormone deficiencies.
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Chapter Five
a,ß-Unsaturated y-keto acids as PAM inhibitors
5.1 Introduction
The results from the binding studies presented in Chapters Two and Three indicate 
that a compound’s geometry plays a major role in determining its binding affinity 
with PAM. A compound which can closely adopt the conformation desired by the 
enzyme for binding displays overall greater affinity. Glycolic acid derivatives were 
established to be PAM inhibitors, displaying similar binding affinities to the enzyme 
as the analogous acylglycines.
a ,ß-Unsaturated y-keto acids were next selected for investigation to examine the 
effects on binding affinity with the enzyme of compounds which mimic the 
geometries of the amide NH and that of the a-carbon centred radical of natural PAM 
substrates.
Like the NH of an acylglycine or the ether O of a glycolic acid derivative, the
. » 2olefinic carbon in the equivalent position of an a ,ß-unsaturated y-keto acid is sp" 
hybridised. Both acylglycines and glycolic acid derivatives display good binding 
affinity to PAM, presumably because the geometric configurations of the compounds 
closely mimic the configuration desired by the enzyme for tight binding.
The geometry of the olefinic carbon positioned adjacent to the carboxyl group of an 
a ,ß-unsaturated y-keto acid is also sp“ hybridised. It mimics the geometry of the 
radical that normally forms at the a-carbon in systems processed as substrates by the 
enzyme. Given the geometric similarities between the a ,ß-unsaturated y-keto acid 
and the acylglycine systems, it was anticipated that derivatives of the former would 
display tight binding towards PAM.
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An RSE value of -29.5 kJ mol’1 was calculated for the acrylate radical 79. It is by 
108.6 kJ mol'1 less stable than the corresponding acylglycine radical 41, and hence 
such radicals are unlikely to form through catalysis by PAM, indicating that a,ß- 
unsaturated y-keto acids are not likely to be substrates even if they bind to the 
enzyme.
OMe
(79)
The phenyl and isopropyl substituted oc,ß-unsaturated y-keto acids 80 and 81 were 
chosen for examination as the interactions of the analogous glycolic acid derivatives 
55 and 56 and acylglycines 13 and 14 had already been studied, as discussed above, 
thus allowing direct comparisons of the interactions with PAM between the different 
classes of compounds.
AcHN AcHN
(80) (81)
The binding affinity of the acrylic acid 80 with PAM has previously been established 
and a K\ value of 90 pM was determined.74 However, as the enzyme assay 
parameters employed in the earlier investigation differ from those of the current 
study, direct comparisons of the literature results cannot be used to derive any 
correlations with the findings from the present work.
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5.2 Syntheses of the a,ß-unsaturated y-keto acids 80 and 81
5.2.1 (5^£)-5-Acetamido-4-oxo-6-phenylhex-2-enoic acid (80)
The preparation of the acrylic acid 80 proceeded according to the method described
75by Luthman and co-workers (Scheme 18).
Scheme 18. Synthesis of (S^-S-acetamido-T-oxo-ö-phenylhex^-enoic acid (80)
A methanolic solution of the acid 32 was treated with thionyl chloride to give the 
methyl ester 82. The 'H NMR spectral data acquired for the methyl ester 82 is 
consistent with literature information. The phosphonate ester 83 was prepared 
following the reported synthetic protocol.77 The ester 82 was added to a mixture of 
dimethyl methylphosphonate and «-butyl lithium and stirred for 1 hour. The ESI 
(+ve) mass spectrum of the ester 83 presented a peak at m/z 336 corresponding to the 
sodiated molecular ion. /-Butyl glyoxylate 84 was generated in two steps from (S)- 
tartaric acid, following an established method.73 The Homer-Wadsworth Emmons 
(HWE) reaction between the phosphonate ester 83 and the glyoxylate 84 was carried 
out according to a reported procedure.73 The 'H NMR spectrum of the ester 85 
displayed two sets of resonances at 6.70 and 7.02 ppm corresponding to the olefinic
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protons. Further evidence supporting the successful synthesis of the ester 85 was 
observed in the ESI (+ve) mass spectrum in which the peak for the molecular ion 
was displayed at m/z 317. Removal of the r-butyl group from the ester 85 proceeded 
via treatment with trifluoroacetic acid to give the acid 80. The 'H NMR spectral 
information obtained for the acid 80 is consistent with data reported/4
5.2.2 (5'^£)-5-Acetamido-7-methyl-4-oxooct-2-enoic acid (81)
(.S’,£)-5-Acetamido-7-methyl-4-oxooct-2-enoic acid (81) was synthesized following 
the protocol exploited in the preparation of the acrylic acid 80 (Scheme 19).
Scheme 19. Synthesis of (S,iT)-5-acetarnido-7-rnethyl-4-oxooct-2-enoic acid (81)
The 1H NMR spectral information obtained for the methyl ester 86 is consistent with 
previously reported data. Formation of the ester 87 was verified by the display of 
the protonated molecular ion at m/z 280 as the base peak in the ESI (+ve) mass 
spectrum. The 'H NMR spectrum of the ester 88 presented resonances at 6.75 and 
7.07 ppm corresponding to the two olefmic protons. The ]H NMR spectrum of the 
acid 81 did not display any evidence of the singlet resonance corresponding to the
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r-butyl group protons of the ester 88. In addition, the ESI (-ve) mass spectrum of the 
acid 81 displayed a peak for the deprotonated molecular ion at m/z 226.
The acrylic acid 80 was prepared following a literature method used to synthesize 
the identical compound. The compound reported in the literature was established to 
be homochiral.74 It is therefore assumed that the acrylic acid 80 is also homochiral.
In addition, the leucine derivative 81 is assumed to exist as a single enantiomer, as it 
was prepared under similar experimental conditions to the acid 80 . However, no 
optical rotation measurements were conducted on the acrylic acids 80 and 81 as their 
syntheses were performed only on a small scale.
5.3 PAM binding studies with the a,ß-unsaturated y-keto acids 80 
and 81
The binding affinities of the a,ß-unsaturated y-keto acids 80 and 81 were determined 
as per the usual protocol, and the results together with those of the corresponding 
acylglycines 13 and 14 and glycolic acid derivatives 55 and 56 are presented in 
Table 10.
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The cc,ß-unsaturated y-keto acids 80 and 81 inhibited PAM activity with IC50 values 
of 0.0007 and 0.642 mM, respectively. Although the binding affinity of the acrylic 
acid 80 had previously been reported, the enzyme assay conditions under which the 
binding values were determined differ from those used in the current binding studies, 
which prevents correlations of the results from the reported work with those 
collected in this study.
The acrylic acid 80 displayed binding affinity one to two orders of magnitude higher 
than that observed with the corresponding acylglycine 13 and glycolic acid 
derivative 55. The enhanced binding effect could be associated with the geometry 
of the olefinic carbon adjacent to the carboxyl group in the acrylic acid 80, which 
resembles the geometry of the a-carbon centred radical formed from the 
corresponding substrate 13 during PAM catalysis.
Alternatively, the greater binding affinity displayed by the acid 80 might not simply 
be as a result of competitive inhibition. In the literature report of its interactions 
with PAM, the acid 80 was established to be a time-dependent inactivator of the 
enzyme.14 The mechanism of inactivation was suggested to proceed via epoxide 
intermediates.42
In any event the enhanced binding affinity cannot be generalised to other a,ß- 
unsaturated y-keto acids, as the leucine derivative 81 exhibited binding affinity 
around one order of magnitude lower than that observed for the corresponding 
acylglycine 14 and glycolic acid derivative 56.
Given the complexity of factors contributing towards the binding affinity of the a,ß- 
unsaturated y-keto acids 80 and 81 with PAM, and the poor binding observed with 
the leucine derived acrylic acid 81, no further investigations with a,ß-unsaturated y- 
keto acids were conducted since more promising results were obtained with an 
alternative class of compounds, as discussed in the next Chapter.
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Chapter Six
Examination o f amino acid based PBA analogues 
as mechanism based PAM inhibitors
6.1 Introduction
As discussed in the Introduction of this thesis, (£)-4-phenyl-3-butenoic acid (PBA) 
(1) has been established to be a suicide substrate of PAM, with a determined K\ 
value of 0.001 mM.28
( 1)
The suggested mechanism of inhibition presented in Scheme 5 proceeds through 
hydrogen atom transfer from the a-carbon to give a delocalised radical resulting in 
termination of the enzyme’s activity.
Theoretical calculations established an RSE value of 100.2 kJ mol’1 for thepropenyl 
radical.
(89)
The propenyl radical 89 is by 21.1 kJ m of1 more stable than the corresponding 
acetamido radical 41 and hence is likely to form. This observation supports the 
mechanism of PAM inhibition by PBA (1) discussed above.
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The interactions of a number of compounds designed to exploit the PBA (1) 
mechanism of enzyme inhibition have also been reported. An IC50 value of 0.4 mM 
was recorded for the tripeptide 90,27 while the tripeptides 91 and 92 were both 
established to inhibit PAM activity, with determined K\ values of 0.020 and > 5 mM, 
respectively.79
Ph
(91) (92)
Although the presence of a hydrophobic substituent has been established to retain 
binding affinity with PAM, in the instance of the tripeptide 90, the position of the 
phenyl substituent near the carboxyl group hindered tight binding. This is in contrast 
to the styryl group of PBA (1), which is suggested to adopt a conformation and 
occupy a position normally reserved for a substrate of PAM, thus preserving binding
97affinity with the enzyme.
The tripeptide 92 was found to be a poor inhibitor of the enzyme. The cyclopropyl 
substituent may have been too sterically demanding to be tolerated by the enzyme 
active site.79
To explore the effect on enzyme inhibition of amino acid based PBA analogues, the 
rra«5-ß,y-unsaturated acids 93 and 94 were selected for investigation.
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BocHN
(93)
BocHN OH
(94)
The basis of the design of the rra«s-ß,y-unsaturated acids shown above was to 
combine two features which are now recognised to retain binding affinity and inhibit 
the activity of PAM. The incorporation of hydrophobic substituents, like a phenyl or 
isopropyl group, has been shown to preserve binding affinity, while the PBA (1) 
system has been proven to effectively inhibit enzyme activity.
In addition to the reasons described above, justifying the selection of the acids 93 
and 94 for investigation, the inhibition constants of the corresponding glycolic acid 
derivatives 55 and 56 are discussed above, thus allowing comparisons of the 
inhibitory effects on PAM by the two classes of compounds.
6.2 Syntheses of the fra/is-ß,y-unsaturated acids 93 and 94
6.2.1 Attempted preparations of the tra/w-ß,y-unsaturated acids 102 and 109
The preparation of the A^-(r-butoxycarbonyl)-substituted fr^ms-ß^-unsaturated acid 
93 has previously been reported.80 The compound 93 was prepared as an 
intermediate in the synthesis of renin inhibitors. The activity of the unsaturated acid 
93 with PAM was not examined in the literature report. The acid 93 was prepared 
following the reaction sequence illustrated in Scheme 20.
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BocHN
di-f-butyl dicarbonate
NaOH
THF/H20
(S)-Phenylalanine r  i1(31) (i) cyclohexene, 
O 1MBH3. THF
B o cH N ^
(ii) MeOH, 2M NaOH 
OH 30% H20 2
(93)
Ph3PH2C C = C S iM e3Br (99) 
"BuLi
THF, -78 °C
BocHN
Scheme 20. Synthesis of (.S,£)-5-[iV-(r-butoxycarbonylarnino)]-6-phenylhex-3-enoic
acid (93)
An attempt was made to prepare the corresponding A-acetylated unsaturated acid 
102 following the reaction scheme outlined above, as the analogous acylglycine 13 
and glycolic acid derivative 55 were prepared as the A-acetylated compounds. The 
reaction sequence towards the acid 102 is outlined in Scheme 21.
Scheme 21. Towards the synthesis o f the A-acetylated acid 102
The Weinreb amide 101 was prepared from a coupling reaction o f the acid 32 with 
the amine 96 using BOP. The 'H NMR spectrum of the amide 101 displayed 
resonances at 3.17 and 3.67 ppm, corresponding to the protons of the A-methylamide 
and A-methoxy functionalities, respectively. However, due to the low yields of
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around 30 percent obtained for the amide 101, an attempt was then made to prepare 
the 7V-benzoylated unsaturated acid 109 following the same experimental protocol. 
It was anticipated that the benzoyl derivatives would be easier to handle. The 
synthetic pathway attempted is depicted in Scheme 22.
BzHN
Scheme 22. Towards the synthesis of the 7V-benzoylated acid 109
The amine 103 was converted to the amide 104 in a Schotten-Baumann reaction. ’ 
Formation of the amide 104 was confirmed by the presence of resonances between 
7.10-7.73 ppm in the ]H NMR spectrum. Deprotection of the ester 104 with lithium 
hydroxide gave the acid 105. The melting point obtained for the acid 105 is 
consistent with reported data.83 Next, the BOP coupling reaction between the acid
105 and N, O-dimethylhydroxylamine (96) was carried out. The 'H NMR spectrum 
of the Weinreb amide 106 displayed singlet resonances at 3.21 and 3.74 ppm, which 
correspond to the protons of the TV-methylamide and N-methoxy functionalities, 
respectively. The aldehyde 107 was generated through the reduction of the amide
106 with lithium aluminum hydride following established procedures.84 The 'H
85NMR spectrum of the aldehyde 107 displayed peaks consistent with the literature. 
The phosphonium bromide salt 99 was synthesized from triphenylphosphine and
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3-(trimethylsilyl)propargyl bromide. The recorded melting point of the bromide salt 
99 is consistent with literature values.86 Next, the Wittig reaction between the 
aldehyde 107 and the phosphonium salt 99 in the presence of «-butyl lithium was 
attempted. The trimethylsilyl intermediate 108 was isolated as a 2.5:1 mixture with 
the Z-isomer. A peak for the molecular ion was observed at m/z 347.1709 in the 
electron impact (El) mass spectrum of the intermediate 108. The mixture was then 
subjected to a hydroboration reaction, in the presence of a mixture of cyclohexene 
and 1 M borane-tetrahydrofuran complex.
The hydroboration reaction was carried out on 70 milligrams of a 2.5:1 mixture of 
the intermediate 108 and the Z-isomer. The 'H NMR spectrum of the crude product 
mixture indicated the presence of the unreacted starting material 108 in addition to a 
large amount of impurities. The presence of the impurities made the recovery of the 
starting material from the reaction mixture difficult. A number of factors may have 
contributed towards the failed attempt to prepare the acid 109, including the small 
scale on which the reaction was carried out and the sensitivity of the reagents in the 
reaction to water.
In addition, the reactions to give the aldehyde 107 and the amide 106 were low 
yielding and the two compounds were prepared in less than 50 percent isolated 
yields, which adversely affected the subsequent synthesis of the intermediate 108 
and the acid 109. Given the unfavourable elements in the syntheses of the N- 
acetylated and A-benzoylated ^ra«5-ß,y-unsaturated acids 102 and 109, a decision 
was made to focus on the preparation of the vV-(t-butoxycarbonyl)-substituted 
analogue 93, as its synthesis had previously been reported, as discussed above. In 
addition to the synthetic sequence towards the acid 93 outlined in Scheme 20, the 
acid had also been prepared via an alternative pathway.87 The key step in the 
reported alternative synthetic sequence to give the acid 93 is outlined in Scheme 23.
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(HO) (111) (112)
I Jones' Oxidation
t
BocHN
Scheme 23. Julia reaction of the sulfone 110 and the aldehyde 111 to give the
alcohol 112
The synthesis of the key intermediate sulfone 110 from the acid 95 is depicted in 
Scheme 24.
PhSH, NaOMe 
THF, 50 °C
m-CPBA 
DCM, 0 °C
( 110) (115)
Scheme 24. Synthesis of (S)-2-[W-/-butoxycarbonylamino)]-3-phenyl-l- 
(phenylsulfonyl)propane (110)
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The acid 95 was reduced to the alcohol 113 following the established experimental 
protocol.64 The !H NMR spectrum of the alcohol 113 displayed two sets of 
resonances located between 3.52-3.58 and 3.65-3.69 ppm, associated with the two 
protons located on the carbon adjacent to the hydroxyl functionality. Next, the 
newly furnished alcohol 113 was stirred in a mixture of triethylamine and 
methansulfonyl chloride at 0 °C to yield the mesylate 114. The 'H NMR data
oo
obtained for the mesylate 114 is consistent with reported data. The mesylate 114 
was then converted to the sulfide 115 following a literature method.64 The ESI 
(+ve) mass spectrum of the sulfide 115 displayed a peak for the protonated 
molecular ion at m/z 344. The sulfide 115 was then oxidised to the corresponding 
sulfone 110 through the use of 3-chloroperoxybenzoic acid. The melting point 
recorded for the sulfone 110 is consistent with the reported value.64
The monosilylated aldehyde 111 was prepared from the diol 116 following literature 
procedures.89 Oxidation of the monosilylated diol 117 under Swem conditions gave 
the aldehyde 111 (Scheme 25).
(116)
TBDMSCI
Im idazole
DMF, -25 °C
TBDMSO
Sw ern O xidation
H
(117) ( 111)
Scheme 25. Synthesis of 3-[(?-butyldimethylsilyl)oxy]propanal (111)
The Julia reaction to couple the sulfone 110 with the aldehyde 111 was attempted
OQ
according to the literature procedure presented in Scheme 23.
The ]H NMR spectrum of the crude product mixture indicated the presence of a 
large amount of impurities. The spectrum also only indicated the presence of a 
negligible amount of the alcohol 112, as signified by the magnitude of the 
resonances observed in the region of the spectrum where the signals of the olefinic 
protons of the Julia reaction product were expected, relative to the other signals. In 
addition, the Julia reaction was only performed on a small scale of 100 milligrams of 
the starting materials 110 and aldehyde 111, which would have made the isolation of 
20 milligrams of the acid 93 necessary for conducting enzyme assays and compound
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characterisation unfeasible. Given the undesirable outcomes in the synthesis o f the 
acid 93 via the synthetic route described above, an attempt was then made to prepare 
the acid 93 following the original literature synthesis80 o f the same compound 
depicted earlier in Scheme 20.
6.2.2 (5'^)-5-[AL(/-Butoxycarbonylamino)l-6-phenylhex-3-enoic acid (93)
Finally, the 7V-/-butoxycarbonyl-protected /rö«s-ß,y-unsaturated acid 93 was 
successfully synthesized following the experimental protocol described by 
Kaltenbronn et ö/.80 (Scheme 20).
The acid 95 was prepared from treating a solution of (S)-phenylalanine (31) with di- 
r-butyl dicarbonate. A peak corresponding to the deprotonated molecular ion was 
observed at m/z 264 in the ESI (-ve) mass spectrum of the acid 95. Next, the 
Weinreb amide 97 was synthesized through a BOP coupling reaction between the 
acid 95 and N, O-dimethylhydroxylamine (96). The 'H NMR spectrum of the amide 
97 displayed characteristic resonances that correspond well with reported 
information.8a Reduction of the amide 97 with lithium aluminium hydride yielded 
the aldehyde 98. The ]H NMR spectral information obtained for the aldehyde 98 is 
consistent with literature data.90 The aldehyde 98 was added to a mixture o f the 
phosphonium bromide salt 99 and «-butyl lithium at -78 °C to give the intermediate 
100. The 'H NMR spectrum of the trimethylsilyl intermediate 100 displayed 
resonances consistent with literature records.91 Hydroboration o f the intermediate 
100 was carried out according to the procedure described by Kaltenbronn et al. 
The deprotonated molecular ion was displayed as a peak at m/z 304.1554 in the high 
resolution ESI (-ve) mass spectrum of the acid 93.
The acid 93 was prepared on a larger scale to that used with the A-benzoylated and 
A-acetylated acids 109 and 102, which facilitated the isolation o f sufficient 
quantities. The intermediate compounds in the synthetic sequence of the acid 93 
were also generally synthesized in higher yields than the intermediates prepared in 
the syntheses o f the acids 109 and 102.
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6.2.3 (5'^£)-5-[Ar-(f-ButoxycarbonyIamino)]-7-methyloct-3-enoic acid (94)
The acid 94 was prepared following the literature protocol used to synthesize the 
same compound.92 In the reported synthesis of the J-butoxycarbonyl-protected acid 
94, the acid was coupled with a dipeptide and the inhibitory activity of the resultant 
product with renin was investigated. The interaction of the acid 94 with PAM was 
not studied in that investigation. The literature synthesis of the acid 94 proceeded in 
a similar manner to the reported synthesis of the phenylalanine derivative 93 and is 
depicted in Scheme 26.80
BocHN
(118) (119) ( 120)
di-f-butyl dicarbonate
NaOH
THF/H20
Ph3PH2CC==CSiM e3Br (99) 
"BuLi
THF, -78 °C
Scheme 26. Synthesis of (tS’,£)-5-[A-(/-butoxycarbonylamino)]-7-methyloct-3-enoic
acid (94)
The DCC coupling reaction between the acid 118 and the amine 96 gave the 
Weinreb amide 119. The 'H NMR spectrum of the amide 119 displayed resonances 
which correspond well to data reported in literature.93 Conversion of the amide 119 
to the aldehyde 120 was carried out following the previously established 
experimental protocol.94 The ESI (+ve) mass spectrum of the aldehyde 120 
exhibited a peak corresponding to the protonated molecular ion at m/z 216. The 
Wittig reaction between the aldehyde 120 and the phosphonium salt 99 was carried
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out according to the procedure described by Johnson.92 The high resolution ESI 
(+ve) mass spectrum of the intermediate 121 presented a peak at m/z 332.2016 for 
the sodiated molecular ion. Hydroboration of the trimethylsilyl intermediate 121 to 
the acid 94 was carried out according to literature protocol.80 The ]H NMR spectrum
09obtained for the acid 94 displayed resonances consistent with reported data. 
Further evidence for the successful synthesis of the acid 94 was provided by the 
display of a peak at m/z 270 for the deprotonated molecular ion in the ESI (-ve) mass 
spectrum.
The acid 93 is reported to be homochiral. ’ Since the synthesis of the leucyl 
derivative 94 was carried out under similar experimental conditions to those used to 
prepare the acid 93, coupled with the measured optical rotation value of -20.6°, it is 
also assumed to be a single enantiomer.
6.3 Interactions of the unsaturated acids 93 and 94 with PAM
The IC50 values of the two ?ra«s-ß,y-unsaturated acids 93 and 94 with PAM were 
determined according to the method described in Chapter Two, and together with 
those of the corresponding glycolic acid derivatives 55 and 56, and the Km values of 
the analogous acylglycines 13 and 14 are provided in Table 11.
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An IC50 value of 0.0026 mM was determined for the phenylalanyl trans-ß,y- 
unsaturated acid 93. The corresponding leucyl derivative 94 displayed an IC50 value 
of 0.0015 mM.
The acids 93 and 94 are more effective at inhibiting PAM activity than the 
corresponding glycolic acid derivatives 55 and 56, by over an order of magnitude.
As discussed in Chapter One, with respect to compounds which undergo competitive 
inhibition, an IC50 value provides a good preliminary approximation of the K\ value. 
However, inhibition of PAM by the olefinic acids 93 and 94 is likely to proceed in a 
similar manner to that proposed for (£)-4-phenyl-3-butenoic acid (PBA) (1), which 
has been established as an irreversible inactivator of the enzyme," and thus the IC50 
values of the acids 93 and 94 do not compare so directly with the K\ value obtained 
for PBA (1) to establish relative potency. Nevertheless, the IC50 values obtained for 
the two /rafts-ß,y-unsaturated acid 93 and 94 indicate that the compounds are potent 
inhibitors of PAM.
In order to determine the mode of PAM inhibition displayed by the trans-ß,y- 
unsaturated acids 93 and 94, the K\ values of the two compounds will need to be 
determined. It is however extremely costly to establish this type of inhibition as a 
large amount of enzyme is required. An individual assay will cost several thousands 
of dollars to perform, therefore, K\ determinations of the acids 93 and 94 were not 
carried out.
Given the effective inhibition of PAM displayed by the olefinic acids 93 and 94, 
derivatives of the /rafts-ß,y-unsaturated acids may be useful in the development of 
therapeutic agents to treat disease states associated with the over production of 
peptide hormones. Incorporation of a /rafts-ß,y-unsaturated acid into peptidic 
systems which resemble specific peptide prohormones would give compounds that 
could interfere with the catalysis of the particular prohormones by the enzyme. The 
peptide analogues of the /rafts-ß,y-unsaturated acids are expected to display potent 
inhibition of the catalysis of the corresponding peptide prohormones by PAM.
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To summarise, the combination of a hydrophobic substituent which has been shown 
to preserve binding affinity with PAM, incorporated in a rra«5-ß,y-unsaturated acid, 
produced two compounds 93 and 94 that displayed effective enzyme inhibition. 
The Pratts-ß,y-unsaturated acids 93 and 94 are by far the most effective PAM 
inhibitors of all the compounds studied thus far as part of the research work 
conducted for this thesis.
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Chapter Seven
Evaluation o f the effect o f methionine based 
compounds on PAM binding affinity in 
comparison with the analogous leucine derivatives
7.1 Introduction
In Chapter Two, the interaction of 6-methylthiohexanoic acid (17) with PAM was 
investigated. The acid 17 was identified as a PAM inhibitor and the incorporation of 
a sulfur-containing group was established to preserve binding affinity with the 
enzyme. The high binding affinity displayed by the sulfide 17 may be a result of the 
sulfur coordinating with a copper of the enzyme.
The availability of the copper is necessary for maintaining normal PAM 
activity.10’95,96 Coordination to the copper renders it unavailable, and consequently 
PAM activity is inhibited.
The incorporation of a copper binding substituent enhances binding affinity with 
PAM and at the same time inhibits the activity of the enzyme.
The interactions of a number of inhibitors designed to exploit PAM’s dependence on 
the presence of copper have been documented. All of the compounds possess a 
substituent aimed at binding with the enzyme’s copper. Examples of the inhibitors 
include the therapeutic agents captopril (2), thiorphan (4) and tiopronin (5) discussed 
in Section 1.4.
In addition, the tripeptides Gly-Cys-Gly and Gly-Met-Gly were found to be effective 
at inhibiting PAM activity, with established K\ values of 0.0031 and 0.023 mM, 
respectively/1 As with the other sulfur containing compounds discussed above, the
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mechanism of PAM inhibition by the tripeptides is likely to involve binding with the 
enzyme’s copper.
To establish the mode of binding of methionine containing compounds to the 
enzyme, and to determine whether the binding affinity of the copper coordinating 
compounds is affected by the same factors as the corresponding analogues derived 
from non-copper binding amino acids, the interactions with PAM of the leucine 
derivatives 14, 122 and 56 and the corresponding methionine analogues 123, 124 
and 125 were studied.
The incorporation of a hydrophobic moiety has been established to retain high 
binding affinity with PAM, as discussed in Chapter Two. The binding affinities of 
the dipeptide 14 and the glycolic acid derivative 56 with PAM have previously been 
reported.7,43 The two compounds displayed similar binding affinities with the 
enzyme, presumably due to the similarities in the geometric configurations adopted 
by the compounds, which are desired by the enzyme for tight binding.
It was envisaged that the dipeptide 122 would exhibit poor binding affinity, as 
substituents at the a-carbon have been established to disrupt binding with PAM, as 
observed with the trifluoroalanine containing dipeptides 47 and 48 discussed in 
Chapter Three. To contrast the binding affinity of the leucyl dipeptide 122 with the 
corresponding methionyl derivative, the dipeptide 124 was selected for examination.
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As mentioned in Chapter Two, the methionylglycine 12 has been established as an 
inhibitor of PAM.52 However, as binding affinity of the dipeptide 12 with the 
enzyme was not determined in the earlier work, the interaction of the dipeptide 123 
with PAM was re-examined as part of the work for this Chapter.
The acid 125 encompasses both a glycolic acid functionality as well as a thio ether 
side chain from methionine, which have both been established to preserve binding 
affinity with PAM. It was anticipated that the two features might act in a 
complementary fashion, thus the acid 125 would display particularly high binding 
affinity with the enzyme.
7.2 Syntheses of the methionine based compounds 123,124 and 125
7.2.1 (5)-A-Acetylmethionylglycine (123)
The dipeptide 123 was prepared according to the reaction sequence outlined in 
Scheme 27.
Ac20 , Et3N
h 2o
LiOH
THF/H20
(S)-Methionine
(126)
AcHN
Scheme 27. Synthesis of (5)-A-acetylmethionylglycine (123)
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The acid 127 was prepared from (^-methionine 126, using acetic anhydride. The 
resonances in the ’H NMR spectrum of the acid 127 are consistent with those 
reported in the literature.97 A mixture of the ester 128 and the acid 127 in 
dichloromethane was treated with triethylamine followed by the addition of l-[(3- 
dimethylamino)propyl]-3-ethylcarbodiimide (EDC) hydrochloride and the resulting 
mixture was stirred overnight. Formation of the ester 129 was verified by the 
exhibition of the peak for the sodiated molecular ion at m/z 285 in the ESI (+ve) 
mass spectrum. Saponification of the ester 129 with lithium hydroxide yielded the 
acid 123. Microanalysis of the dipeptide 123 confirmed the purity of the compound.
7.2.2 (S^)-A-Acetylniethionylalanine (124)
The synthetic pathway employed in the preparation of the dipeptide 124 is outlined 
in Scheme 28.
SOCI2
MeOH
LiOH
THF/H20
(R)-Alanine
(130)
AcHN
Scheme 28. Synthesis of (5',^)-A-acetylmethionylalanine (124)
The acid 127 was prepared as per above. The methyl ester 131 was successfully 
prepared from treating a methanolic solution of the amino acid 130 with thionyl 
chloride. Formation of the methyl ester 131 was confirmed by the singlet resonance
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observed in the ’H NMR spectrum at 3.81 ppm, which corresponds to the three 
protons of the methyl ester group. The coupling reaction between the acid 127 and 
the methyl ester 131 was carried out using BOP. A peak corresponding to the 
molecular ion was observed at m/z 276.1145 in the high resolution El mass spectrum 
of the ester 132. Saponification of the ester 132 using lithium hydroxide gave the 
acid 124. The !H NMR spectrum obtained for the acid 124 matches the reported 
data.98 The high resolution El mass spectrum displayed a peak corresponding to the 
molecular ion at m/z 262.0987, confirming the formation of the acid 124.
Only one set of resonances was observed in the ]H NMR spectrum of the dipeptide 
124, which confirmed the absence of diastereomers. This, together with the optical 
rotation value of -12.0° recorded for the dipeptide 124 is the basis of the assumption 
that it is present as a single stereoisomer.
An optical rotation value of -3.8° was recorded for the dipeptide 123, it is therefore 
also assumed to be homochiral.
7.2.3 (^-(^“-(A-AcetylmethionyOglycoIic acid (125)
The glycolic acid derivative 125 was synthesized as illustrated in Scheme 29.
Scheme 29. Synthesis of (S)-Ou-(A-acetylmethionyl)glycolic acid (125)
The acid 127 was prepared following the experimental protocol described earlier in 
this Chapter. A mixture of the acid 127 and f-butyl bromoacetate was heated at 
reflux and stirred overnight to give the ester 133. The ESI (+ve) mass spectrum of
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the ester 133 displayed the sodiated molecular ion at m/z 328 as the base peak. The 
deprotection of the ester 133 was carried out with trifluoroacetic acid. The singlet 
resonance corresponding to the /-butyl protons of the ester 133 was not present in the 
!H NMR spectrum of the acid 125, indicating the reaction was successful.
An optical rotation of -63.8° was obtained for the acid 125; it is therefore assumed 
to be present as a single enantiomer.
7.3 Synthesis of the leucylalanine dipeptide 122
7.3.1 (S^-TV-Acetylleucylalanine (122)
fSV/^-TV-Acetylleucylalanine (122) was synthesized following the experimental 
protocol used to prepare the dipeptide 124 (Scheme 30).
Scheme 30. Synthesis of (iS,Ä)-A-acetylleucylalanine (122)
The acid 35 was prepared following the experimental procedures described in 
Chapter Two and the methyl ester 131 was prepared according to the protocol 
described earlier in this Chapter. The coupling reaction between the amine 131 and
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the acid 35 was carried out using BOP. The high resolution ESI (+ve) mass 
spectrum of the ester 134 exhibited a peak at m/z 281.1469 corresponding to the 
sodiated molecular ion. Saponification of the ester 134 was carried out in the 
presence of lithium hydroxide. The ESI (+ve) mass spectrum of the acid 122 
presented the sodiated molecular ion at m/z 267 as the base peak.
Only one set of resonances was observed in the 'H NMR spectrum of the dipeptide 
122, indicating the absence of diastereomers. Furthermore, an optical rotation value 
of - 44 . 8°  was recorded for the acid 122, leading to the assumption that it is 
homochiral.
7.4 PAM binding affinities of compounds 123,124,125 and 122
The binding affinities of compounds 123, 124, 125 and 122 with PAM were 
established according to the protocol described in Chapter Two. The results from 
these binding studies, together with the IC50 values o f the acids 17 and 16, the KM 
value of the dipeptide 14 and the K\ value of the leucylglycolic acid 56 are presented 
in Table 12.
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The dipeptide 123 inhibited PAM activity with an IC50 value of 0.03 mM. The 
dipeptide 123 displayed similar binding affinity to PAM as the analogous leucyl 
dipeptide 14. The corresponding thio ether 17 also displayed similar binding affinity 
to the enzyme as its acid analogue 16.
The similarities in binding affinities observed with the acylglycines 123 and 14, and 
the acids 17 and 16 suggest that the mode of binding of compounds with a copper 
coordinating group to PAM may be similar to that of the corresponding compounds 
which lack the copper binding feature but have a hydrophobic group.
An IC50 value of 0.2 mM was recorded for the dipeptide 124, while the 
corresponding leucyl dipeptide 122 did not display any activity. The a-alkylated 
dipeptides 124 and 122 displayed poorer binding affinity to PAM than the 
corresponding unsubstituted dipeptides 123 and 14, respectively. This was the 
expected outcome, as substituents at the a-carbon of glycine-based substrates have 
been determined to disrupt binding with the enzyme."
However, the methionyl dipeptide 124 displayed binding affinity that was greater by 
over an order of magnitude than that observed with the leucyl derivative 122. This 
result is inconsistent with the similarities in binding affinities observed with the 
acylglycines and the acids discussed above. The disparity in binding between the 
dipeptides 124 and 122 indicates that the binding affinity of a compound with a 
copper coordinating substituent is not always affected to the same extent as the 
corresponding compound possessing a hydrophobic group, in the presence of another 
factor which has been established to disrupt binding.
The binding study results for the a-alkylated dipeptides 124 and 122 also suggest 
that the mode of binding to PAM of the methionine-containing compounds might 
differ in some ways to that of the analogous compounds derived from non copper­
binding amino acids. The key interaction between the methionine containing 
compounds with PAM is suggested to be through coordination with the copper in the 
active site.
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The glycolic acid derivative 125 was expected to exhibit high binding affinity with 
PAM as it incorporates two features which have been established to maintain high 
binding affinity with the enzyme. It was proposed that the glycolic acid 
functionality, together with the thio ether ligand could act in a synergistic manner to 
give a compound which would display tight binding to the enzyme. Unfortunately 
this was not the case.
The methionylglycolic acid derivative 125 displayed binding affinity that was by 
over an order of magnitude poorer than that observed with the corresponding 
acylglycine 123. In contrast, the leucine derivative 56 displayed similar binding 
affinity to PAM as the analogous acylglycine 14.
The reduced binding affinity displayed by the acid 125 is likely to be associated with 
the arrangement of the compound’s functional groups with respect to the key 
recognition points in the active site, which may be preventing tight binding.
In summary, the methionyl dipeptides 123 and 124 displayed higher binding affinity 
with PAM that the analogous leucyl derivatives 14 and 122, respectively, which 
highlights the significance of the thio ether functional group for maintaining binding 
affinity with the enzyme. In the case of the glycolic acid derivative 125, the poor 
binding affinity displayed could be due to the arrangement of its functional groups 
within the active site, which may not be ideal for tight binding with PAM. Given the 
overall positive binding study results obtained for the compounds possessing a 
copper coordinating functional group examined as part of the research conducted for 
this Chapter, compounds discussed in the next Chapter of this thesis also possess a 
copper-binding substituent.
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Chapter Eight
Investigation o f the effect o f
and 1,3-diaminopropanesubstituted amino acids
on interactions with PAM
8.1 Introduction
The incorporation of a copper coordinating substituent has been established to 
preserve binding affinity with PAM as observed with the sulfur containing 
compounds discussed in Chapter Seven. In order to determine the effect of amino 
acid derivatives bearing 1,2-diaminoethane and 1,3-diaminopropane groups, which 
have been well established to form complexes with copper,100' 104 the interactions of 
the two diamines 135 and 136 with the enzyme were explored.
It was envisaged that the 1,2-diaminoethane moiety of the diamine 135 and the 1,3- 
diaminopropane ligand of the diamine 136 would coordinate with the copper in the 
PAM active site, thus inhibiting the enzyme’s activity.
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8.2 Syntheses of the diamines 135 and 136
8.2.1 (5)-Ar2-BenzyIoxycarbonyl-2,6-diamino-4-azahexanoic acid (135)
The key steps in the synthesis of the azahexanoic acid 135 are outlined in Scheme 
31.
LiOH
t h f /h2o
Scheme 31. Synthesis of (^-A^-benzyloxycarbonyl^ö-diamino-T-azahexanoic acid
(135)
The ester 139 was prepared following the reported synthesis of the same 
compound.105 Preparation of the first of the two key components in the synthesis of 
the ester 139 is depicted in Scheme 32.
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(141) (142) (143)
SOCI2
MeOH
CbzNH
Scheme 32. Synthesis of methyl (£)-7V'-benzyloxycarbonyl-2,3-diaminopropionate
(137)
A mixture of the amino acid 141 in a sodium bicarbonate solution was treated with 
benzyl chloroformate. A multiplet resonance corresponding to the five aromatic 
protons was observed between 7.14-7.36 ppm in the 'H NMR spectrum of the acid 
142. The conversion of the acid 142 to the amine 143 proceeded through treatment 
with diacetoxyiodobenzene. A peak corresponding to the protonated molecular ion 
was observed at m/z 239 in the ESI (+ve) mass spectrum of the amine 143. 
Treatment of a methanolic solution of the amine 143 with thionyl chloride gave the 
ester 137. The melting point obtained for the ester 137 is consistent with the 
reported data.105
Next, the second key component in the synthesis of the ester 139, the aldehyde 138, 
was prepared. An initial attempt was made to synthesize the aldehyde 138 from the 
aminoethanol 144 (Scheme 33).
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di-f-butyl dicarbonate oxalyl chloride
O
(144) (145) (138)
Scheme 33. Attempted synthesis of the aldehyde 138 from the alcohol 144
The amine 144 was treated with di-?-butyl dicarbonate to give the carbamate 145. 
The !H NMR spectrum of the carbamate 145 displayed resonances consistent with 
the literature data.106 Attempts were made to oxidise the alcohol 145 under Swem 
oxidation conditions. The !H NMR spectra of the crude product mixtures did not 
display the characteristic singlet resonance corresponding to the aldehyde proton, 
indicating the oxidation reactions were not successful. Given that several 
unsuccessful attempts were made to prepare the glycinal 138 via the synthetic 
pathway described above, an alternative route for the synthesis of the glycinal 138 
was identified and tried.
The aldehyde 138 was successfully prepared from glycine 146 as illustrated in 
Scheme 34.
di-f-butyl dicarbonate 
THF/1M NaOH
HN.
/
\
,OMe
(146) (147) (96)
DCC, DMAP 
Et3N
DCM
OMe
O
(148)
u a ih 4
THF, 0 °C
(138)
Scheme 34. Synthesis of A-(/-butoxycarbonyl)glycinal (138)
The carbamate 147 was successfully prepared from the amine 146 following 
treatment with di-^-butyl dicarbonate. The !H NMR spectral data obtained for the
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acid 147 is consistent with the literature records.107 The Weinreb amide 148 was 
generated from a coupling reaction between the acid 147 and the amine 96 using 
A,A’-dicyclohexylcarbodiimide. The !H NMR spectrum of the amide 148 displayed 
two singlet resonances at 3.20 and 3.71 ppm, corresponding to the A-methyl and N- 
methoxy protons, respectively. Following the established experimental protocol, 
reduction of the Weinreb amide 148 with lithium aluminium hydride gave the 
aldehyde 138.94 The ’H NMR spectrum of the aldehyde 138 displayed resonances 
consistent with the literature data.94
Next, an attempt was made to prepare the azahexanoic acid 135 following the 
method outlined earlier in Scheme 31.
A mixture of the glycinal 138 and the methyl ester 137 in a solution of 1% acetic 
acid and methanol was treated with sodium cyanoborohydride. The ESI (+ve) mass 
spectrum of the ester 139 presented a peak for the protonated molecular ion at m/z 
396. Deprotection of the methyl ester 139 with lithium hydroxide yielded the acid 
140. The ’H NMR spectrum of the acid 140 did not display the singlet resonance 
corresponding to the protons of the methyl ester functionality, confirming the 
reaction was successful. The ESI (-ve) mass spectrum of the acid 140 displayed a 
peak at m/z 380 corresponding to the deprotonated molecular ion. Removal of the t- 
butoxycarbonyl group from the amide 140 was achieved via treatment with 4M 
hydrochloric acid in 1,4—dioxane to yield the diamine 135. The ]H NMR spectrum 
of the diamine 135 did not display any evidence of the singlet resonance 
corresponding to the protons of a r-butoxycarbonyl group. Further evidence for the 
successful synthesis of the diamine 135 was provided by the high resolution ESI 
(+ve) mass spectrum which presented a peak for the protonated molecular ion at m/z 
282.1462.
8.2.2 (iS^-A^-Benzyloxycarbonyl^J-diamino^-azaheptanoic acid (136)
The synthesis of the azaheptanoic acid 136 initially proceeded following the protocol 
used in the preparation of the azahexanoic acid 135. As with the diamine 135, the
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crucial step in the synthesis of the diamine 136, was the reductive alkylation reaction 
between the ester 137 and the aldehyde 149 to give the azalysinate 150 (Scheme 35).
Scheme 35. Synthesis of the azalysinate 150 from the ester 137 and the aldehyde
149
The ß-alaninal 149 was synthesized following the experimental protocol employed 
in the preparation of the glycinal 138 from glycine 146 expressed above (Scheme 
36).
ß-Alanine
di-f-butyl dicarbonate
BocHN
THF/1M NaOH
O
OH
(28) (151) (96) (152)
LiAIH4 
THF, 0°C
O
(149)
Scheme 36. Synthesis of A-(/-butoxycarbonyl)-ß-alaninal (149)
The carbamate 151 was prepared from ß-alanine (28) with di-J-butyl dicarbonate. A 
peak corresponding to the sodiated molecular ion was observed at m/z 212 in the ESI 
(+ve) mass spectrum of the carbamate 151. The acid 151 was coupled with the 
amine 96 using A,A’-dicyclohexylcarbodiimide to give the Weinreb amide 152. The 
ESI (+ve) mass spectrum of the amide 152 presented a peak at m/z 255
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corresponding to the sodiated molecular ion. The amide 152 was reduced to give the 
aldehyde 149 using lithium aluminium hydride. The ’H NMR spectrum of the 
aldehyde 149 displayed resonances that correspond with the literature data.108
The reductive alkylation reaction between the methyl ester 137 and the aldehyde 149 
was carried out according to the experimental protocol utilised in the synthesis of the 
ester 139, as outlined earlier in Scheme 35.
A peak for the sodiated molecular ion was observed at m/z 422 in the ESI (+ve) mass 
spectrum of the ester 150, confirming its successful synthesis. However, the ’H 
NMR spectrum of the product mixture indicated the presence of a large amount of 
impurities and the crude yield of the reaction was less than 10 percent, which was 
equivalent to 15 milligrams; this made the isolation of the ester 150 and the 
subsequent reactions to synthesize the diamine 136 impractical. Consequently, an 
attempt was made to prepare the azalysinate 150 following the reported procedure 
for its synthesis (Scheme 37).109
(153) (154) (155)
(150) (157) (156)
Scheme 37. Synthesis of methyl-(5)-TV"-benzyloxycarbonyl-A7-(?-butoxycarbonyl)-
2,7-diamino-4-azaheptanoate (150)
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The ester 154 was obtained by heating to reflux a mixture of (5)-serine (153) in 
methanol with acetyl chloride. The ]H NMR spectrum of the ester 154 displayed 
resonances which correspond well with data reported in the literature.110 The 
instalment of the benzyloxy group to the amine 154 proceeded with the addition of 
triethylamine and benzyl chloroformate to a solution of the amine 154. The ESI 
(+ve) mass spectrum of the carbamate 155 exhibited the sodiated molecular ion at 
m/z 276 as the base peak. Conversion of the alcohol 155 to the bromide 156 was 
carried out in the presence of triphenylphosphine and A-bromosuccinimide. The ]H 
NMR spectrum of the bromide 156 displayed resonances which correspond well 
with data reported in the literature.109 A mixture of the bromide 156, potassium 
fluoride:celite and A-(?-butoxycarbonyl)-l,3-diaminopropane (157) was heated at 
reflux to give the azalysinate 150. The ESI (+ve) mass spectrum of azalysinate 150 
displayed a peak for the sodiated molecular ion at m/z 410.
The two remaining steps in the synthesis of the diamine 136 from the azalysinate 
150 were carried out following the reaction sequence depicted in Scheme 38.
Scheme 38. Synthesis of (^-A'-benzyloxycarbonyl^^-diamino^-azaheptanoic
acid (136)
Hydrolysis of the ester 150 with lithium hydroxide gave the acid 158. The high 
resolution ESI (+ve) mass spectrum of the acid 158 displayed a peak corresponding 
to the protonated molecular ion at m/z 396.2135. The successful synthesis of the 
azaheptanoic acid 136 proceeded via treatment of the amide 158 with 4M 
hydrochloric acid in 1,4-dioxane. The high resolution ESI (+ve) mass spectrum of 
the diamine 136 exhibited a peak for the protonated molecular ion at m/z 296.1618.
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The esters 139 and 150 were prepared following the literature methods employed in 
the syntheses of the same compounds, which were reported to be homochiral.105,109 
The deprotection reaction conditions employed in the preparation the diamines 135 
and 136 from the esters 139 and 150, respectively, are not expected to result in 
racemisation as peptidic systems exposed to similar conditions are reported to be 
homochiral.111 Thus both the diamines 135 and 136 are assumed to be homochiral. 
The optical rotations of the azahexanoic acid 135 and the azaheptanoic acid 136 
were not determined as their syntheses were conducted on only a small quantity of 
starting materials.
8.3 Interactions of the diamines 135 and 136 with PAM
The binding affinities of the diamines 135 and 136 with PAM were established 
following the protocol described in Chapter Two. The azahexanoic acid 135 
inhibited the activity of the enzyme, with a determined IC50 value of 1.9 mM.
Interestingly, the diamine 136 behaved in a similar manner to the two ß-oxa acids 67 
and 68 discussed in Chapter Four. According to the results from the binding studies, 
the percentage of the substrate 22 turned over increased as the concentration of the 
diamine 136 in the sample increased. At concentrations of 0.1, 1.0 and 5.0 mM of 
the azaheptanoic acid 136, the yields of the amidated product 23 were greater by 
factors of 1.3, 2.8 and 7.8 respectively, relative to the sample with no diamine 136 
present.
As suggested with the two ß-oxa acids 67 and 68, the effect on the enzyme’s activity 
displayed by the diamine 136 may also be due to an activating allosteric effect 
imposed on PAM by the compound, which resulted in modifications to the active 
site that improved the binding of the substrate 22.
The poor binding affinity exhibited by the diamine 135 may be attributed to the 
position of the diamino ligand, as substituents at the a-carbon of glycine-based 
substrates have been established to disrupt binding with PAM ."
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In addition, the poor binding affinity displayed by the diamine 135 may be 
associated with the ability of both amino groups to coordinate to the enzyme’s 
copper. As illustrated in the PHM-substrate crystal structure in Figure 1, the two 
coppers (Cuh and Cum) are held in place by coordination with residues within the 
enzyme active site. Copper H (Cuh) is coordinated with the nitrogens of three 
histidine residues (Hisl07, Hisl08 and Hisl72), while Copper M (Cum) is 
coordinated to the sulfur of the methionine (Met314) and the nitrogens of two 
histidine (His242 and His244) residues. In order for the amino groups of the 
diamine 135 to effectively coordinate to either one of the coppers in the enzyme 
active site, at least one of the original copper coordinating ligands will have to be 
displaced. This may not have been possible as both sulfur-containing substituents 
and imidazole groups have been established to coordinate effectively with
copper 112,113
In summary, the poor binding affinity displayed by the diamine 135 may be affected 
by a number to factors including the position of the diamino substituent, as well as 
the ability of the amino groups of the substituent to coordinate with the copper in the 
enzyme active site. In contrast, the diamine 136 appeared to act as an activator of 
the enzyme, by inducing the production of the amidated product 23. This suggests 
that the diamine 136 may also be useful in the development of therapeutic remedies 
for conditions associated with low hormone levels.
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Chapter Nine
Conclusions
The results presented in this thesis have shown that binding affinity with PAM is 
influenced by a number of factors including the presence and absence of particular 
functional groups, and the relationships between the various features of a compound 
with the recognition points within the enzyme active site.
The results from the preliminary investigation into the effects of recognition features 
on binding affinity with PAM established that the incorporation of a hydrophobic 
group or a sulfur containing substituent was beneficial towards preserving binding 
affinity with the enzyme. The high binding affinities to PAM observed with the 
compounds possessing aromatic or aliphatic groups are in agreement with the 
presence of a hydrophobic pocket within the enzyme’s active site, observed in the 
crystal structure of a PHM-substrate complex shown in Figure 1 9 The hydrophobic 
moiety of a compound is likely to reside in the hydrophobic pocket, enhancing the 
compound’s binding affinity to the enzyme. The presence of copper in the enzyme 
active site was also confirmed in the crystal structure in Figure 1 and the high 
binding affinity observed with the sulfur containing compounds to PAM is likely to 
be due to the coordination of the sulfur to the enzyme’s copper. As a consequence of 
the results from this section of work, compounds investigated in subsequent sections 
of the thesis all possessed either a hydrophobic moiety or a copper coordinating 
group.
In addition, the results presented in Chapter Two of the Results and Discussion 
established the importance of the distance between key substrate recognition features 
such as a free carboxyl group, the hydrophobic substituent and the amido moiety in 
maintaining high binding affinity with the enzyme. Deviation from the desired 
configuration preferred for tight binding with PAM led to a loss in binding affinity, 
as observed with the ß-alanyl derivatives in contrast to the analogous acylglycines.
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The results described in Chapter Three of the Results and Discussion highlighted the 
importance of a compound’s geometry in contributing to binding affinity to PAM. 
While both glycolic acid derivatives and y-keto acids were established to be 
inhibitors of PAM, the glycolic acid derivatives displayed significantly higher 
binding affinity to the enzyme. The binding affinities displayed by the glycolic acid 
derivatives were comparable to those of the corresponding acylglycines. The 
geometric configurations adopted by the two classes of compounds may closely 
mimic the configuration desired by PAM for tight binding. Given the effective 
inhibition of PAM displayed by the glycolic acid derivatives, investigations into 
their in vivo effects have been taking place. The results from the preliminary 
experiments showed that the two glycolic acid derivatives 58 and 59 actively 
reduced the levels of the peptide hormone Substance P produced by rat DRG cells.19 
Future work will involve the development of more potent inhibitors and testing the 
effectiveness of those compounds in cell-based assays and potentially in animal and 
human models.
The results from the research described in Chapter Four of the Results and 
Discussion highlight the importance of the presence of the ester carbonyl group of 
glycolic acid derivatives in preserving binding affinity with PAM. The ß-oxa acid 
67 displayed binding that was by over two orders of magnitude less strong than that 
observed with the analogous glycolic acid derivative 55. In contrast, the two ß-oxa 
acids 68 and 69 appeared to enhance the activity of PAM. Future work may 
concentrate on the elucidation of the interactions of the two ß-oxa acids 68 and 69 
with PAM that are resulting in the observed activation effect. Furthermore, future 
work may also involve the development of analogues of the two ß-oxa acids 68 and 
69, which may be useful in the development of drug therapies to treat conditions 
associated with low hormone levels.
The results from the research described in Chapter Five of the Results and 
Discussion indicate that the high binding affinity observed with the a,ß-unsaturated 
y-keto acid 80 may be attributed to the similarities in geometry of the olefinic carbon 
adjacent to the carboxyl group in the acid to the geometry of the a-carbon centred 
radical formed from the corresponding acylglycine 13. Alternatively, as the acrylic
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acid 80 has been established as an inactivator of PAM,14 the tight binding displayed 
by the acid may be related to the mechanism of enzyme inactivation. Nevertheless, 
the enhanced binding affinity observed with the acid 80 could not be generalised to 
other compounds in its class. The leucine derivative 81 exhibited binding affinity 
which was by around one order of magnitude less than that observed with the 
corresponding acylglycine 14 and glycolic acid derivative 56.
The results presented in Chapter Six of the Results and Discussion, established that 
the combination of two features - a hydrophobic moiety and a /rafls-ß/y-unsaturated 
acid - which have been determined to preserve binding affinity with PAM produced 
two compounds 93 and 94 that were effective inhibitors of PAM. The two acids 93 
and 94 were the most effective inhibitors of PAM studied as part of the research 
conducted for this thesis. Given the effective inhibition of PAM displayed by trans- 
ß,y-unsaturated acids, future work may focus on peptidic derivatives of the acids 
more closely resembling particular peptide prohormones, which may be useful in the 
development of therapeutic agents that can be administered to treat conditions linked 
with the over production of peptide hormones.
The results described in Chapter Seven of the Results and Discussion highlighted the 
significance of the thio ether substituent in preserving binding affinity with the 
enzyme. As indicated by the differences in binding affinities observed between the 
a-alkylated dipeptides 124 and 122, the binding affinity of the dipeptide bearing a 
copper coordinating functionality 124 was not affected to the extent of the 
corresponding derivative with a non copper-binding substituent 122. The poor 
binding affinity of the methionyl glycolic acid 125 to PAM also highlighted the 
significance of the arrangement of a compound’s functional groups with respect to 
key recognition features of the enzyme active site in influencing binding affinity to 
PAM, even in the presence of a copper-binding group which has been established to 
preserve binding affinity with the enzyme. Based on the results from this section of 
work, future studies may investigate analogues of peptide prohormones with a 
sulfur-containing group at the penultimate position, which may be useful towards the 
development of drug treatments for conditions associated with an excess of peptide 
hormones. A number of sulfur-containing compounds have been reported to inhibit
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the production of peptide hormones including the benzyl ester 6  discussed in the 
Introduction section, which inhibited the production of Substance P, displaying an 
IC50 value of 3 pM .39
The results presented in Chapter Eight of the Results and Discussion section 
suggested that the poor binding affinity exhibited by the diamine 135 could be 
associated with the position of the diamino ligand, which may have prevented tight 
binding with the enzyme. It may therefore be of interest to compare the binding 
affinities of the compounds 159 and 160 to that of the diamines 135 and 136. The 
compounds 159 and 160 are glycine-extended versions of the diamines 135 and 136, 
respectively.
However, the compounds 159 and 160 are not anticipated to display tight binding 
with the enzyme, as the binding of the diamine 135 to PAM may also be affected by 
the ability of both the amino groups of the diamine 135 to coordinate with the 
enzyme’s copper.
In contrast to the diamine 135, the diamine 136 behaved in a similar manner to the 
two ß-oxa acids 68 and 69 discussed in Chapter Four, and appeared to activate the 
enzyme’s activity. As suggested with the two ß-oxa acids 68 and 69, future work 
may entail establishing the interactions between the diamine 136 and the enzyme, as 
well as in the development of derivatives of the diamine 136 which may also be 
useful towards the development of drug remedies to treat conditions associated with 
depleted levels of hormones.
In conclusion, the results from the research presented in this thesis have established 
the importance of the presence of a number of functional groups including a copper-
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binding substituent and a hydrophobic moiety, as well as the compound’s geometric 
configuration in preserving binding affinity with the enzyme. These results provide 
valuable information that can be used in the design of compounds to be investigated 
in future studies. In addition, the results also provide a number of possible leads 
towards the development of compounds which may be useful in treating conditions 
associated with an over-production of peptide hormones, as well as compounds that 
may potentially be used as therapeutic treatments for conditions linked with low 
hormone levels.
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Chapter Ten
Experimental
10.1 General
Melting points were performed on a MPA 100 Optimelt Automated Melting Point 
System -  Digital Image Processing Technology by Stanford Research Systems and 
on a Kofler hot-stage melting point apparatus and visualised with a Reichert
# 1 i i  #
microscope. H and C NMR spectra were recorded on Varian Gemini 300 and 
Inova 300 spectrometers. Chemical shifts are reported as 5 in parts per million and 
coupling constants are reported as J  values in Hz. The multiplicity of signals is 
abbreviated as follows: br = broad signal, d = doublet, dd = doublet of doublets, ddd 
= doublet of doublet of doublets, dt = doublet of triplets, m = multiplet, q = quartet, s 
= singlet, t = triplet. Methanol-^ with an isotopic purity of 99.8% was purchased 
from Apollo Scientific Ltd. DMSO-dö with an isotopic purity of 99.9%, chloroform- 
d with an isotopic purity of 99.8% and D2 O with an isotopic purity of 99.8% were 
purchased from Cambridge Isotope Laboratories, Inc. Chloroform-^ (CDCI3) was 
referenced at 8 7.26 for ]H and 77.0 for 13C spectroscopy. D2 O was referenced at 8 
4.79 for ’H spectroscopy. DMSO-o^ ((CDs^SO) was referenced at 8 2.50 for 'H and 
39.5 for l3C spectroscopy. Methanol-^ (CD3OD) was referenced at 8 = 3.31 for ]H 
and 49.0 for C spectroscopy.
Electron impact (El) mass spectra were recorded using a VG AutoSpec M series 
sector (EBE) mass spectrometer. Electrospray ionisation (ESI) spectra were 
recorded on a VG Quattro II triple quadrupole mass spectrometer. Microanalyses 
were carried out on a Carlo Erba 1106 automatic analyser, by the Research School of 
Chemistry Microanalytical Service at the Australian National University. Optical 
rotations were determined using a Perkin Elmer 241 polarimeter.
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Semi-preparative high performance liquid chromatography (HPLC) was conducted 
using a Waters 600 controller with a Waters Alliance 2996 photodiode array 
sampler, together with a Waters 717plus autosampler and a Waters fraction collector 
III. A Phenomenex Luna C l8 5 pm column (250 x 10 mm) and a YMC-Pack ODS 
AQ C l8 5 pm column (250 x 20 mm) were used in preparative separations. 
Analytical HPLC was carried out on a Waters Alliance 2695 separations Module, 
with a Waters 2996 photodiode array detector. A Waters Symmetry C l8 5 pm 
column (250 x 4.6 mm) was used in analytical separations. Both HPLC systems 
were used in conjunction with a IBM data station, and the data were collected and 
processed with the Empower Pro-Empower 2 software.
Preparative flash chromatography was performed with Scharlau silica gel 60 (230- 
400 mesh ASTM). Visualisation was either by ultra-violet (UV) radiation or 
development in phosphomolybdic acid or potassium permanganate dips.
Recombinant solutions of peptidylglycine alpha-amidating enzyme (PAM) were 
purchased from Wako Pure Chemical Industries. Tripeptide (/?)-Tyr-(S)-Val-Gly- 
OH (22) used in the enzyme assays was acquired from Bachem AG. (^)-Alanine, ß- 
alanine, (^-ascorbic acid, (S)-asparagine, bovine liver catalase, 6-bromohexanoic 
acid, r-butyl bromoacetate, diacetoxyiodobenzene, AGV’-dicyclohexylcarbodiimide, 
A-(3-dimethylaminopropyl)-A’-ethylcarbodiimide, dimethyl methylphosphonate, 
MO-dimethylhydroxylamine, di-/-butyl dicarbonate, glycine, glycine methyl ester 
hydrochloride, 4M hydrochloric acid solution in 1,4-dioxane, (iS)-leucine, lithium 
hydroxide monohydrate, 2-[A-morpholino]ethanesulfonic acid (MES) hydrate, (S)- 
methionine, methyltriphenylphosphonium chloride, 7-oxooctanoic acid, (S)- 
phenylalanine, potassium fluoride on celite (50% wt), (S)-serine, sodium 
thiomethoxide, (<S)-tartaric acid, 3-(trimethylsilyl)propargyl bromide, Tween* 20 and 
(5)-valine were purchased from Sigma-Aldrich, Inc. Castro’s reagent 
(benzotriazolyloxytris(dimethylamino)phosphonium hexafluorophosphate, BOP) 
was bought from Auspep Pty Ltd and 7V-(/-butoxycarbonyl)-l,3-diaminopropane was 
purchased from TCI America Organic Chemicals. All HPLC solvents were 
purchased from Labscan Asia Co., Ltd. Water was purified by a ELGA Purelab 
Classic UV water purification system.
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10.2 Enzyme assay conditions and HPLC traces
PAM enzyme inhibition assays were performed with 2 pM copper sulfate, 0.1 mM 
substrate fft)-Tyr-(5)-Val-Gly (22), 3 mM ascorbic acid, 100 pg/mL bovine liver 
catalase, 0.01% Tween" 20 and 1% ethanol, in the presence of nominated 
concentrations of inhibitors in 100 mM MES buffer at pH 6.6.
The assays were initiated by the addition of a 30 pL enzyme solution (3.75 pg of 
enzyme in a 550 pL MES buffer solution) to give a total volume of 60 pL and at a 
final enzyme concentration of 43.7 nmol L*1. The assay mixtures were incubated at 
37 °C for 1 hour. The assays were quenched by the addition of 30 pL of 1M sodium 
hydroxide, followed by the addition of 30 pL of 1M hydrochloric acid to neutralise 
the assay solutions. Two aliquots of 20 pL of each of the assay solutions were taken 
and diluted to 110 pL with Milli-Q water and the duplicate solutions were analysed 
by HPLC. The ratio of substrate (#)-Tyr-(S)-Val-Gly (22) to the product (/?)-Tyr- 
(5)-Val-NH2 (23) was identified by integration of percentage peak areas appearing 
on HPLC traces, which determined the amount of substrate 22 processed at specific 
inhibitor concentrations.
The following Figures 4, 5, 6, and 7 are representative HPLC traces from enzyme 
assays of the compound 80 at concentrations 0, 0.1, 1.0, 10 pM, respectively. The 
peak at fo8.7 minutes corresponds to the amide product 23 and the peak observed at 
/r9.1 minutes corresponds to the starting material 22.
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0.10 -
- 0.10 -
25.00 30.0010.00 15.00
Minutes
20.00
Figure 4. HPLC trace of inhibitor 80 at concentration 0 pM
0.20 -
0.10 -
- 0.10 -
30.0010.00 15.00 20.00 25.00
Minutes
Figure 5. HPLC trace of inhibitor 80 at concentration 0.1 pM
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M O  -
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Minutes
Figure 6. HPLC trace of inhibitor 80 at concentration 1.0 pM
0.20 -
0.10 -
- 0.10 -
25.00 30.0010.00 15.00 20.00
Minutes
Figure 7. HPLC trace of inhibitor 80 at concentration 10 pM
10.3 Inhibitory concentration (IC50) value determinations
Integration of the peaks of the substrate 22 and the amidated product 23 in the HPLC 
traces were used to determine the percentage of substrate turnover in the enzyme 
assays.
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A Dixon plot is generated from plotting the reciprocal of the average rate of turnover 
of substrate against the concentration of the inhibitor. The Dixon plot for the PAM 
assay with the inhibitor 80 is provided in Figure 8.
18.000C
y = 1509.2x + 1 .1367 
r2 =  0 .9864
>  10.000t
4.0000
0.0000
Figure 8. Dixon plot for the activity of the inhibitor 80 against PAM
Using the equation generated from the line of best fit illustrated in Figure 8, the IC50 
of an inhibitor is determined as the value of -x  when y = 0. The IC50 value of the 
inhibitor 80 was established to be 0.0007 mM.
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10.4 Synthetic Procedures 
10.4.1 Experimental for Chapter Two 
7-methyloct-7-enoic acid (20)
(20)
«-Butyl lithium (1.6M in hexanes, 6.2 mL, 9.9 mmol) was added dropwise to a 
stirred suspension of methyltriphenylphosphonium chloride (18) (3.0 g, 9.7 mmol) in 
tetrahydrofuran at -78 °C under a nitrogen atmosphere. The mixture was stirred at -  
78 °C for 45 minutes, then treated with a solution of 7-oxooctanoic acid (19) (0.8 g, 
4.7 mmol) in tetrahydrofuran (10 mL). The mixture was warmed to room 
temperature and stirred for 90 minutes. The reaction was quenched by the addition 
of water (15 mL). The solution was extracted with diethyl ether (3 x 50 mL) and the 
combined organic extracts were washed with 0.1M sodium hydroxide solution (3 x 
35 mL). The combined aqueous extracts were acidified to pH 2 with 1M 
hydrochloric acid then washed with diethyl ether (3 x 50 mL). The organic extracts 
were dried, filtered and concentrated under reduced pressure to give a colourless oil. 
The residue was subjected to flash silica gel column chromatography, eluting with 
hexanes/ethyl acetate (9:1 to 3:2) to give the title compound 20 (0.4 g, 52%) as a 
colourless oil.
JH NMR (300 MHz, CDCty): 5 1.23-1.50 (m, 5H), 1.64 (m, 4H), 2.09 (t, J =  1A Hz, 
2H), 2.36 (t, J =  7.5 Hz, 2H), 4.62 (s, 1H), 4.69 (s, 1H). MS (ESI) (-ve): m/z 155 
(M-H+, 100%). HRMS (ESI) calcd. for C9Hi50 2 [M-H]+ m/z 155.1072, found 
155.1065. The 'H NMR spectral data obtained are consistent with reported 
information.53
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7-methyl-7-octanoic acid (16)
.OH
(16)
7-Methyl-oct-7-enoic acid (20) (70 mg, 0.5 mmol) was added to a suspension of 
activated palladium on carbon (10%, 5 mg) in ethanol (5 mL) under a hydrogen 
atmosphere. The mixture was stirred overnight at room temperature then filtered 
through a pad of celite. The filtrate was concentrated under reduced pressure to give 
a yellow oil. The residue subjected to Kugelrohr vacuum distillation to give the title 
compound 16 (40 mg, 56%) as a colourless oil.
'H NMR (300 MHz, CDC13): 5 0.86 (d, 8.4 Hz, 6H), 1.14-1.19 (m, 1H), 1.28-
1.35 (m, 5H), 1.47-1.68 (m, 3H), 2.35 (t, J =  7.5 Hz, 2H). MS (ESI) (-ve): m/z 157 
(M-H+, 100%). HRMS (ESI) calcd. for C9H1702 [M -H f m/z 157.1228, found 
157.1221. The 'H NMR spectral data collected are consistent with literature data/ 3
6-MethyIthiohexanoic acid (17)
A mixture of 6-bromohexanoic acid (21) (1.9 g, 10 mmol) and sodium 
thiomethoxide (1.4 g, 20 mmol) in methanol (10 mL) was stirred and heated to 
reflux for 6 hours. The mixture was cooled to 25 °C, diluted with water (10 mL) and 
acidified to pH 1 with 1M hydrochloric acid. The solution was washed with 
chloroform (3 x 50 mL) and the combined organic extracts were dried, filtered and 
solvent evaporation under reduced pressure gave a yellow oil. The oil was subjected 
to distillation on a Kugelrohr instrument to yield the title compound 17 (1.2 g, 72%) 
as a yellow oil.
o
(17)
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*H NMR (300 MHz, CDC13): 5 1.37-1.48 (m, 2H), 1.54-1.69 (m, 4H), 2.07 (s, 3H), 
2.35 (t, J  = 7.5 Hz, 2H), 2.48 (t, J  = 1 2  Hz, 2H). MS (El): m/z 162 (M+, 53%). 
HRMS (El) calcd. for C7H 14O2S [M]~* m/z 162.0715, found 162.0714. The acquired 
'H NMR spectral information are consistent with reported data. 54
ß-Alanine methyl ester hydrochloride (29)
o
(29)
Thionyl chloride (3.3 mL, 44.9 mmol) was added dropwise to a suspension of ß- 
alanine (28) (1.0 g, 11.2 mmol) in methanol (30 mL). The mixture was stirred 
overnight at room temperature before it was concentrated under reduced pressure to 
yield a white solid. The solid was redissolved in methanol (20 mL) and evaporated 
under reduced pressure twice to remove excess hydrochloric acid, to give the title 
compound 29 (1.0 g, 64%) as a white solid.
Mp. 109-110 °C (lit.,55 110-112 °C). ]H NMR (300 MHz, D20): 5 2.66 (t, J =  6.4 
Hz, 2H), 3.13 (t, J  = 6.4 Hz, 2H), 3.59 (s, 3H). MS (ESI) (+ve): m/z 104 (M+H+, 
100%). HRMS (El) calcd. for C4H9NO2 [Mf 'm / z  103.0633, found 103.0632. The 
'H NMR spectral characteristics are consistent with literature values.55
TV-Benzoyl-ß-alanine methyl ester (30)
BzHN
(30)
ß-Alanine methyl ester hydrochloride (29) (1.0 g, 7.2 mmol) was dissolved in ethyl 
acetate (20 mL), to which a solution of sodium bicarbonate (1.2 g, 14.5 mmol) in
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water (20 mL) and benzoyl chloride (1.3 mL, 10.7 mmol) were added. The mixture 
was stirred at room temperature overnight and then extracted with ethyl acetate (2 x 
50 mL). The combined organic extracts were washed successively with saturated 
sodium bicarbonate solution (3 x 25 mL), 1M hydrochloric acid (3 x 25 mL), brine 
solution (3 x 25 mL) then dried and filtered. The filtrate was concentrated under 
reduced pressure to give a white solid. The solid was recrystallised from diethyl 
ether, to afford the title compound 30 (0.7 g, 47%) as white crystals.
Mp. 66-67 °C. !H NMR (300 MHz, CDC13): 6 2.66 (t, J =  6.0 Hz, 2H), 3.70-3.76 
(m, 2H), 3.71 (s, 3H), 6.89 (br s, 1H), 7.40-7.50 (m, 3H), 7.75-7.78 (m, 2H). MS 
(ESI) (+ve): m/z 230 (M+Na+, 100%). HRMS (ESI) calcd. for CiiH13N 0 3Na 
[M+Na]+ m/z 230.0793, found 230.0791. The ’H NMR spectral information are 
consistent with previously reported data.56
TV-Benzoyl-ß-alanine (24)
o
B zH N ^  ^
(24)
A solution of lithium hydroxide (50 mg, 2.0 mmol) in water (15 mL) was added to a 
solution of vV-benzoyl-ß-alanine methyl ester (30) (300 mg, 1.5 mmol) in 
tetrahydrofuran (15 mL). The mixture was stirred overnight at room temperature 
and acidified to pH 3 with 1M hydrochloric acid. The solution was extracted with 
ethyl acetate (3 x 40 mL) and the combined organic extracts were dried, filtered and 
concentrated under reduced pressure to give the title compound 24 (260 mg, 90%) as 
a white solid.
Mp. 117-118 °C (lit.,114 117-118 °C). *H NMR (300 MHz, CD3OD): 6 2.63 (t, J  = 
6.9 Hz, 2H), 3.62 (t, J  = 6.9 Hz, 2H), 7.42-7.60 (m, 2H), 7.77-7.81 (m, 3H). MS 
(ESI) (-ve): m/z 192 (M-H+, 79%). HRMS (ESI) calcd. for C]0H i0NO3 [M-H]+ m/z
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192.0661, found 192.0654. The acquired ’H NMR spectral data are consistent with 
data previously reported.57
(iS)-./V-AcetyIphenylalanine (32)
AcHN
(32)
Triethylamine (5.9 mL, 42.4 mmol) and acetic anhydride (8.6 mL, 90.8 mmol) were 
added to a solution of OS)-phenylalanine (31) (5.0 g, 30.2 mmol) in water (350 mL). 
The mixture was stirred at room temperature overnight then acidified to pH 1 with 
1M hydrochloric acid and extracted with ethyl acetate (3 x 200 mL). The combined 
organic extracts were dried, filtered and concentrated under reduced pressure to give 
a white solid, which was recrystallised from ethanol to give the title compound 32 
(3.2 g, 51%) as a white solid.
Mp. 171-172 °C (lit.,58 171-172 °C). *H NMR (300 MHz, CDCl3/(CD3)2SO): 5 
1.78 (s, 3H), 2.89 (dd, J =  6.6, 13.8 Hz, 1H), 3.01 (dd, J =  5.4, 13.8 Hz 1H), 4.68 
(dd, 7 = 5 .1 , 5.1 Hz, 1H), 6.56 (br d, J  = 7.5 Hz, 1H), 6.99-7.12 (m, 5H). MS (ESI) 
(+ve): m/z 208 (M+H+, 100%). HRMS (El) calcd. for Cn H13N 0 3 [M]+* m/z 
207.0895, found 207.0898. The obtained 'H NMR spectral data are consistent with 
values reported in literature.115
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(S^TV-Acetylphenylalanyl-ß-alanine methyl ester (33)
AcHN
(33)
ß-Alanine methyl ester hydrochloride (29) (0.5 g, 3.6 mmol), BOP reagent (2.4 g, 
5.3 mmol), and A, A-diisopropylethylamine (3.4 mL, 19.4 mmol) were added to a 
solution of (^-A-acetylphenylalanine (32) (1.1 g, 5.3 mmol) in dichloromethane (15 
mL). The mixture was stirred overnight at room temperature then partitioned 
between brine (100 mL) and ethyl acetate (100 mL). The organic extract was 
washed with 0.3M citric acid (3 x 40 mL), saturated sodium bicarbonate solution (3 
x 40 mL) and brine solution (3 x 40 mL) then dried and filtered. The filtrate was 
concentrated under reduced pressure to give the title compound 33 (0.3 g, 29%) as a 
light yellow solid.
Mp. 146-147 °C. [a]23D +2.0 (c 0.5, EtOH). *H NMR (300 MHz, CDC13): 5 1.99 
(s, CH3), 2.24-2.47 (m, CH2), 2.96 (dd, J =  8.4, 13.5 Hz, 1H), 3.07 (dd, J =  6.3, 13.5 
Hz, 1H), 3.26-3.38 (m, 1H), 3.41-3.52 (m, 1H), 3.64 (s, 3H), 4.52-4.59 (m, 1H), 6.11 
(br s, 1H), 6.18 (br d, J  = 6.9 Hz, 1H), 7.18-7.32 (m, 5H). 13C NMR (75 MHz, 
CDC13): 6 23.8, 34.2, 35.4, 39.5, 52.5, 55.4, 127.6, 129.3, 129.9, 137.2, 170.7, 171.5, 
173.1. MS (ESI) (+ve): m/z 293 (M +H \ 67%). HRMS (El) calcd. for C15H20N2O4 
[M+'] m/z 292.1423, found 292.1426.
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0S)-7V-AcetylphenylalanyI-ß-alanine (25)
AcHN
(25)
(^-A-Acetylphenylalanyl-ß-alanine methyl ester (33) (100 mg, 0.3 mmol) was 
dissolved in tetrahydrofuran (10 mL) to which a solution of lithium hydroxide (11 
mg, 0.5 mmol) in water (10 mL) was added. The resulting mixture was stirred at 
room temperature for 2 hours, acidified to pH 3 with 1M hydrochloric acid and 
extracted with ethyl acetate (3 x 30 mL). The combined organic extracts were dried, 
filtered and concentrated under reduced pressure to give a pink solid, which was 
recrystallised from chloroform to yield the title compound 25 (32 mg, 34%) as a 
white solid.
Mp. 158-159 °C. 'H NMR (300 MHz, (CD3)2SO): 5 1.73 (s, 3H), 2.30 (t, J  = 6.9 
Hz, 2H), 2.69 (dd, J  — 9.9, 13.5 Hz, 1H), 2.91 (d d ,J= 4 .8 , 13.5 Hz, 1H), 3.14-3.30 
(m, 2H), 4.38-4.43 (m, 1H), 7.14-7.27 (m, 5H), 8.04-8.11 (m, 2H). MS (ESI) (-ve): 
m/z 277 (M-H+, 14%). HRMS (El) calcd. for C i4H18N20 4  [M]+‘ m/z 278.1267, 
found 278.1269. The ’H NMR spectral characteristics are consistent with literature 
data.59
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(^-TV-Acetylleucine (35)
AcHN
O
.OH
(35)
Triethylamine (7.5 mL, 53.4 mmol) and acetic anhydride (3.8 mL) were added to a 
suspension of (S)-leucine (34) (5.0 g, 38.1 mmol) in water (200 mL). The mixture 
was stirred overnight at room temperature, acidified to pH 1 with 2M hydrochloric 
acid and extracted with ethyl acetate (3 x 200 mL). The combined organic extracts 
were dried, filtered and concentrated under reduced pressure to give a white solid, 
which was recrystallised from ethanol/hexanes to give the title compound 35 (2.3 g, 
35%) as white crystals.
Mp. 189-190 °C (lit.,61 189-190 °C). *H NMR (300 MHz, CD3OD): 8 0.92 (d, J  = 
6.3 Hz, 3H), 0.96 (d, J =  6.6 Hz, 3H), 1.58-1.78 (m, 3H), 1.98 (s, 3H), 4.38-4.42 (m, 
1H). 13C NMR (75 MHz, CD3OD): 5 21.7, 22.3, 23.4, 26.0, 41.5, 52.1, 173.4, 
176.1. MS (ESI) (+ve): m/z 196 (M+Na+, 70%). HRMS (El) calcd. for C8H15N 0 3 
[MY 'm/z  173.1052, found 173.1053. Anal. Calcd. forC 8Hi5N 0 3: C, 55.47; H, 8.73; 
N, 8.09. Found: C, 55.46; H, 8.35; N, 7.83%.
(^-TV-Acetylleucyl-ß-alanine methyl ester (36)
A suspension of ß-alanine methyl ester hydrochloride (29) (1.0 g, 7.2 mmol) in N,N- 
dimethylformamide (50 mL) was treated with A,A-diisopropylethylamine (1.7 mL,
o o
(36)
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9.7 mmol) and the mixture was stirred at room temperature for 5 minutes under a 
nitrogen atmosphere. (S)-./V-Acetylleucine (35) (1.8 g, 10.7 mmol), BOP reagent (4.7 
g, 10.7 mmol) and A,A-diisopropylethylamine (5.1 mL, 29.1 mmol) were then added 
to the mixture, which was stirred overnight at room temperature. The mixture was 
treated with brine solution (100 mL) and extracted with ethyl acetate (4 x 50 mL). 
The combined organic extracts were washed successively with 0.3M citric acid (3 x 
30 mL), saturated sodium bicarbonate solution (3 x 30 mL) and brine solution (3 x 
30 mL). The solution was dried, filtered and concentrated under reduced pressure to 
give a yellow solid. The crude product was recrystallised from dichloromethane to 
yield the title compound 36 (0.2 g, 11%) as a white solid.
Mp. 125-126 °C. *H NMR (300 MHz, CDC13): 5 0.92 (d, J =  1.8 Hz, 3H), 0.94 (d, 
J =  1.8 Hz, 3H), 1.47-1.64 (m, 3H), 2.00 (s, 3H), 2.54 (t, 6.1 Hz, 2H), 3.45-3.57
(m, 2H), 3.70 (s, 3H), 4.36-4.43 (m, 1H), 6.08 (br d, J=  8.1 Hz, 1H), 6.66 (br s, 1H). 
13C NMR (75 MHz, CDC13): 6 22.2, 22.7, 22.9, 23.0, 24.7, 33.7, 34.9, 41.3, 51.8, 
170.3, 172.4, 172.5. MS (ESI) (+ve): m/z 281 (M+Na+, 100%). HRMS (ESI) 
calcd. for Ci2H22N20 4Na [M+Na]+ m/z 281.1477, found 281.1476.
(,S)-7V-Acetylleucyl-ß-alanine (26)
AcHN
(5)-A-Acetylleucyl-ß-alanine methyl ester (36) (50 mg, 0.2 mmol) was dissolved in 
tetrahydrofuran (5 mL), to which a solution of lithium hydroxide (10 mg, 0.3 mmol) 
in water (5 mL) was added. The resulting suspension was stirred overnight at room 
temperature. The mixture was acidified to pH 3 with 1M hydrochloric acid and 
extracted with ethyl acetate (4 x 20 mL) then dried, filtered and concentrated under 
reduced pressure. The crude product was recrystallised from dichloromethane to 
yield the title compound 26 (19 mg, 41%) as a white solid.
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Mp. 158-159 °C. *H NMR (300 MHz, CD3OD): 5 0.91 (d, J  = 6.4 Hz, 3H), 0.94 (d, 
.7=6.4 Hz, 3H), 1.51-1.56 (m, 2H), 1.59-1.68 (m, 1H), 1.97 (s, 3H), 2.48 (t, .7=6.7 
Hz, 2H), 3.37-3.44 (m, 2H), 4.29-4.34 (m, 1H). 13C NMR (75 MHz, CDC13): 5 
21.5, 22.1, 22.4, 24.4, 33.3, 34.8, 40.6, 51.5, 171.3, 172.8, 174.1. MS (ESI) (+ve): 
m/z 267 (M+Na+, 100%). HRMS (ESI) calcd. for Cn H2oN204Na [M+Na]~ m/z 
267.1321, found 267.1326.
10.4.2 Experimental for Chapter Three 
/-Butyl (TV-acetylleucyl)acetate (64)
AcHN
(64)
A suspension of (S)-iV-acetylleucme (35) (2.0 g, 11.5 mmol) and 1,1’- 
carbonyldiimidazole (1.9 g, 11.5 mmol) in tetrahydrofuran (40 mL) was stirred at 
room temperature under a nitrogen atmosphere for 2 hours. It was then added 
dropwise to a solution that had been prepared from tetrahydrofuran (40 mL), 
diisopropylamine (9.7 mL, 69 mmol), «-butyl lithium (1.6M in hexanes, 29 mL, 46 
mmol) and /-butyl acetate (6.2 mL, 46.0 mmol), maintained at -78 °C. The resulting 
mixture was stirred for 40 minutes, then 1M hydrochloric acid (100 mL) was added 
and the solution was warmed to room temperature. It was then extracted with ethyl 
acetate (3 x 100 mL) and the combined organic extracts were dried, filtered and 
concentrated under reduced pressure to give a yellow oil. The oil was 
chromatographed on flash silica gel, eluting with hexanes/ethyl acetate (2:1), to give 
the title compound 64 (1.6 g, 53%) as a colourless oil.
*H NMR (300 MHz, CDC13): 6 0.91-0.95 (m, 6H), 1.45 (s, 9H), 1.63-1.67 (m, 3H), 
2.01 (s, 3H), 3.41 (d, J =  15.6 Hz, 1H), 3.51 (d, J  = 15.6 Hz, 1H), 4.69-4.76 (m, 1H), 
6.08 (br d, J  = 6.0 Hz, 1H). 13C NMR (75 MHz, CDC13): 6 21.3, 22.7, 23.1, 24.6,
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27.7, 39.2, 47.5, 56.7, 81.9, 166.1, 170.2, 202.9. MS (ESI) (+ve): m/z 294 (M+Na", 
100%). HRMS (El) calcd. for C 14H25NO4 [M]*’ m/z 272.1862, found 272.1851. 
Anal. Calcd. for C 14H25NO4 : C, 61.97; H, 9.29; N, 5.16. Found: C, 61.71; H, 9.29; 
N, 5.18%.
/-Butyl 3-(7V-acetylleucyl)-3-(/-butoxycarbonylmethyl)propionate (65)
AcHN
A solution of /-butyl (iV-acetylleucyl)acetate (64) (1.0 g, 3.7 mmol) in 
tetrahydrofuran (15 mL) was added to a suspension of sodium hydride (100 mg, 5.5 
mmol) in tetrahydrofuran (25 mL) maintained at 0 °C under a nitrogen atmosphere. 
After 10 minutes a solution of /-butyl bromoacetate (1.1 mL, 7.4 mmol) in 
dichloromethane (15 mL) was added dropwise to the mixture, which was then stirred 
overnight at room temperature. 1M Hydrochloric acid (100 mL) was then added and 
the solution was extracted with ethyl acetate (3 x 70 mL). The combined organic 
extracts were washed with brine solution (100 mL), dried and filtered through flash 
silica gel. The filtrate was concentrated under reduced pressure and the residue was 
chromatographed on flash silica gel, eluting with hexanes/ethyl acetate (4:1 to 1:1), 
to give a ca. 1:1 mixture of the diastereomers of the title compound 65 (500 mg, 
36%) as colourless oil.
*H NMR (300 MHz, CDC13): 5 0.86-0.93 (m, 12H), 1.34 (s, 9H), 1.35 (s, 9H), 1.36 
(s, 9H), 1.39 (s, 9H), 1.55-1.69 (m, 6 H), 1.94 (s, 3H), 1.96 (s, 3H), 2.61-2.81 (m, 
4H), 4.00-4.08 (m, 2H), 4.74-4.81 (m, 1H), 4.96-5.04 (m, 1H), 6.22 (br d, J  = 9.0 
Hz, 1H), 6.35 (br d, J  = 9.0 Hz, 1H). 13C NMR (75 MHz, CDC13): 8  22.1, 22.3, 
23.7, 23.8, 25.6, 25.8, 28.4, 28.7, 33.9, 34.7, 39.8, 41.5, 52.6, 53.1, 56.7, 57.0, 81.8, 
81.9, 83.1, 83.9, 167.5, 167.9, 170.5, 170.9, 171.1, 171.4, 204.4, 205.5. MS (ESI) 
(+ve): m/z 386 (M+H+, 100%). HRMS (El) calcd. for C20H35NO6 [M]+* m/z
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385.2464, found 385.2468. Anal. Calcd. for C20H35NO6: C, 62.31; H, 9.15; N, 3.63. 
Found: C, 62.39; H, 8.94; N, 3.85%.
3-(ALAcetylleucyl)propionic acid (63)
AcHN
(63)
A solution of /-butyl 3-(A-acetylleucyl)-3-(/-butoxycarbonylmethyl)propionate (65) 
(100 mg, 0.3 mmol) and trifluoroacetic acid (3 mL) in dichloromethane (30 mL) was 
heated at reflux overnight, then it was cooled and concentrated under reduced 
pressure to yield the title compound 63 (50 mg, 84%) as a colourless oil.
NMR (300 MHz, CDCI3): 5 0.94 (d, J =  6.0 Hz, 3H), 0.97 (d, J=  6.0 Hz, 3H), 
1.39-1.49 (m, 1H), 1.59-1.65 (m, 2H), 2.11 (s, 3H), 2.66-2.70 (m, 2H), 2.81-2.89 (m, 
2H), 4.71-4.76 (m, 1H), 6.56 (br d, J=  9.0 Hz, 1H). 13C NMR (75 MHz, CDC13): 8  
21.9, 23.1, 23.5, 25.2, 27.8, 34.9, 40.4, 56.9, 171.3, 177.0, 208.5. MS (ESI) (+ve): 
m/z 252 (M+Na+, 100%). HRMS (El) calcd. for CnH 19N 0 4 [ M f  m/z 229.1314, 
found 229.1320. Anal. Calcd. for C, ,Hi9N 0 4: C, 57.63; H, 8.35; N, 6.11. Found: C, 
57.50; H, 8.11; N, 5.99%.
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10.4.3 Experimental for Chapter Four 
(.S)-iV-AcetyIphenyIalaninol (70)
AcHN
(70)
(5)-A-Acetylphenylalanine (32) (5.0 g, 24.1 mmol) was dissolved in tetrahydrofuran 
(20 mL), to which triethylamine (4.1 mL, 28.9 mmol) and ethyl chloroformate (2.3 
mL, 24.1 mmol) were added. The resulting mixture was stirred at -5  °C under a 
nitrogen atmosphere for 30 minutes then filtered, and the precipitate was washed 
with tetrahydrofuran (30 mL). The filtrate was added to a suspension of sodium 
borohydride (2.3 g, 60.3 mmol) in water (20 mL). The resulting suspension was 
stirred at 0 °C for 4 hours, extracted with diethyl ether (2 x 50 mL) and 
dichloromethane (2 x 50 mL). The combined organic extracts were dried and 
filtered, and solvent evaporation gave the title compound 70 (4.4 g, 94%) as a white 
solid.
Mp. 99-100 °C (lit.,65 100-102 °C). NMR (300 MHz, CDC13): 8 1.98 (s, 3H), 
2.89 (d, 7  = 7.2 Hz, 2H), 3.59 (dd,7 = 5 .1 , 11.1 Hz, 1H), 3.69 (dd, 7 = 3 .6 , 11.1 Hz, 
1H), 4.14-4.19 (m, 1H), 6.11 (br d, 7 =  7.5 Hz, 1H), 7.30-7.36 (m, 5H). MS (ESI) 
(+ve): m/z 232 (M+KT, 100%). The ’H NMR spectral characteristics reported are 
consistent with literature data.6'
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(5)-f-Butyl-5-acetamido-3-oxa-6-phenylhexanoate (71)
AcHN
(71)
(-S)-7V-Acetylphenylalaninol (70) (0.8 g, 3.8 mmol) was added to suspension of 
sodium hydride (95%) (0.3 g, 12.5 mmol) in A, A-dimethylformamide (25 mL) under 
a nitrogen atmosphere. The mixture was stirred at room temperature for 2 hours 
then cooled to 0 °C. r-Butyl bromoacetate (2.3 mL, 15.5 mmol) was added to the 
mixture and stirred at 0 °C for 30 minutes, and stirred at room temperature for a 
further 2 hours. The mixture was diluted with saturated ammonium chloride solution 
(25 mL) and washed with ethyl acetate (100 mL). The organic extract was washed 
successively with saturated ammonium chloride solution (3 x 20 mL), saturated 
sodium bicarbonate solution (3 x 20 mL) and brine solution (3 x 20 mL), dried, 
filtered and concentrated under reduced pressure to give a yellow oil. The crude 
product was chromatographed on flash silica gel, eluting with hexanes/ethyl acetate 
(2:1 to 1:2) then ethyl acetate, to give the title compound 71 (0.4 g, 31%) as a 
colourless oil.
!H NMR (300 MHz, CDCI3): 6 1.48 (s, 9H), 1.99 (s, 3H), 2.84 (dd, J=  9.0, 13.5 Hz, 
1H), 3.00 (dd, J =  6.0, 13.5 Hz, 1H), 3.39 (dd, J = 3.3, 9.6 Hz, 1H), 3.47 (dd, J=  3.6, 
9.6 Hz, 1H), 3.88 (d, J=  16.5 Hz, 1H), 4.03 (d, J  = 16.5 Hz, 1H), 4.15-4.22 (m, 1H), 
6.65 (br d, J  = 6.3 Hz, 1H), 7.18-7.31 (m, 5H). 13C NMR (75 MHz, CDCI3): 8 23.1, 
27.9, 36.9, 50.6, 68.4, 71.2, 81.8, 126.1, 128.2, 129.2, 138.0, 169.7, 170.0. MS 
(ESI) (+ve): m/z 330 (M+Na+, 100%). HRMS (ESI) calcd. for Ci7H25N04Na 
[M+Na]+ m/z 330.1681, found 330.1681.
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(lS)-5-Acetamido-3-oxa-6-phenylhexanoic acid (67)
AcHN OH
(67)
A solution of (Y)-/-butyl-5-acetamido-3-oxa-6-phenylhexanoate (71) (250 mg, 0.8 
mmol) and trifluoroacetic acid (3.5 mL) in dichloromethane (20 mL) was stirred 
overnight at room temperature then concentrated under reduced pressure to give a 
brown oil. The residue was subjected to preparative high performance liquid 
chromatography to give the title compound 67 (35 mg, 17%) as a colourless oil.
*H NMR (300 MHz, CD3OD): 8 1.94 (s, 3H), 2.82 (dd, J =  7.8, 13.8 Hz, 1H), 2.95 
(dd, J =  7.2, 13.8 Hz, 1H), 3.52 (d, J =  4.2 Hz, 2H), 4.12 (s, 2H), 4.16-4.26 (m, 1H), 
7.19-7.33 (m, 5H). 13C NMR (75 MHz, CDC13): 8 21.7, 36.5, 51.8, 67.6, 70.7, 
126.8, 128.6, 129.1, 136.9, 173.5, 174.4. MS (ESI) (-ve): m/z 250 (M-H+, 30%). 
HRMS (ESI) calcd. for Ci3H16N 0 4 [M-H]+ m/z 250.1079, found 250.1081. HPLC: 
/r22.2 min (column: YMC-Pack ODS-AQ, 250 x 20 mm; (75:25) water (containing 
0.1% TFA): acetonitrile; flow rate: 10.0 cm3 min'1).
(5)-N-Acetylleucinol (72)
(72)
Triethylamine (3.9 mL, 27.7 mmol) and ethyl chloroformate (2.2 mL, 23.1 mmol) 
were added to a suspension of (5)-A-acetylleucine (35) (4.0 g, 23.1 mmol) in 
tetrahydrofuran (20 mL) at 0 °C under a nitrogen atmosphere. The mixture was 
stirred at -5  °C for 30 minutes, the white precipitate was filtered and washed with
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tetrahydrofuran (30 mL). The filtrate was added to a cooled suspension of sodium 
borohydride (2.2 g, 57.7 mmol) in water (20 mL). The mixture was stirred at 0 °C 
for 4 hours then extracted with diethyl ether (2 x 50 mL) and dichloromethane (4 x 
50 mL). The combined organic extracts were dried, filtered and concentrated under 
reduced pressure. The crude product was recrystallised from diethyl ether to yield 
the title compound 72 (1.8 g, 50%) as a white solid.
Mp. 66-67 °C. !H NMR (300 MHz, CDC13): 6 0.91 (d, J=  3.5 Hz, 3H), 0.93 (d, /  = 
3.5 Hz, 3H), 1.27-1.42 (m, 2H), 1.56-1.67 (m, 1H), 2.01 (s, 3H), 3.51 (dd, J =  5.7, 
11.1 Hz, 1H), 3.67 (dd, J  = 3.6, 11.1 Hz, 1H), 3.98-4.07 (m, 1H), 6.44 (d ,J= 8 .4  Hz, 
1H). MS (ESI) (+ve): m/z 160 (M+H+, 88%). HRMS (ESI) calcd. for C8Hi8N 0 2 
[M+H]+ m/z 160.1338, found 160.1334.
(lS)-f-Butyl-5-acetamido-7-methyI-3-oxaoctanoate (73)
AcHN
(^-/V-Acetylleucinol (72) (1.0 g, 6.3 mmol) was added to a suspension of sodium 
hydride (0.3 g, 13.8 mmol) in 7V,7V-dimethylformamide (25 mL) under a nitrogen 
atmosphere. The mixture was stirred at room temperature for 2 hours and cooled to 
0 °C. r-Butyl bromoacetate (3.7 mL, 25.2 mmol) was added to the mixture and 
stirred at 0 °C for 30 minutes, and stirred at room temperature for a further 2 hours. 
The solution was treated with saturated ammonium chloride solution (20 mL) and 
extracted with ethyl acetate (150 mL). The organic extract was washed with 
saturated ammonium chloride solution (3 x 30 mL), saturated sodium bicarbonate 
solution (3 x 30 mL) and brine solution (3 x 30 mL). The solution was dried, filtered 
and concentrated under reduced pressure. The residue was subjected to flash silica 
gel column chromatography, eluting with hexanes/ethyl acetate (2:1 to 1:1 to 1:2) to 
give the title compound 73 (0.4 g, 25%) as a yellow oil.
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lH  NMR (300 MHz, CDC13): 8 0.89 (d, J =  5.4 Hz, 6H), 1.30-1.66 (m, 3H), 1.45 (s, 
9H), 1.97 (s, 3H), 3.45 (dd, J  = 3.3, 9.4 Hz, 1H), 3.56 (dd, J =  3.6, 9.4 Hz, 1H), 3.93 
(d, J — 16.8 Hz, 1H), 3.97 (d ,J =  16.8 Hz, 1H), 4.06-4.13(m, 1H),6.25 (br d, 7= 8 .1  
Hz, 1H). 13C NMR (75 MHz, CDC13): 5 22.2, 22.7, 23.1, 24.6, 27.8, 40.4, 47.0, 
68.6, 73.5, 81.7, 169.7, 169.8. MS (ESI) (+ve): m/z 296 (M+Na~, 82%). HRMS 
(ESI) calcd. for C i^ N C C N a  [M+Na]^ m/z 296.1838, found 296.1839.
(l$)-5-Acetamido-7-methyl-3-oxaoctanoic acid (68)
AcHN
(68)
Trifluoroacetic acid (3 mL) was added to a suspension of (iS)-r-butyl-5-acetamido-7- 
methyl-3-oxaoctanoate (73) (200 mg, 0.7 mmol) in dichloromethane (20 mL) and 
stirred overnight at room temperature. The mixture was concentrated under reduced 
pressure to give a brown oil. The residue was subjected to preparative high 
performance liquid chromatography to give the title compound 68 (25 mg, 16%) as a 
colourless oil.
NMR (300 MHz, (CD3)2SO): 5 0.80 (d, J=  6.6 Hz, 3H), 0.84 (d, J=  6.6 Hz, 3H), 
1.24-1.30 (m, 2H), 1.52-1.60 (m, 1H), 1.77 (s, 3H), 3.26-3.38 (m, 2H), 3.87-3.94 (m, 
1H), 3.97 (s, 2H), 7.67 (br d, J=  8.4 Hz, 1H). 13C NMR (75 MHz, CD3OD): 5 22.4, 
22.7, 23.6, 25.9, 41.3, 52.2, 68.9, 74.7, 172.9, 174.2. MS (ESI) (-ve): m/z 216 (M- 
H+, 73%). HRMS (ESI) calcd. for CioH]8N 04 [M-H]+ m/z 216.1236, found 
216.1235. HPLC: tR 28.2 min (column: YMC-Pack ODS-AQ, 250 x 20 mm; 
(80:20) water (containing 0.1% TFA): acetonitrile; flow rate: 10.0 cm3 min’1).
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(iS^-TV-Acetylvaline (75)
AcHl
o
.OH
(75)
A suspension of (^-valine (74) (5.0 g, 42.7 mmol) in water (150 mL) was treated 
with triethylamine (8.3 mL, 59.7 mmol) and acetic anhydride (12.1 mL, 128.0 
mmol). The mixture was stirred overnight at room temperature, acidified to pH 1 
with 2M hydrochloric acid and washed with ethyl acetate (3 x 100 mL). The 
combined organic extracts were dried, filtered and concentrated under reduced 
pressure to give the title compound 75 (4.2 g, 62%) as a white solid.
Mp. 162-163 °C (lit.,66 164-165 °C). ’H NMR (300 MHz, D20): 6 0.77 (d, J =  3.6 
Hz, 3H), 0.80 (d, J =  3.6 Hz, 3H), 1.88 (s, 3H), 1.95-2.06 (m, 1H), 4.05 (d, J  = 5.7 
Hz, 1H). MS (ESI) (-ve): m/z 158 (M-H*, 100%). The obtained *H NMR spectral 
characteristics are consistent with literature data.116
(A)-A-Acetylvalinol (76)
Triethylamine (4.2 mL, 30.1 mmol) and ethyl chloroformate (2.4 mL, 25.1 mmol) 
were added to a cooled suspension of (^-A-acetylvaline (75) (4.0 g, 25.1 mmol) in 
tetrahydrofuran (20 mL) under a nitrogen atmosphere. The mixture was stirred at -5  
°C for 30 minutes, and the white precipitate was filtered and washed with 
tetrahydrofuran (30 mL). The filtrate was added dropwise to a suspension of sodium 
borohydride (2.4 g, 62.7 mmol) in water (20 mL) and the resulting mixture was 
stirred at 0 °C for 4 hours and extracted with diethyl ether (2 x 50 mL) and
(76)
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dichloromethane (2 x 50 mL). The combined organic extracts were dried, filtered 
and concentrated under reduced pressure to give the title compound 76 (2.4 g, 66%) 
as a white solid.
Mp. 75-76 °C (lit.,117 76-77 °C). NMR (300 MHz, CDC13): 5 0.93 (d, J =  6.6 
Hz, 3H), 0.95 (d, J  = 6.6 Hz, 3H), 1.81-1.92 (m, 1H), 2.04 (s, 3H), 3.60-3.76 (m, 
3H), 5.92 (br d, J =  8.4 Hz, 1H). 13C NMR (75 MHz, CDC13): 6 18.8, 19.4, 23.4, 
28.9, 57.1, 63.7, 171.3. MS (ESI) (+ve): m/z 146 (M+H+, 78%). HRMS (ESI) 
calcd. for C7H15N 0 2Na [M+Na]+ m/z 168.1000, found 168.0993.
6S)-f-Butyl-5-acetamido-6-methyl-3-oxaheptanoate (77)
(^-A-Acetylvalinol (76) (0.8 g, 5.2 mmol) was added to a stirred suspension of 
sodium hydride (95%) (0.4 g, 14.6 mmol) in A,A-dimethylformamide (25 mL) under 
a nitrogen atmosphere. The mixture was stirred at room temperature for 2 hours, 
then cooled to 0 °C. ?-Butyl bromoacetate (3.1 mL, 20.7 mmol) was added to the 
mixture and stirred at 0 °C for 30 minutes, and stirred at room temperature for a 
further 2 hours, then treated with saturated ammonium chloride solution (20 mL) and 
washed with ethyl acetate (100 mL). The organic extract was washed with saturated 
ammonium chloride solution (3 x 20 mL), saturated sodium bicarbonate solution (3 x 
20 mL) and brine solution (3 x 20 mL) then dried, filtered and concentrated under 
reduced pressure. The residue was subjected to flash silica gel column 
chromatography, eluting with hexanes/ethyl acetate (2:1 to 1:2) then ethyl acetate, to 
give the title compound 77 (0.2 g, 18%) as a colourless oil.
*H NMR (300 MHz, CDC13): 5 0.91 (d, 7.1 Hz, 3H), 0.95 (d, J =  7.1 Hz, 3H),
1.44 (s, 9H), 1.84-1.97 (m, 1H), 1.99 (s, 3H), 3.37-3.41 (m, 1H), 3.69-3.79 (m, 3H), 
3.88 (d, J =  16.5 Hz, 1H), 3.94 (d ,J =  16.5 Hz, 1H), 6.34 (brd, J =  8.4 Hz, 1H). 13C
(77)
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NMR (75 MHz, CDC13): 5 19.5, 23.6, 28.3, 29.5, 54.6, 69.0, 71.9, 82.1, 170.2, 
170.3. MS (ESI) (+ve): m/z 282 (M+Na+, 55%). HRMS (ESI) calcd. for 
C13H25N04Na [M +Naf m/z 282.1681, found 282.1669.
(S)-5-Acetamido-6-methyl-3-oxaheptanoic acid (69)
Trifluoroacetic acid (3 mL) was added to a stirred suspension of (Y)-?-butyl-5- 
acetamido-6-methyl-3-oxaheptanoate (77) (200 mg, 0.8 mmol) in dichloromethane 
(20 mL). The mixture was stirred overnight and concentrated under reduced 
pressure to give a brown oil. The residue was subjected to preparative high 
performance liquid chromatography to give the title compound 69 (30 mg, 19%) as a 
colourless oil.
'H NMR (300 MHz, CD3OD): 5 0.91 (d, J=  6.7 Hz, 3H), 0.94 (d, J  = 6.7 Hz, 3H), 
1.83-1.94 (m, 1H), 1.97 (s, 3H), 3.51 (dd, .7=4.4, 9.9 Hz, 1H), 3.62 (dd, 7 = 5 .4 , 9.9 
Hz, 1H), 3.74-3.79 (m, 1H), 4.06 (s, 2H). 13C NMR (75 MHz, CDC13): 8 18.8, 18.9, 
21.4, 28.9, 56.1, 67.6, 70.9, 174.4, 174.8. MS (ESI) (-ve): m/z 202 (M-H+, 30%). 
HRMS (ESI) calcd. for C9Hi6N 0 4 [M -H f m/z 202.1079, found 202.1076. HPLC: 
/r 16.0 min (column: YMC-Pack ODS-AQ, 250 x 20 mm; (82:18) water (containing 
0.1% TFA): acetonitrile; flow rate: 10.0 cm3 m in 1).
(69)
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10.4.4 Experimental for Chapter Five 
(5)-7V-Acetylphenylalanine methyl ester (82)
AcHN
(82)
Thionyl chloride (2.8 mL, 38.6 mmol) was added to a suspension of (S)-N- 
acetylphenylalanine (32) (2.0 g, 9.7 mmol) in methanol (60 mL) and the mixture was 
stirred at room temperature for 5 hours. The solution was concentrated under 
reduced pressure to yield the title compound 82 (2.1 g, 98%) as a white solid.
Mp. 90-91 °C (lit.,118 90-91 °C). *H NMR (300 MHz, CDC13): 8 2.08 (s, 3H), 3.08 
(dd, J =  9.0, 13.8 Hz, 1H), 3.18 (d d ,J =  5.7, 13.8 Hz, 1H), 3.72 (s, 3H), 4.79-4.87 
(m, 1H), 6.55 (br s, 1H), 7.03-7.12 (m, 2H), 7.21-7.31 (m, 3H). MS (ESI) (+ve): 
m/z 244 (M+Na~, 22%). The acquired ‘H NMR spectral data are consistent with 
previously reported data.76
0S)-Dimethyl-3-acetamido-2-oxo-4-phenylbutylphosphonate (83)
AcHN
(83)
«-Butyl lithium (1.6M in hexanes, 28.3 mL, 45.2 mmol) was added dropwise to a 
solution of dimethyl methylphosphonate (4.9 mL, 45.2 mmol) in tetrahydrofuran 
(50 mL) maintained at -78 °C under a nitrogen atmosphere, and stirred for 30
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minutes. A solution of (5)-A-acetylphenylalanine methyl ester (82) (2.0 g, 9.0 
mmol) in tetrahydrofuran (40 mL) was added dropwise. The mixture was stirred at -  
78 °C for 1 hour, quenched with 10% aqueous acetic acid (20 mL) and extracted 
with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with 
10% aqueous sodium bicarbonate (3 x 40 mL) and brine solution (3 x 40 mL). The 
solution was dried, filtered and concentrated under reduced pressure. The residue 
was chromatographed on flash silica gel, eluting with acetonitrile/diethyl ether (1:1 
to 5:1) then acetonitrile, to yield the title compound 83 (0.5 g, 16%) as a yellow oil.
!H NMR (300 MHz, CDC13): 5 2.03 (s, 3H), 2.99-3.39 (m, 4H), 3.78-3.84 (m, 6H), 
4.87 (ddd, J  = 6.0, 6.0, 6.0 Hz, 1H), 6.54 (br d, J  = 7.5 Hz, 1H), 7.24-7.39 (m, 5H). 
MS (ESI) (+ve): m/z 336 (M+Na+, 66%). HRMS (El) calcd. for C14H20NO5P [Mf* 
m/z 313.1079, found 313.1082. The acquired 'H NMR spectral data are consistent 
with previously reported data.74
/-Butyl glyoxylate (84)
A mixture of /-butyl alcohol (5.6 mL, 58.0 mmol), A,A’-dicyclohexylcarbodiimide 
(10.0 g, 48.5 mmol) and cuprous chloride (0.2 g, 2.0 mmol) was stirred at room 
temperature over 5 days. (S)-Tartaric acid (2.4 g, 16.0 mmol) in dichloromethane 
(70 mL) was added to the mixture, and stirring was continued at room temperature 
for 28 hours. The mixture was filtered through a pad of celite and washed with 
dichloromethane (100 mL). The solution was partitioned between dichloromethane 
and water (100 mL). The organic extract was dried, filtered and concentrated under 
reduced pressure to give a yellow solid, which was subjected to flash silica gel 
column chromatography eluting with diethyl ether/pentane to yield a white solid. 
The solid (l.Og, 3.8 mmol) was dissolved in methanol (20 mL) and treated with a 
solution of sodium periodate (980 mg, 4.5 mmol) in water (10 mL). The mixture
o
o
(84)
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was stirred at 0 °C for 80 minutes. The white precipitate was taken up in water (70 
mL) and extracted with diethyl ether (3 x 70 mL). The combined organic extracts 
were dried, fdtered and concentrated under reduced pressure to give the title 
compound 84 (0.4 g, 99%) as a yellow oil. The residue was used in the synthesis of 
(5',£)-r-butyl-5-acetamido-4-oxo-6-phenylhex-2-enoate (85) without further 
purification.
(S^-Z-Biityl-S-acetamido^-oxo-ö-pheiiylhex-Z-enoate (85)
AcHN
(85)
To a suspension of (5)-dimethyl-3-acetamido-2-oxo-4-phenylbutylphosphonate (83) 
(450 mg, 1.4 mmol) in acetonitrile (10 mL) was added a solution of /-butyl 
glyoxylate (84) (431 mg, 3.8 mmol) in acetonitrile (10 mL), lithium chloride (61 mg, 
1.4 mmol) and triethylamine (0.2 mL, 1.4 mmol). The mixture was stirred at 0 °C 
under a nitrogen atmosphere for 70 minutes, warmed to room temperature, quenched 
with 10% aqueous citric acid (8 mL) and extracted with diethyl ether (3 x 50 mL). 
The combined organic extracts were dried, filtered and concentrated under reduced 
pressure. The residue was chromatographed on flash silica gel, eluting with 
pentane/diethyl ether (2:1 to 1:1 to 1:2) then diethyl ether, to give the title compound 
85 (163 mg, 36%) as a yellow oil.
JH NMR (300 MHz, CDC13): 6 1.55 (s, 9H), 2.00 (s, 3H), 3.08 (dd, J = 5.4, 14.0 Hz, 
1H), 3.19 (dd, .7=6.6, 14.0 Hz, 1H), 5.13 (ddd, J  = 5.4, 6.6, 6.9 Hz, 1H), 6.11 (br d, 
J =  6.9 Hz, 1H), 6.70 (d, J =  15.9 Hz, 1H), 7.02 (d, 15.9 Hz, 1H), 7.04-7.07 (m,
2H), 7.20-7.31 (m, 3H). 13C NMR (75 MHz, CDC13): 6 22.9, 27.9, 37.0, 58.2, 82.1, 
127.1, 128.5, 129.3, 130.2, 134.6, 135.3, 164.0, 169.7, 197.1. MS (El) (+ve): m/z
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317 (M~\ 100%). HRMS (El) calcd. for C ,gH23N04 [M]+‘ m/z 317.1627, found 
317.1625.
(SV£)-5-Acetamido-4-oxo-6-phenyIhex-2-enoic acid (80)
AcHN
(80)
A suspension of (5',£)-/-butyl-5-acetamido-4-oxo-6-phenylhex-2-enoate (85) (50 mg, 
0.2 mmol) dissolved in dichloromethane (10 mL) was treated with trifluoroacetic 
acid (1.0 mL). The mixture was stirred overnight at room temperature and 
concentrated under reduced pressure. Recrystallisation of the product from ethyl 
acetate/hexanes yielded the title compound 80 (20 mg, 38%) as a white solid.
Mp. 105-106 °C (lit. ,74 1 05-107 °C). 'H NMR (300 MHz, (CDC13): ö 1.87 (s, 3H), 
2.99 (dd, J  — 6.3, 13.9 Hz, 1H), 3.16 (dd, J  = 6.3, 13.9 Hz, 1H), 4.88-4.96 (m, 1H), 
6.73 (d, J  = 15.9 Hz, 1H), 6.99-7.01 (m, 1H), 7.11 (d, J  = 15.9 Hz, 1H), 7.13-7.30 
(m, 5H). MS (El) (+ve): m/z 261 (M+‘, 63%). HRMS (El) calcd. for C14H15NO4 
[M]+* m/z 261.1001, found 261.0997. Anal. Calcd. for C 14Hi5N0 4: C, 64.36; H, 
5.79; N, 5.36. Found: C, 64.35; H, 5.90; N, 5.19%. The *H NMR spectral 
information are consistent with literature information.74
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(SyiV-Acetylleucine methyl ester (86)
AcHN
(86)
Thionyl chloride (1.7 mL, 23.1 mmol) was added to a suspension of (S)-N- 
acetylleucine (35) (2.0 g, 11.5 mmol) dissolved in methanol (25 mL) at 0 °C. The 
mixture was warmed to room temperature and stirred overnight under a nitrogen 
atmosphere. Solvent evaporation under reduced pressure gave the title compound 86 
(2.0 g, 93%) as a colourless oil.
'H NMR (300 MHz, CDC13): Ö 0.91 (d, J=  5.8 Hz, 3H), 0.94 (d, J  = 5.8 Hz, 3H), 
1.65-1.81 (m, 3H), 2.41 (s, 3H), 3.72 (s, 3H), 4.57 (m, 1H). MS (ESI) (+ve): m/z 
188 (M +H \ 27%). HRMS (ESI) calcd. for C9Hi8N 0 3 [M+H]+ m/z 188.1287, found 
188.1281. The 'H NMR spectral information obtained are consistent with previously
7 0
reported data.
(5)-Dimethyl-3-acetamido-5-methyl-2-oxohexylphosphonate (87)
(87)
«-Butyl lithium (1.6M in hexanes, 40.1 mL, 64.1 mmol) was added to a mixture of 
dimethyl methylphosphonate (6.9 mL, 64.1 mmol) in tetrahydrofuran (40 mL) 
maintained at -78 °C under a nitrogen atmosphere. After 30 minutes a solution of 
(^-A-acetylleucine methyl ester (86) (1.5 g, 8.0 mmol) in tetrahydrofuran (20 mL) 
was added dropwise and stirred at -78 °C for 1 hour, quenched with 10% aqueous
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acetic acid (25 mL), warmed to room temperature and extracted with ethyl acetate (3 
x 50 mL). The combined organic extracts were washed with 10% aqueous sodium 
bicarbonate (3 x 50 mL) and brine solution (3 x 50 mL). The solution was dried, 
filtered and concentrated under reduced pressure. The residue was chromatographed 
on flash silica gel, eluting with acetonitrile to give the title compound 87 (0.6 g, 
28%) as a yellow oil.
’H NMR (300 MHz, CDC13): 5 0.90 (d, J  = 2.1 Hz, 3H), 0.92 (d, J =  2.1 Hz, 3H), 
1.58-1.76 (m, 3H), 2.04 (s, 3H), 2.99-3.38 (m, 2H), 3.68-3.78 (m, 6H), 4.63-4.70 (m, 
1H), 6.57 (br d, J =  8.1 Hz, 1H). 13C NMR (75 MHz, CDC13): 5 21.2, 22.6, 22.9, 
24.5, 36.8, 38.6, 38.8, 57.2, 57.3, 170.3, 201.5. MS (ESI) (+ve): m/z 280 (M+H+, 
100%). HRMS (ESI) calcd. for CnH^NOsP [M +Hf m/z 280.1314, found 
280.1317.
(5yE)-r-Butyl-5-acetamido-7-methyl-4-oxooct-2-enoate (88)
AcHN
(88)
A suspension of (5)-dimethyl-3-acetamido-5-methyl-2-oxohexylphosphonate (87) 
(450 mg, 1.6 mmol) in acetonitrile (15 mL) was treated with freshly prepared Lbutyl 
glyoxylate (84) (431 mg, 3.8 mmol) in acetonitrile (10 mL), lithium chloride (68 mg, 
1.6 mmol) and triethylamine (0.2 mL, 1.6 mmol). The mixture was stirred at 0 °C 
under a nitrogen atmosphere for 70 minutes, warmed to room temperature, quenched 
with 10% aqueous citric acid (10 mL) and extracted with diethyl ether (3 x 50 mL). 
The combined organic extracts were dried, filtered then concentrated under reduced 
pressure. The residue was chromatographed on flash silica gel, eluting with 
hexanes/ethyl acetate (2:1 to 1:1 to 1:2), to yield the title compound 88 (160 mg, 
35%) as a yellow oil.
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*H NMR (300 MHz, CDCI3): 5 0.92 (d, J =  6.3 Hz, 3H), 0.99 (d, J =  6.3 Hz, 3H), 
1.21-1.73 (m, 3H), 1.51 (s, 9H), 2.03 (s, 3H), 4.98-4.91 (m, 1H), 6.01 (br d, .7=7.8 
Hz, 1H), 6.75 (d, J  = 15.9 Hz, 1H), 7.07 (d, J =  15.9 Hz, 1H). 13C NMR (75 MHz, 
CDCI3): 5 21.6, 22.8, 23.1, 24.8, 27.8, 40.2, 55.6, 82.1, 134.3, 135.5, 164.2, 170.1, 
198.5. MS (ESI) (+ve): m/z 306 (M+Na+, 100%). HRMS (ESI) calcd. for 
C15H25N04Na [M+Na]+ m/z 306.1681, found 306.1680.
(5^)-5-Acetamido-7-methyl-4-oxooct-2-enoic acid (81)
AcHN
(81)
Trifluoroacetic acid (1.5 mL) was added dropwise to a solution of (S,is)-Lbutyl-5- 
acetamido-7-methyl-4-oxooct-2-enoate (88) (100 mg, 0.4 mmol) in dichloromethane 
(15 mL). The mixture was stirred overnight at room temperature and solvent 
evaporation under reduced pressure gave a yellow oil. The residue was subjected to 
preparative high performance liquid chromatography to give the title compound 81 
(30 mg, 37%) as a yellow oil.
*H NMR (300 MHz, (CD3)2SO): 5 0.84 (d, J =  6.6 Hz, 1H), 0.87 (d, J=  6.6 Hz, 1H), 
1.42 (dd, J =  7.2, 7.5 Hz, 2H), 1.56-1.62 (m, 1H), 1.85 (s, 3H), 4.45 (dt, J =  7.2, 7.5 
Hz, 1H), 6.57 (d, J  = 15.6 Hz, 1H), 7.10 (d, J =  15.6 Hz, 1H), 8.35 (d, J  = 12  Hz, 
1H). 13C NMR (75 MHz, (CD3)2SO): S 21.3, 22.2, 23.0, 24.3, 37.9, 55.8, 131.9, 
136.3, 166.3, 169.7, 198.6. MS (ESI) (-ve): m/z 226 (M-H+, 8%). HRMS (ESI) 
calcd. for C nH 16N 0 4 [M-H]~ m/z 226.1079, found 226.1074. HPLC: tR 20.5 min 
(column: YMC-Pack ODS-AQ, 250 x 20 mm; (80:20) water (containing 0.1% TFA): 
acetonitrile; flow rate: 10.0 cm3 m in 1).
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10.4.5 Experimental for Chapter Six 
(S)-7V-ff-Butoxycarbonyl)phenylalanine (95)
BocHN
(95)
Sodium hydroxide (1.5 g, 38.5 mmol) and di-/-butyl dicarbonate (4.2 g, 19.2 mmol) 
were added to a mixture of (5)-phenylalanine (31) (2.9 g, 17.5 mmol) in 
tetrahydrofuran/water (1:1) (58 mL). The mixture was stirred at room temperature 
overnight and the organic layer was concentrated under reduced pressure. The 
aqueous layer was extracted with dichloromethane (3 x 50 mL) and the combined 
organic extracts were dried, filtered and concentrated under pressure to give the title 
compound 95 (3.4 g, 73%) as a white solid.
Mp. 86-87 °C (lit.,119 85-87 °C). 'H NMR (300 MHz, CDC13): 8 1.27 (s, 9H), 3.08 
(dd, J  = 6.6, 13.8 Hz, 1H), 3.20 (dd, 7 = 5 .7 , 13.8 Hz, 1H), 4.57-4.64 (m, 1H), 4.94 
(d, J =  7.8 Hz, 1H), 7.17-7.34 (m, 5H). MS (ESI) (-ve): m/z 264 (6%, M-H+). The 
obtained ]H NMR spectral data are consistent with literature information.120
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(^)-A^-(/-Butoxycarbonyl)phenylalanine TV-methoxy-TV-methylamide (97)
BocHN
(97)
A suspension of (£)-7V-(?-butoxycarbonyl)phenylalanine (95) (2.7 g, 10.0 mmol) in 
dichloromethane (40 mL) was treated with triethylamine (1.4 mL, 10.0 mmol). The 
mixture was treated with BOP (4.4 g, 10.0 mmol), A,0-dimethylhydroxylamine (96) 
(1.1 g, 11.0 mmol) and triethylamine (1.5 mL, 11.0 mmol), and stirred at room 
temperature for 1 hour. The mixture was diluted with dichloromethane (200 mL) 
and washed successively with 3M hydrochloric acid (3 x 30 mL), saturated sodium 
bicarbonate solution (3 x 30 mL), and brine solution (3 x 30 mL). The organic 
extract was dried, filtered and concentrated under reduced pressure. The crude 
product was subjected to flash silica gel column chromatography, eluting with 
hexanes/ethyl acetate (1:1) to give the title compound 97 (2.9 g, 95%) as a colourless 
oil.
!H NMR (300 MHz, CDCI3): 5 1.37 (s, 9H), 2.86 (dd, J =  6.9, 13.3 Hz, 1H), 3.04 
(dd, J  = 6.0, 13.3 Hz, 1H), 3.15 (s, 3H), 3.64 (s, 3H), 4.90-4.97 (m, 1H), 5.19 (br d, J  
= 8.4 Hz, 1H), 7.14-7.30 (s, 5H). MS (ESI) (+ve): m/z 309 (M+H+, 98%). HRMS 
(ESI) calcd. for C 16H25N2O4 [M+H]+ m/z 309.1814, found 309.1813. The obtained 
'H NMR spectral characteristics are consistent with previously reported data.84
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(S^A-^-ButoxycarbonyOphenylalaninal (98)
BocHN
(98)
Lithium aluminium hydride (1.0M in tetrahydrofuran, 3.3 mL, 3.3 mmol) was added 
dropwise to a solution of the (5)-A-(/-butoxycarbonyl)-phenylalanine A-methoxy-A- 
methylamide (97) (820 mg, 2.7 mmol) in tetrahydrofuran (20 mL) at 0 °C under a 
nitrogen atmosphere. After 20 minutes, the reaction was quenched by the addition of 
a solution of potassium hydrogen sulfate (620 mg, in 10 mL water). The mixture 
was washed with diethyl ether (3 x 30 mL). The combined organic extracts were 
washed with 3M hydrochloric acid (3 x 20 mL), saturated sodium bicarbonate 
solution (3 x 20 mL) and brine solution (3 x 20 mL). The extracts were dried, 
filtered and concentrated under reduced pressure to give the title compound 98 (530 
mg, 82%) as a white solid.
Mp. 80-81 °C (lit.,121 82 °C). *H NMR (300 MHz, CDC13): 5 1.43 (s, 9H), 3.12 (d, 
J =  6.6, 2H), 4.42 (dt, J =  6.6 Hz, 6.9 Hz, 1H), 5.05 (br d, J =  6.0 Hz, 1H), 7.15-7.34 
(m, 5H), 9.63 (s 1H). MS (El) (+ve): m/z 249 (M+\  92%). HRMS (El) calcd. for 
C14H19NO3 [Mf* m/z 249.1365, found 249.1370. The obtained *H NMR spectral 
information are consistent with previously reported values.90
[ 1-(TrimethylsilyI)propyn-3-yl)]triphenylphosphonium bromide (99)
Ph3PH2C C = C S iM e 3Br
(99)
A mixture of 3-(trimethylsilyl)propargyl bromide (1.1 mL, 7.8 mmol), 
triphenylphosphine (2.7 g, 10.2 mmol) in benzene (7.5 mL) was stirred in the dark
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for 18 hours. The brown precipitate was filtered and washed with hexanes (15 mL), 
and the filtrate was concentrated under reduced pressure to give the title compound 
99 (2.6 g, 74%) as a brown solid.
Mp. 157-158 °C (lit.,86 155-159 °C). NMR (300 MHz, CDC13): 5 -0.05 (s, 9H), 
5.13 (d, J  -  15.0 Hz, 2H), 7.27-7.96 (m, 15H). MS (ESI) (+ve): m/z 373 ((M-Br)+ 
100%). The ]H NMR spectral information are consistent with literature data.92
(5,£)-5-[A^-(/-butoxycarbonylamino)]-6-phenyI-l-trimethylsilylhex-3-en-l-yne
( 100)
BocHN
A suspension of [l-(trimethyls\lyd)propyn-3-yl)]triphenylphosphonium bromide (99) 
(295 mg, 0.7 mmol) in tetrahydrofuran (5 mL) was treated with «-butyl lithium 
(1.6M in diethyl ether, 0.4 mL, 0.7 mmol). The mixture was stirred at -78 °C for 1 
hour under a nitrogen atmosphere, then treated with a solution of (S)-N-(t- 
butoxycarbonyl)phenylalaninal (98) (163 mg, 0.7 mmol) in tetrahydrofuran (5 mL). 
The mixture was stirred at -78 °C for 1 hour, warmed to room temperature and 
stirred overnight. The solution was concentrated under reduced pressure and the 
residue was triturated with diethyl ether. The organic extract was washed with brine 
solution (3 x 20 mL) then dried, filtered and concentrated under reduced pressure to 
give a brown oil. The residue was chromatographed on flash silica gel, eluting with 
dichloromethane to yield the title compound 100 (98 mg, 45%) as a colourless oil.
]H NMR (300 MHz, CDC13): 5 0.16 (s, 9H), 1.37 (s, 9H), 2.79-2.81 (m, 2H), 4.49 
(m, 1H), 5.60 (d, J =  15.9 Hz, 1H), 6.12 (d, J =  15.9 Hz, 1H), 7.17-7.31 (m, 5H). 
MS (ESI) (+ve): m/z 366 (M+Na+, 24%). HRMS (ESI) calcd. for C2oH29N02NaSi
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[M+Na] m/z 366.1865, found 366.1879. The 'H NMR spectral information 
obtained are consistent with literature values.91
(5'rE)-5-[A^-(/-Butoxycarbonylamino)]-6-phenyIhex-3-enoic acid (93)
BocHN
(93)
Cyclohexene (0.2 mL, 1.7 mmol) was added to a suspension of borane- 
tetrahydrofuran complex (1.0M in tetrahydrofuran, 0.9 mL, 0.9 mmol) and stirred at 
0 °C for 1 hour under a nitrogen atmosphere. (S,£)-5-|W-(r-Butoxycarbonylamino)]- 
6-phenyl-l-trimethylsilylhex-3-en-l-yne (100) (90 mg, 0.3 mmol) in tetrahydrofuran 
(1 mL) was added dropwise. The resulting mixture was stirred at 0 °C for 1 hour, 
and was then treated with methanol (0.3 mL), 2M sodium hydroxide (0.5 mL), 
hydrogen peroxide (0.3 mL, 30% w/v) and stirred at room temperature for 1 hour. 
The mixture was poured into water (4 mL) containing 2M sodium hydroxide (0.4 
mL) and extracted with diethyl ether ( 3 x 1 5  mL). The aqueous layer was acidified 
to pH 2 with 1M hydrochloric acid and extracted with diethyl ether (3 x 15mL). The 
organic extracts were dried, filtered and concentrated under reduced pressure to give 
the title compound 93 (60 mg, 74%) as a colourless oil.
lH  NMR (300 MHz, CDC13): 5 1.38 (s, 9H), 2.83 (d, J =  6.9 Hz, 2H), 3.09 (d, J  = 
5.7 Hz, 2H), 4.42 (br s, 1H), 5.45-5.61 (m, 2H), 7.16-7.31 (m, 5H). MS (ESI) (-ve): 
m/z 304 (M-H+, 48%). HRMS (ESI) calcd. for C17H22NO4 [M -H f m/z 304.1549, 
found 304.1554. The ]H NMR spectral data are consistent with previously reported 
information.89
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(S^A^-Butoxycarbonyrileucine (118)
BocHN
O
OH
(118)
Sodium hydroxide (3.4 g, 83.8 mmol) and di-/-butyl dicarbonate (9.2 g, 41.9 mmol), 
were added to a suspension of (^-leucine (34) (5.0 g, 38.1 mmol) in a 1:1 mixture of 
tetrahydrofuran and water (127 mL). The mixture was stirred at room temperature 
overnight and the organic layer was concentrated under reduced pressure. The 
aqueous layer was extracted with dichloromethane (3 x 70 mL), acidified to pH 4 
with 1M hydrochloric acid and extracted with dichloromethane (3 x 70 mL). The 
combined organic extracts were dried, filtered and concentrated under reduced 
pressure to give the title compound 118 (7.8 g, 89%) as a white solid.
Mp. 72-73 °C (lit.,122 72-74 °C). !H NMR (300 MHz, CDC13): 5 0.95 (d, J  = 6.3 
Hz, 6H), 1.44 (s, 9H), 1.48-1.76 (m, 3H), 4.27-4.35 (m, 1H),4.89 (br d, J=  8.4 Hz, 
1H). MS (ESI) (-ve): m/z 230 (M-H+, 100%). HRMS (ESI) calcd. for C iiH2oN 0 4 
[M-H]~ m/z 230.1392, found 230.1387. The ’H NMR spectral information acquired 
are consistent with literature values.123
(5}-A^-(/-ButoxycarbonyI)leucine 7V-methoxy-./V-methylamide (119)
Triethylamine (2.7 mL, 19.5 mmol) was added to a solution of 7V,0-dimethyl 
hydroxylamine (96) (1.9 g, 19.5 mmol) in dichloromethane (50 mL). The mixture
BocHN
o
(119)
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was treated with flS)-A^-(r-butoxycarbonyl)leucine (118) (5.0 g, 21.6 mmol) in 
dichloromethane (30 mL), A^ TV’-dicyclohexylcarbodiimide (5.2 g, 25.3 mmol), 
triethylamine (5.4 mL, 38.9 mmol) and a catalytic amount of 4- 
dimethylaminopyridine. The mixture was stirred at room temperature for 1 hour and 
the white precipitate was filtered. The filtrate was washed successively with 0.3M 
citric acid (3 x 35 mL), saturated sodium carbonate solution (3 x 35 mL), brine 
solution (3 x 35 mL), then dried, filtered and concentrated under reduced pressure. 
The residue was chromatographed on flash silica gel, eluting with hexanes/ethyl 
acetate (9:1 to 3:2 to 1:1), to give the title compound 119 (1.8 g, 33%) as a light 
yellow oil.
’H NMR (300 MHz, CDC13): 5 0.92 (d, J  = 6.6 Hz, 3H), 0.96 (d, J =  6.6 Hz, 3H), 
1.42 (s, 9H), 1.45-1.82 (m, 3H), 3.19 (s, 3H), 3.78 (s, 3H), 4.67-4.83 (m, 1H), 5.07 
(br d, J =  9.0 Hz, 1H). MS (ESI) (+ve): m/z 297 (M+Na+, 100%). HRMS (ESI) 
calcd. for C n ^ ^ C U N a  [M +Naf m/z 297.1790, found 297.1792. The acquired ]H 
NMR spectral information are consistent with reported data.93
(S)-A^-(r-Butoxycarbonyl)leucinal (120)
BocHN
O
( 120)
Lithium aluminium hydride (1.0M in tetrahydrofuran, 13.7 mL, 13.7 mmol) was 
added dropwise to a suspension of (S)-jV-(Lbutoxycarbonyl)leucine ALmethoxy-./V- 
methylamide (119) (750 mg, 2.7 mmol) in tetrahydrofuran (60 mL) under a nitrogen 
atmosphere. The mixture was stirred at 0 °C for 30 minutes, and quenched with a 
potassium hydrogen sulfate solution (1.4 g in 10 mL water). The organic layer was 
concentrated under reduced pressure, and the aqueous layer was extracted with 
dichloromethane (3 x 60 mL). The combined organic extracts were washed with 3M 
hydrochloric acid (3 x 20 mL), brine solution (2 x 30 mL), saturated sodium
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bicarbonate solution (3 x 20 mL) then brine solution (2 x 30 mL). The organic 
extracts were dried, filtered and concentrated under reduced pressure to give the title 
compound 120 (460 mg, 78%) as a colourless oil.
]H NMR (300 MHz, CDC13): 5 0.95 (d, J =  6.6 Hz, 6H), 1.23-1.89 (m, 3H), 1.44 (s, 
9H), 4.20-4.27 (m, 1H), 4.95 (br s, 1H), 9.58 (s, 1H). MS (ESI) (+ve): m/z 216 
(M+H+, 95%). The 'H NMR spectral information is consistent with published 
information.124
(SVE)-5-[N-(f-Butoxycarbonyl)amino]-7-methyI-l-trimethylsilyoct-3-en-l-yne
( 121)
BocHN
«-Butyl lithium (1.6M in hexanes, 1.3 mL, 2.1 mmol) was added dropwise to a 
mixture of [l-(trimethylsilyl)propyn-3-yl)]triphenylphosphonium bromide (99) (970 
mg, 2.1 mmol) in tetrahydrofuran (40 mL) under a nitrogen atmosphere. The 
mixture was stirred at -78 °C for 1 hour and treated with a solution of (<S)-N-(t- 
butoxycarbonyl)leucinal (120) (460 mg, 2.1 mmol) in tetrahydrofuran (20 mL), then 
warmed to room temperature. Solvent evaporation under reduced pressure gave a 
red oil, which was triturated with diethyl ether. The organic extract was 
concentrated under reduced pressure, treated with 1M sodium bicarbonate solution 
(30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic 
extracts were washed with 10% hydrochloric acid (3 x 30 mL) and brine solution (2 
x 50 mL), then dried and filtered. Solvent evaporation under reduced pressure gave 
a red oil, which was chromatographed on flash silica gel, eluting with 
hexanes/dichloromethane (1:1) then dichloromethane, to yield the title compound 
121 (345 mg, 52%) as a yellow solid.
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Mp. 89-90 °C (lit.,92 89-90 °C). *H NMR (300 MHz, CDC13): 6 0.17 (s, 9H), 0.91 
(d, J  = 6.6 Hz, 6H), 1.30-1.35 (m, 2H), 1.43 (s, 9H), 1.61-1.70 (m, 1H), 4.17-4.22 
(m, 1H), 4.36-4.38 (m, 1H), 5.64 (d, J  = 15.9 Hz, 1H), 6.07 (dd, J  = 6.0, 15.9 Hz, 
1H). MS (ESI) (+ve): m/z 332 (M+Na~, 100%). HRMS (ESI) calcd. for 
Ci7H3iN 02SiNa [M+Na]+ m/z 332.2022, found 332.2016. The acquired ’H NMR 
spectral data are consistent with literature values.92
(4S'rE)-5-[A^-(^-Butoxycarbonylamino)]-7-methyloct-3-enoic acid (94)
BocHN
(94)
Cyclohexene (0.3 mL, 3.4 mmol) in tetrahydrofuran (2 mL) was added dropwise to a 
mixture of borane-tetrahydrofuran complex (1.0M in tetrahydrofuran, 1.7 mL, 1.7 
mmol) under a nitrogen atmosphere and stirred at 0 °C for 1 hour. (5',£)-5-[N-(r- 
Butoxycarbonyl)amino]-7-methyl-l-trimethylsilyoct-3-en-l-yne (121) (150 mg, 0.5 
mmol) in tetrahydrofuran (0.6 mL) was added dropwise. The mixture was stirred for 
1 hour at 0 °C, treated with methanol (0.6 mL), 2M sodium hydroxide (0.9 mL) and 
30% hydrogen peroxide (w/v) (0.6 mL), and stirred at room temperature for 1 hour. 
The mixture was poured into water (10 mL) containing 2M sodium hydroxide (0.9 
mL) and extracted with diethyl ether (3 x 25 mL). The aqueous layer was acidified 
to pH 2 with 1M hydrochloric acid and extracted with diethyl ether (3 x 25 mL). 
The organic extracts were washed with brine solution (3 x 20 mL), then dried and 
filtered. Solvent evaporation under reduced pressure gave the title compound 94 (82 
mg, 63%) as a colourless oil.
|cx]23d -20.6 (c 0.5, EtOH). ’H NMR (300 MHz, CDC13): S 0.91 (d, J = 6.6 Hz, 6H), 
1.27-1.37 (m, 2H), 1.44 (s, 9H), 1.58-1.73 (m, 1H), 3.11 (d, J  = 6.6 Hz, 2H), 4.13 
(m, 1H), 5.51 (dd, J  = 5.7, 15.6 Hz, 1H), 5.65-5.75 (m, 1H). MS (ESI) (-ve): m/z 
270 (M-H+, 38%). HRMS (ESI) calcd. for C14H24NO4 [M-H]+ m/z 270.1705, found
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270.1714. The obtained *H NMR spectral information are consistent with reported 
data.92
10.4.6 Experimental for Chapter Seven 
(^-TV-Acetylmethionine (127)
Triethylamine (6.5 mL, 46.9 mmol) and acetic anhydride (9.5 mL, 100.0 mmol) 
were added to a suspension of (S)-methionine (126) (5.0 g, 33.5 mmol) in water (250 
mL). The mixture was stirred overnight at room temperature, acidified to pH 1 with 
1M hydrochloric acid then extracted with ethyl acetate (3 x 200 mL). The combined 
organic extracts were dried, filtered and concentrated under reduced pressure. The 
residue was triturated with hexanes to give the title compound 127 (4.3 g, 67%) as a 
white solid.
Mp. 104-105 °C (lit.,125 106 °C). !H NMR (300 MHz, (CDC13): 5 1.88-2.19 (m, 
2H), 1.99 (s, 3H), 2.06 (s, 3H), 2.50 (t, J  = 7.5 Hz, 2H), 4.58 (dt, J  = 4.9, 7.6 Hz, 
1H), 6.93 (br d, J =  7.6 Hz, 1H). MS (ESI) (-ve): m/z 190 (M-H+, 100%). HRMS 
(ESI) calcd. for C7H13N 0 3SNa [M+Na]+ m/z 214.0514, found 214.0505. The ’H 
NMR spectral data obtained are consistent with literature values.97
o
(127)
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(5)-7V-AcetylmethionylgIycine methyl ester (129)
(129)
Triethylamine (1.5 mL, 10.4 mmol) was added to a suspension of glycine methyl 
ester hydrochloride (128) (1.3 g, 10.4 mmol) in dichloromethane (70 mL) and stirred 
at -5  °C for 30 minutes. The mixture was then treated with (^-vV-acetylmethionine 
(127) (1.5 g, 7.8 mmol) and A^3-dimethylaminopropyl)-7V7-ethylcarbodiimide 
hydrochloride (1.6 g, 8.1 mmol), stirred at -5  °C for 1 hour, warmed to room 
temperature and stirred overnight. The mixture was extracted with water (2 x 100 
mL) and the combined aqueous extracts were washed with ethyl acetate (3 x 100 
mL). The combined organic extracts were dried, filtered and concentrated under 
reduced pressure to give the title compound 129 (0.5 g, 26%) as a white solid.
Mp. 109-110 °C. ’H NMR (300 MHz, CDC13): 8 1.94-2.15 (m, 2H), 2.04 (s, 3H), 
2.11 (s, 3H), 2.52-2.66 (m, 2H), 3.75 (s, 3H), 3.97 (dd, J =  5.4, 18.3 Hz, 1H), 4.10 
(dd, J — 6.0, 18.3 Hz, 1H), 4.70 (dt, 7 = 6 .9 , 7.8 Hz, 1H), 6.68 (br s, 1H), 7.11 (br s, 
1H). 13C NMR (75 MHz, CDC13): 8 15.1, 22.8, 29.8, 31.5, 41.0, 51.8, 52.1, 169.8, 
170.6, 172.1. MS (ESI) (+ve): m/z 285 (M+Na+, 100%). HRMS (ESI) calcd. for 
CioH18N20 4SNa [M+Na]+ m/z 285.0885, found 285.0886.
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(S^-TV-Acetylmethionylglycine (123)
AcHN
O
OH
(123)
Lithium hydroxide (38 mg, 1.6 mmol) in water (12 mL) was added to a suspension 
of (S)-Af-acetylmethionylglycine methyl ester (129) (300 mg, 1.1 mmol) in 
tetrahydrofuran (12 mL) and stirred at room temperature overnight. The mixture 
was acidified to pH 3 with 1M hydrochloric acid and extracted with ethyl acetate (3 
x 50 mL). The combined organic extracts were dried, filtered and concentrated 
under reduced pressure. The crude product was recrystallised from ethyl acetate to 
yield the title compound 123 (133 mg, 47%) as a white solid.
Mp. 112-113 °C. [a]23D -3.8 (c 2.0, EtOH). *H NMR (300 MHz, D20): 8 1.91- 
2.17 (m, 2H), 2.03 (s, 3H), 2.09 (s, 3H), 2.51-2.70 (m, 2H), 3.97 (s, 2H), 4.44-4.49 
(m, 1H). 13C NMR (75 MHz, CD3OD): 5 15.2, 22.5, 30.9, 32.7, 41.7, 53.8, 172.7, 
173.4, 174.4. MS (ESI) (-ve): m/z 247 (M-H+, 100%). HRMS (ESI) calcd. for 
C9H 16N2 0 4 S [M-H]+ m/z 247.0752, found 247.0751. Anal. Calcd. for C9H]5N20 4S: 
C, 43.54; H, 6.49; N, 11.28. Found: C, 43.60; H, 6.36; N, 11.04%. The obtained ]H
125
NMR spectral information are consistent with information previously reported.
(R)-Alanine methyl ester hydrochloride (131)
Thionyl chloride (6.5 mL, 89.8 mmol) was added dropwise to a mixture of {R)~ 
alanine (130) (2.0 g, 22.4 mmol) in methanol (40 mL). The mixture was stirred at
o
(131)
141
Experimental -  Chapter Ten
room temperature overnight and concentrated under reduced pressure. 
Recrystallisation of the crude product from dichloromethane yielded the title 
compound 131 (2.1 g, 67%) as white crystals.
Mp. 108-109 °C (lit. , 127 109-1 10 °C). [a]23D -0.4 (c 2.0, EtOH). *H NMR (300 
MHz, CDC13): 8 1.72 (d, J = 7.2 Hz, 3H), 3.81 (s, 3H), 4.26-4.30 (m, 1H), 4.88 (br s, 
2H). MS (ESI) (+ve): m/z 104 (M+H+, 100%). HRMS (ESI) calcd. for 
C4H9N 0 2Na [M+Na]+ m/z 126.0531, found 126.0526. The 'H NMR spectral 
characteristics are consistent with literature data.128
(SVfl)-7V-Acetylmethionylalanine methyl ester (132)
MTV-Diisopropylethylamine (2.0 mL, 11.6 mmol) was added dropwise to a mixture 
of (^-TV-acetylmethionine (127) (612 mg, 3.2 mmol), (/?)-alanine methyl ester 
hydrochloride (131) (300 mg, 2.1 mmol) and BOP reagent (1.4 g, 3.2 mmol) in 
dichloromethane (20 mL). The mixture was stirred overnight at room temperature 
and treated with brine solution (100 mL). The mixture was extracted with ethyl 
acetate (4 x 50 mL) and the combined organic extracts were washed successively 
with 0.3M citric acid (3 x 50 mL), saturated sodium bicarbonate solution (3 x 50 
mL) and brine solution (3 x 50 mL). The organic material was dried, filtered and 
concentrated under reduced pressure to give the title compound 132 (117 mg, 20%) 
as a white solid.
Mp. 130-131 °C. *H NMR (300 MHz, CDC13): 8 1.41 (d, J  = 6.9 Hz, 3H), 1.88- 
2.15 (m, 2H), 2.02 (s, 3H), 2.10 (s, 3H), 2.44-2.58 (m, 2H), 3.74 (s, 3H), 4.47-4.56 
(m, 1H), 4.59-4.80 (m, 1H), 6.56 ( b r d , J = 6 . 9  Hz, 1H), 7.05 ( b r d , J = 7 . 2  Hz, 1H).
(132)
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MS (El) (+ve): m/z 276 (M", 3%). HRMS (El) calcd. for C,iH2oN20 4S [M]~* m/z 
276.1144, found 276.1145.
(,S,jR)-yV-Acetylmethionylalanine (124)
AcHN
(124)
A suspension of (5',/?)-A-acetylmethionylalanine methyl ester (132) (150 mg, 0.5 
mmol) in tetrahydrofuran (5 mL) was treated with lithium hydroxide (18 mg, 0.5 
mmol) in water (5 mL). The mixture was stirred at room temperature for 2 hours, 
acidified to pH 3 with 1M hydrochloric acid and extracted with ethyl acetate (3 x 40 
mL). The combined organic extracts were dried, filtered and concentrated under 
reduced pressure. The solid was recrystallised from ethyl acetate/hexanes to give the 
title compound 124 (30 mg, 21%) as a white solid.
Mp. 148-149 °C. [cc]23d -12.0 (c 0.5, EtOH). *H NMR (300 MHz, D20): 6 1.22 (d, 
J  = 7.5 Hz, 3H), 1.73-1.96 (m 2H), 1.84 (s, 3H), 1.91 (s, 3H), 2.31-2.48 (m, 2H), 
4.17 (q, J =  7.5 Hz, 1H), 4.25 (dd, J  = 6.0, 6.0 Hz, 1H). MS (ESI) (+ve): m/z 285 
(M+Na+, 52%). HRMS (El) calcd. for C10H18N2O4 [M]+* m/z 262.0987, found 
262.0987. The acquired 'H NMR spectral information are consistent with literature 
data.98
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f-Butyl (^ -^ “-(A-acetylmethionyOglycolate (133)
AcHN
(133)
(5)-7V-Acetylmethionine (127) (500 mg, 2.6 mmol) and 7-butyl bromoacetate (0.4 
mL, 2.6 mmol) were added to a mixture of potassium carbonate (360 mg, 2.6 mmol) 
in acetone (60 mL). The mixture was heated at reflux overnight under a nitrogen 
atmosphere, cooled to room temperature and extracted with ethyl acetate (2 x 50 
mL). The organic extracts were dried, filtered and concentrated under reduced 
pressure to give the title compound 133 (703 mg, 89%) as a colourless oil.
]H NMR (300 MHz, CDC13): 5 1.45 (s, 9H), 1.98-2.29 (m, 2H), 2.02 (s, 3H), 2.09 
(s, 3H), 2.59 (t, .7=7.3 Hz, 2H), 4.43 (d, / =  15.6 Hz, 1H), 4.64 (d, J=  15.6 Hz, 1H), 
4.77-4.84 (m, 1H), 6.35 (br d, J  = 8.1 Hz, 1H). 13C NMR (75 MHz, CD3OD): 5 
15.4, 23.1, 27.9, 29.8, 31.6, 51.5, 61.7, 82.8, 166.1, 169.9, 171.5. MS (ESI) (+ve): 
m/z 328 (M+Na+, 100%). HRMS (ESI) calcd. for Ci3H24N 0 5S [M +H f m/z 
306.1375, found 306.1392.
(5)-0a-(A-acetyImethionyl)glycoIic acid (125)
AcHN
(125)
A suspension of 7-butyl (<S)-Oa-(A-acetylmethionyl)glycolate (133) (200 mg, 0.7 
mmol) in dichloromethane (20 mL) was treated with trifluoroacetic acid (2.5 mL).
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The mixture was stirred overnight at room temperature and concentrated under 
reduced pressure to give a colourless oil. The residue was subjected to preparative 
high performance liquid chromatography to give the title compound 125 (120 mg, 
69%) as a colourless oil.
[a]23D -63.8 (c 0.5, EtOH). *H NMR (300 MHz, CDC13): 6 1.94-2.25 (m, 2H), 2.01 
(s, 3H), 2.08 (s, 3H), 2.56 (t, J=  7.5 Hz, 2H), 4.59 (d, J =  16.2 Hz, 1H), 4.75 (d, J  = 
16.2 Hz, 1H), 4.73-4.78 (m, 1H). ,3C NMR (75 MHz, CD3OD): 5 15.3, 22.7, 29.8, 
31.3, 51.4, 61.2, 169.4, 170.9, 171.6. MS (ESI) (-ve): m/z 248 (M-H+, 12%). 
HRMS (ESI) calcd. for C9H,5N05SNa [M +Naf m/z 272.0569, found 272.0577. 
HPLC: tR 19.3 min (column: YMC-Pack ODS-AQ, 250 x 20 mm; (85:15) water 
(containing 0.1% TFA): acetonitrile; flow rate: 10.0 cm3 min'1).
(iS'^-A-Acetylleucylalanine methyl ester (134)
AcHN
(134)
(/?)-Alanine methyl ester hydrochloride (131) (0.5 g, 3.6 mmol) in N,N- 
dimethylformamide (30 mL) was treated with ^TY-diisopropylethylamine (0.8 mL, 
4.8 mmol). The mixture was stirred at room temperature for 5 minutes under a 
nitrogen atmosphere and treated with (^-A-acetylleucine (35) (0.9 g, 5.3 mmol), 
BOP (2.4 g, 5.3 mmol) and A(A,-diisopropylethylamine (2.5 mL, 14.5 mmol). The 
mixture was stirred overnight at room temperature, treated with brine solution (50 
mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic extracts 
were washed successively with 0.3M citric acid (3 x 30 mL), saturated sodium 
bicarbonate solution (3 x 30 mL) and brine solution (3 x 30 mL). The organic 
material was dried, filtered and concentrated under reduced pressure. The crude 
product was recrystallised from diethyl ether to yield the title compound 134 (0.1 g, 
9%) as a white solid.
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Mp. 133-134 °C. !H NMR (300 MHz, CDC13): 5 0.91 (d, J = 3 .3  Hz, 3H), 0.94 (d, 
J =  3.3 Hz, 3H), 1.40 (d, J =  7.2 Hz, 3H), 1.48-1.73 (m, 3H), 2.02 (s, 3H), 3.74 (s, 
3H), 4.46-4.58 (m,2H), 6.22 ( b r d , J =  8.4 Hz, 1H), 6.91 (br d, J=  7.2 Hz, 1H). 13C 
NMR (75 MHz, CD3OD): 5 17.9, 22.1, 22.8, 22.9, 24.7, 41.0, 48.0, 51.3, 52.3, 
170.4, 172.0, 173.1. MS (ESI) (+ve): m/z 281 (M+Na+, 100%). HRMS (ESI) 
calcd. for Ci2H22N20 4Na [M+Na]+ m/z 281.1477, found 281.1469. Anal. Calcd. for 
C 12H22N2O4: C, 55.80; H, 8.58; N, 10.84. Found: C, 55.92; H, 8.44; N, 10.86%.
(5V/?)-7V-Acetylleucylalanine (122)
AcHN
( 122)
(S’vß)-Ar-Acetylleucylalanine methyl ester (134) (75 mg, 0.3 mmol) in
tetrahydrofuran (5 mL) was treated with a solution of lithium hydroxide (10 mg, 0.4 
mmol) in water (5 mL). The mixture was stirred overnight at room temperature, 
acidified to pH 3 with 1M hydrochloric acid and extracted with ethyl acetate (4 x 20 
mL). The combined organic extracts were dried, filtered, and concentrated under 
reduced pressure to give the title compound 122 (55 mg, 75%) as a white solid.
Mp. 153-154 °C. [a]23D -44.8 (c 0.5, EtOH). *H NMR (300 MHz, CD3OD): S 0.91 
(d, J  = 6.4 Hz, 3H), 0.95 (d, J  = 6.4 Hz, 3H), 1.38 (d, J  = 7.2 Hz, 3H), 1.53-1.67 (m, 
3H), 1.98 (s, 3H), 4.33-4.45 (m, 2H). 13C NMR (75 MHz, CD3OD): 6  17.7, 22.0, 
22.5, 23.4, 25.9, 42.0, 53.0, 173.3, 174.6, 175.8. MS (ESI) (+ve): m/z 267 (M+Na+, 
100%). HRMS (ESI) calcd. for Cn^olS^CUNa [M +Naf m/z 267.1321, found 
267.1316. Anal. Calcd. for Cn H2oN20 4 : C, 54.08; H, 8.25; N, 11.47. Found: C, 
54.01; H, 8.42; N, 11.07%.
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10.4.7 Experimental for Chapter Eight
(SyTV-Benzyloxycarbonylasparagine (142)
o
CbzNH
O
(142)
Benzyl chloroformate (6.5 mL, 45.4 mmol) was added to a mixture of (S)-asparagine 
(141) (5.0 g, 37.8 mmol) in saturated sodium bicarbonate (60 mL) and stirred for 3 
hours at room temperature then acidified to pH 3 with 2M hydrochloric acid. The 
white precipitate was filtered, washed with water (15 mL) and a small amount of ice- 
cold ethanol. The solid was suspended in diethyl ether and filtered to give the title 
compound 142 (6.4 g, 63%) as a white solid.
Mp. 162-163 °C (lit.,129 163-165 °C). ‘H NMR (300 MHz, (CD3)2SO): 5 2.37-2.57 
(m, 2H), 4.28-4.36 (m, 1H), 5.01 (s, 2H), 6.95 (br s, 1H), 7.14-7.36 (m, 6H), 7.49 (br 
d, J =  8.4 Hz, 1H). MS (ESI) (-ve): m/z 265 (M-H+, 5%). HRMS (ESI) calcd. for 
Ci2Hi4N20 5 Na [M+Na]* m/z 289.0800, found 289.0790. The ’H NMR spectral 
information are consistent with literature data.1
(5)-Ar-Benzyloxycarbonyl-2,3-diaminopropionic acid (143)
Diacetoxyiodobenzene (4.3 g, 13.4 mmol) was added to a suspension of (S)-N- 
benzyloxycarbonylasparagine (142) (3.0 g, 11.2 mmol) in a mixture of ethyl
CbzNH
O
(143)
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acetate/acetonitrile/water (48/49/27 mL) and stirred at 15 °C for 30 minutes, warmed 
to room temperature and stirred for a further 2.5 hours. The mixture was cooled to 
5 °C, the white solid was filtered and washed with ethyl acetate (30 mL) to give the 
title compound 143 (2.2 g, 83%) as a white solid.
Mp. 226-227 °C (lit. , 105 227-228 °C). *H NMR (300 MHz, (CD3)2SO/TFA): 8  3.01- 
3.28 (m, 2H), 4.26-4.33 (m, 1H), 5.05 (s, 2H), 7.26-7.34 (m, 5H), 7.69 (d, J  = 8.7 
Hz, 1H), 7.90 (br s, 3H). MS (ESI) (+ve): m/z 239 (M+H+, 20%). HRMS (ESI) 
calcd. for C11H 15N2O4 [M+H]+ m/z 239.1032, found 239.1024. The *H NMR 
spectral data are consistent with those previously reported.10"^
Methyl (S)-/V2-benzyloxycarbonyl-2,3-diaminopropionate hydrochloride (137)
CbzNH
Thionyl chloride (1.2 mL, 16.7 mmol) was added to a mixture of (S)-N- 
benzyloxycarbonyl-2,3-diaminopropionic acid (143) (2.0 g, 8.4 mmol) in methanol 
(35 mL) and stirred overnight at room temperature. Solvent evaporation under 
reduced pressure gave the title compound 137 (2.1 g, 87%) as a white solid.
Mp. 156-157 °C (lit. , 105 156-157 °C). [a]23D -45.4 (c 0.5, EtOH). *H NMR (300 
MHz, D20): 8  3.16 (dd, J=  9.0, 13.6 Hz, 1H), 3.39 (dd, 7 = 5 .1 , 13.6 Hz, 1H), 3.70 
(s, 3H), 4.50-4.55 (m, 1H), 5.10 (s, 2H), 7.37 (s, 5H). MS (ESI) (+ve): m/z 253 
(M+H+, 20%). HRMS (ESI) calcd. for C]2H 17N20 4 [M+H]+ m/z 253.1188, found 
253.1180. The ]H NMR spectral characteristics are consistent with literature data. 105
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7V-(f-Butoxycarbonyl)glycine (147)
BocHN
O
(147)
1M Sodium hydroxide (67 mL) and di-/-butyl dicarbonate (14.5 g, 66.6 mmol) were 
added to a suspension of glycine (146) (5.0 g, 66.6 mmol) in tetrahydrofuran (150 
mL), stirred overnight at room temperature then acidified to pH 2 with saturated 
potassium hydrogen sulfate. The mixture was extracted with ethyl acetate ( 3 x1 0 0  
mL), dried, filtered and concentrated under reduced pressure to give the title 
compound 147 (9.8 g, 84%) as a white solid.
Mp. 87-88 °C (lit.,131 88-90 °C). !H NMR (300 MHz, CDC13): 5 1.45 (s, 9H), 3.91- 
3.98 (m, 2H), 5.07 (br s, 1H), 6.87 (br s, 1H). MS (ESI) (+ve): m/z 198 (M+Na+, 
77%). HRMS (ESI) calcd. for C7Hi3N 04Na [M +Naf m/z 198.0742, found 
198.0730. The !H NMR spectral data are consistent with reported data.107
7V-(f-ButoxycarbonyI)glycine jV-methoxy-TV-methyl amide (148)
^ O M e
(148)
Triethylamine (4.3 mL, 30.7 mmol) was added to a solution of N,0- 
dimethylhydroxylamine hydrochloride (96) (3.0 g, 30.7 mmol) in dichloromethane 
(40 mL). jV-(J-Butoxycarbonyl)glycine (147) (5.9 g, 33.8 mmol) in dichloromethane 
(30 mL), AyV’-dicyclohexylcarbodiimide (8.3 g, 39.8 mmol) and 4- 
dimethylaminopyridine (3 mg) were added to the mixture and stirred for 1 hour at 
room temperature. The white precipitate was filtered and the filtrate was diluted 
with dichloromethane (50 mL) and washed with 0.3M citric acid (3 x 30 mL), 
saturated sodium bicarbonate solution (3 x 30 mL) and brine solution (3 x 30 mL).
149
Experimental -  Chapter Ten
The organic extract was dried, filtered and concentrated under reduced pressure to 
give a red solid. The crude product was chromatographed on flash silica gel, eluting 
with hexanes/ethyl acetate (2:1 then 1:1) to give the title compound 148 (2.4 g, 36%) 
as a white solid.
Mp. 101-102 °C (lit.,94 102 °C). lU  NMR (300 MHz, CDC13): 6 1.45 (s, 9H), 3.20 
(s, 3H), 3.71 (s, 3H), 4.08-4.09 (m, 2H), 5.27 (br s, 1H). MS (ESI) (+ve): m/z 241 
(M+Na+, 35%). HRMS (ESI) calcd. for C9Hi8N20 4 Na [M+Na]+ m/z 241.1164, 
found 241.1152. The !H NMR spectral information are consistent with literature 
data.94
7V-(f-Butoxycarbonyl)glycinal (138)
(138)
Lithium aluminium hydride (0.7 g, 18.3 mmol) was added to a mixture of N-{t- 
butoxycarbonyl)glycine TV-methoxy-jV-methyl amide (148) (1.0 g, 4.6 mmol) in 
tetrahydrofuran (25 mL) under a nitrogen atmosphere. The mixture was stirred for 
20 minutes at 0 °C and quenched with a potassium hydrogen sulfate solution (1.4 g 
in 10 mL of water). The organic layer was concentrated under reduced pressure and 
the aqueous layer was extracted with dichloromethane (3 x 50 mL). The combined 
organic extracts were washed with 3M hydrochloric acid (3 x 40 mL), brine solution 
(3 x 40 mL), saturated sodium bicarbonate solution (3 x 40 mL) and brine solution (3 
x 40 mL). The organic extract was dried, filtered and concentrated under reduced 
pressure to give the title compound 138 (0.7 g, 94%) as a colourless oil. The oil was 
used in the synthesis methyl (5)-7V2-benzyloxycarbonyl-A76-(/-butoxycarbonyl)-2,6- 
diamino-4-azahexanoate (139) without further purification.
!H NMR (300 MHz, CDC13): 5 1.41 (s, 9H), 4.01-4.03 (m, 2H), 9.60 (s, 1H). The 
'H NMR spectral characteristics are consistent with those previously reported.94
150
Experimental -  Chapter Ten
Methyl (5r)-A^ 2-benzyloxycarbonyl-A^-(^-butoxycarbonyl)-2,6-diamino-4 
-azahexanoate(139)
Methyl (5)-A^ '?-benzyloxycarbonyl-2,3-diaminopropionate hydrochloride (137) (1.0 
g, 3.5 mmol) was added to a suspension of 7V-(Lbutoxycarbonyl)glycinal (138) (0.7 
g, 4.1 mmol) in a 1% acetic acid/methanol solution (25 mL) and stirred at room 
temperature under a nitrogen atmosphere. Sodium cyanoborohydride (311 mg, 5.0 
mmol) was added to the mixture in ten portions over 45 minutes and stirred 
overnight at room temperature. The mixture was cooled to 0 °C, treated with a 5% 
sodium bicarbonate solution (100 mL) and washed with ethyl acetate (150 mL). The 
organic layer was extracted with water (3 x 70 mL), dried, filtered and concentrated 
under reduced pressure to give a yellow oil which was subjected to flash silica gel 
column chromatography, eluting with dichloromethane/ethyl acetate (3:1 to 1:1) then 
ethyl acetate, to yield the title compound 139 (0.6 g, 43%) as a colourless oil.
]H NMR (300 MHz, CDC13): 5 1.42 (s, 9H), 2.74-2.78 (m, 2H), 3.03-3.11 (m, 2H), 
3.19-3.21 (m, 2H), 3.76 (s, 3H), 4.49-4.54 (m, 1H), 5.12 (s, 2H), 4.95, (br s, 1H), 
5.99 (br d, J =  7.8 Hz, 1H), 7.31-7.36 (m, 5H). MS (ESI) (+ve): m/z 396 (M+H+, 
100%). The 'H NMR spectral information are consistent with previously reported 
information.105
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(SVA^-Benzyloxycarbonyl-A^-^-butoxycarbonyty-l^-diamino^-azahexanoic 
acid (140)
A suspension of methyl (^-A^-benzyloxycarbonyl-TV6-(r-butoxycarbonyl)-2,6- 
diamino-4-azahexanoate (139) (300 mg, 0.8 mmol) in tetrahydrofuran (15 mL) was 
treated with lithium hydroxide (25 mg, 1.1 mmol) in water (15 mL) and stirred 
overnight at room temperature. The mixture was acidified to pH 3 with 1M 
hydrochloric acid and extracted with ethyl acetate (3 x 50 mL). The combined 
organic extracts were dried, filtered and concentrated under reduced pressure to give 
the title compound 140 (220 mg, 76%) as a colourless oil.
’H NMR (300 MHz, (CD3)2SO): S 1.37 (s, 9H), 2.91-2.98 (m, 2H), 3.08-3.24 (m, 
4H), 4.19-4.26 (m, 1H), 5.04 (s, 2H), 7.00-7.04 (m, 1H), 7.29-7.37 (m, 5H), 7.55 (br 
d, J=  8.1 Hz, 1H). MS (ESI) (-ve): m/z 380 (M-H+, 55%). HRMS (ESI) calcd. for 
C i8H26N306 [M-H]+ m/z 380.1821, found 380.1836.
OSVA^-Benzyloxycarbonyl-l^-diamintM-azahexanoic acid (135)
A mixture of (5)-A?-benzyloxycarbonyl-A/6-(^-butoxycarbonyl)-2,6-diamino-4- 
azahexanoic acid (140) (20 mg, 0.06 mmol) in 4M hydrochloric acid in 1,4-dioxane 
(3 mL) was stirred at 0 °C for 30 minutes and at room temperature for 1 hour.
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Solvent evaporation under reduced pressure gave a yellow solid. The crude product 
was subjected to preparative high performance liquid chromatography to yield the 
title compound 135 (10 mg, 59%) as a colourless oil.
'H NMR (300 MHz, CD3OD): 8 3.36-3.42 (m, 5H), 3.54-3.60 (m, 1H), 4.50-4.51 
(m, 1H), 5.13 (s, 2H), 7.28-7.39 (m, 5H). I3C NMR (75 MHz, CD3OD): 8 36.9, 
45.9, 47.6, 67.5, 68.3, 129.0, 129.2, 129.5, 158.9, 171.7, 184.3. MS (ESI) (+ve):
282 (M+H+, 48%). HRMS (ESI) calcd. for C13H2oN30 4 [M +H f m/z 282.1454, 
found 282.1462. HPLC: ?r 17.6 min (column: YMC-Pack ODS-AQ, 250 x 20 mm; 
(87:13) water (containing 0.1% TFA): acetonitrile; flow rate: 10.0 cm3 min'1).
(S)-Serine methyl ester hydrochloride (154)
(6)-Serine (153) (5.0 g, 47.6 mmol) was added to a mixture of acetyl chloride (9.8 
mL, 137.9 mmol) in methanol (65 mL) at 0 °C. The mixture was heated at reflux for 
2 hours, cooled to room temperature and solvent evaporation under reduced pressure 
gave the title compound 154 (5.6 g, 76%) as a white solid.
Mp. 163-164 °C (lit.,110 164 °C). |<x]23D +4.0 (c 0.5, EtOH). 'H NMR (300 MHz, 
CDC13/(CD3)2S0): 8 3.17 (s, 3H), 3.78-3.83 (m, 2H), 3.93-3.97 (m, 1H), 8.66 (br s, 
2H). MS (ESI) (-ve): m/z 118 (M-H+, 20%). The 'H NMR spectral information are
O
•  HCI
(154)
consistent with previously reported data.110
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(5)-2-(A^-BenzyIoxycarbonyI)serine methyl ester (155)
o
HO'.-A OMe
NHCbj
(155)
Triethylamine (14.8 mL, 106.0 mmol) and benzyl chloroformate (7.0 mL, 49.1 
mmol) were added to a suspension of (S)-serine methyl ester hydrochloride (154) 
(5.0 g, 32.2 mmol) in dichloromethane (100 mL). The mixture was stirred at room 
temperature for 5 hours and washed with water (3 x 50 mL). The organic extract 
was dried, filtered and concentrated under reduced pressure to give a yellow oil. The 
residue was subjected to flash silica gel column chromatography, eluting with 
hexanes/ethyl acetate (3:1 to 1:1 to 1:2) to yield the title compound 155 (1.1 g, 14%) 
as a yellow oil.
*H NMR (300 MHz, CDC13): 6 3.76 (s, 3H), 3.88-4.01 (m, 2H), 4.43-4.46 (m, 1H), 
5.11 (s, 2H), 5.80 (br s, 1H), 7.31-7.36 (m, 5H). MS (ESI) (+ve): m/z 276 (M+Na+, 
100%). The ]H NMR spectral data are consistent with the literature data.109
(5)-2-(./V-Benzyloxycarbonyl)-3-bromo-serine methyl ester (156)
7V-Bromosuccinimide (0.7 g, 3.9 mmol) was added slowly to a mixture of (S)-N- 
benzyloxycarbonylserine methyl ester (155) (0.5 g, 1.9 mmol) and
triphenylphosphine (1.0 g, 3.9 mmol) in 77,77-dimethylformamide (20 mL). The 
mixture was heated to 50 °C under a nitrogen atmosphere and stirred for 30 minutes. 
The mixture was treated with methanol (2 mL), and after 5 minutes, diethyl ether (10 
mL) was added. The mixture was washed with water (15 mL), saturated sodium
o
NHCbz
(156)
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bicarbonate solution (15 mL) and brine solution (15 mL), then dried and filtered. 
Solvent evaporation under reduced pressure gave an orange oil. The residue was 
subjected to flash silica gel column chromatography eluting with hexanes/ethyl 
acetate (6:1 to 4:1) to yield the title compound 156 (0.2 g, 27%) as a colourless oil.
’H NMR (300 MHz, CDC13): 5 3.72-3.86 (m, 2H), 3.81 (s, 3H), 4.80-4.85 (m, 1H), 
5.13 (s, 2H), 5.70 (br d, 5.7 Hz, 1H), 7.31-7.38 (m, 5H). MS (ESI) (+ve): m/z 
337 (M+Na+, 79Br, 60%) and 339 (M+Na+, 81Br, 58%). The 'H NMR spectral data 
obtained are consistent with data previously reported.109
Methyl (iS)-TVl 2-benzyloxycarbonyl-A^7-(t-butoxycarbonyl)-2,7-diamino-4- 
azaheptanoate(150)
NHBoc
CbzNH
(150)
A mixture of (S)-2-(A-benzyloxycarbonyl)-3-bromo-serine methyl ester (156) (450 
mg, 1.4 mmol) in acetonitrile (25 mL) was stirred at room temperature for 1 hour. 
Potassium fluoride on celite (50% wt) (700 mg) and A-(/-butoxycarbonyl)-1,3- 
diaminopropane (157) (570 mg, 3.3 mmol) in acetonitrile (2.5 mL) were added to the 
mixture, which was heated to reflux overnight and cooled to room temperature. The 
mixture was filtered through a pad of celite, washed with acetonitrile (100 mL) and 
solvent evaporation under reduced pressure gave a yellow oil. The residue was 
subjected to flash silica gel column chromatography eluting with 
chloroform/methanol (99:1 to 97:3) to yield the title compound 150 (220 mg, 27%) 
as a yellow oil.
lH  NMR (300 MHz, CDC13): S 1.42 (s, 9H), 1.56-1.62 (m, 2H), 2.62-2.63 (m 2H),
2.91-3.05 (m, 2H), 3.14-3.16 (m, 2H), 3.75 (s, 3H), 4.42-4.45 (m, 1H), 5.11 (s, 2H),
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5.83 (br d, J  = 6.6 Hz, 1H), 7.28-7.36 (m, 5H). MS (ESI) (+ve): m/z 410 (M+H+, 
100%). HRMS (ESI) calcd. for C2oH3iN306Na [M+Na]+ m/z 432.2111, found 
432.2118. The collected ’H NMR spectral data are consistent with literature 
information.109
0S)-7V2-BenzyloxycarbonyI-7V7-(f-butoxycarbonyl)-2,7-diamino-4-azaheptanoic 
acid (158)
NHBoc
CbzNH
(158)
A suspension of methyl (5)-A2-benzyloxycarbonyl-Ar7-(?-butoxycarbonyl)-2,7- 
diamino-4-azaheptanoate (150) (300 mg, 0.6 mmol) in tetrahydrofuran (20 mL) was 
treated with lithium hydroxide (23 mg, 0.9 mmol) in water (20 mL) and stirred 
overnight at room temperature. The mixture was acidified to pH 3 with 1M 
hydrochloric acid and extracted with ethyl acetate (3 x 50 mL). The combined 
organic extracts were dried, filtered and concentrated under reduced pressure to give 
the title compound 158 (162 mg, 84%) as a colourless oil.
*H NMR (300 MHz, (CD3)2SO): 6 1.44 (s, 9H), 1.70-1.75 (m, 2H), 2.86-2.97 (m, 
4H), 3.10-3.14 (m, 1H), 3.25-3.30 (m, 1H), 4.30-4.37 (m, 1H), 5.04 (s, 2H), 6.94- 
6.97 (m, 1H), 7.29-7.36 (m, 5H). 7.71 (d, J=  8. 1 Hz, 1H). MS (ESI) (+ve): m/z 396 
(M+H+, 100%). HRMS (ESI) calcd. for C i9H30N3O6 [M+H]+ m/z 396.2135, found 
396.2120.
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(N)-A2-Benzyloxycarbonyl-2,7-diamino-4-azaheptanoic acid (136)
CbzNH
(136)
A mixture of (S)-A2 -benzyloxycarbonyl-./V7-(/-butoxycarbonyl)-2,7-diamino-4- 
azaheptanoic acid (158) (60 mg, 0.2 mmol) in 4M hydrochloric acid in 1,4-dioxane 
(4 mL) was stirred at 0 °C for 30 minutes and at room temperature for 1 hour. 
Solvent evaporation under reduced pressure gave a yellow solid, which was 
subjected to preparative high performance liquid chromatography to yield the title 
compound 136 (18 mg, 40%) as a colourless oil.
‘H NMR (300 MHz, CD3 OD): 5 2.06-2.14 (m, 2H), 3.01-3.06 (m, 2H), 3.15-3.21 
(m, 2H), 3.37-3.40 (m, 1H), 3.54-3.60 (m, 1H), 4.53 (m, 1H), 5.14 (s, 2H), 7.29-7.41 
(m, 5H). 13C NMR (75 MHz, CD3 OD): 8  24.2, 25.1, 30.7, 37.9, 46.1, 68.2, 129.0, 
129.2, 129.5, 129.6, (carbonyl carbon signals not detected). MS (ESI) (+ve): m/z 
296 (M+H", 47%). HRMS (ESI) calcd. for CMH2 2 N3 O4  [M+H]+ m/z 296.1610, 
found 296.1618. HPLC: ?r 15.2 min (column: YMC-Pack ODS-AQ, 250 x 20 mm; 
(85:15) water (containing 0.1% TFA): acetonitrile; flow rate: 10.0 cm min' ).
157
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